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CHAPTER 1 
General introduction 
 
 
 
 Oxidants and the lung 
 Given its direct contact to the external environment and their function, the 
lungs are highly susceptible to oxidant induced damage caused by oxidative stress 
and are therefore equipped with high levels of anti-oxidants to counteract oxidative 
insult. Oxidants can be inhaled from the environment, coming for instance from 
cigarette smoke that contains an estimated 10
15
 radicals per puff [1] or oxidants 
can be produced endogenously by non-phagocytic cells through mitochondrial 
respiration as well as by inflammatory cells upon activation following inhalation of 
pathogens or irritants. Oxidants or reactive oxygen species (ROS) are involved in 
cellular biology, but when their levels outbalance detoxifying anti-oxidants they can 
cause oxidative stress. Oxidative stress can result in macromolecule damage, 
including lipids, proteins, and nucleic acids, potentially causing cellular dysfunction 
and death [2-4].  
 
COPD and oxidative stress 
 
 Chronic obstructive pulmonary disease or COPD is a chronic inflammatory 
disease of the lungs characterized by chronic bronchitis and emphysema [5].  
COPD occurs primarily in chronic cigarette smokers and the pathogenesis of 
COPD is not yet fully resolved, but mechanisms like immune alterations, proteolytic 
and oxidative disruption and endothelial dysfunction are well established to 
contribute to the disease [6-9] . Other factors such as genetic predisposition, and 
environmental and dietary factors, are likely to influence the risk of a smoker to 
develop the disease as well as to the heterogeneity of the disease observed 
between patients [10, 11]. Oxidative stress, due to imbalance between high 
oxidative insults by cigarette smoke and inflammation, and lowered or insufficient 
anti-oxidant levels, is an important hallmark of COPD. Oxidative stress in patients 
with COPD has been described locally in the lungs as well as in the systemic 
circulation [12] as the disease manifests itself also systemically, by elevated 
inflammatory cytokines in plasma. Increased levels of both oxidants and oxidative 
products of proteins, lipids, DNA and sugars have been measured. Oxidative 
stress is generally correlated to inflammation, as inflammatory cells are the main 
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source of oxidant production [13]. Besides directly damaging cellular content, 
oxidants can also trigger the activation of several pathways in the cell. These 
pathways include the activator pathway-1 (AP-1) and nuclear factor κB (NF- κB), 
responsible for the gene transcription of the inflammatory cytokines associated with 
airway inflammation in COPD, such as interleukin (IL)-6 and 8 and tumor necrosis 
factor α (TNFα) [14-17]. Secretion of these cytokines leads to the recruitment of 
inflammatory cells like macrophages and neutrophils, the latter upon activation can 
cause even more oxidative damage to surrounding cells and tissue due to 
oxidative burst.  
 
COPD and glutathione  
 
As described above, the lung continuously encounters oxidants from 
inhalation and is therefore well equipped with a myriad of antioxidants, and in 
particular with a high concentration of the antioxidant glutathione (GSH). In the 
epithelial lining fluid, up to a 140-fold increase from plasma levels of GSH are 
present [18]. Glutathione alone can scavenge free radicals; however, it is most 
efficient when acting in concert with GSH peroxidase (GPx), glutathione reductase 
(GSR), and the hexose monophosphate shunt system that regenerates NADPH, 
the electron donor needed to reduce oxidized GSH, known as GSSG [18]. The 
ratio of GSH/GSSG is often used to asses the redox status of a cell or tissue. 
Cigarette smoke is known to acutely deplete GSH, for instance by directly reacting 
with GSH to form nonreducible glutathione-aldehyde derivatives [19], thereby 
decreasing the lungs’ anti-oxidant capacity and making it vulnerable to oxidant-
induced injury. Also, GSH plays an important role in maintaining the integrity of the 
lung airspace epithelial barrier. Upon depletion of GSH in epithelial cells of the 
lung, increased permeability and loss of barrier function was reported [20, 21].  
Apart from activating inflammatory pathways, oxidants can also trigger 
transcription of antioxidant-protective genes. Many anti-oxidant genes, for example 
glutathione S-transferases, heme oxygenase-1 and the rate limiting enzyme in 
GSH synthesis γ-glutamylcysteine ligase (GCL), are regulated by the transcription 
factor Nuclear Factor (erythroid-derived 2)-like 2  (Nrf2). Therefore, as an adaptive 
response to oxidative stress, levels of GSH have reported to be increased in the 
epithelial lining fluid of chronic smokers [22]. This increase in epithelial lining fluid 
GSH after chronic cigarette smoking might however not be sufficient to counteract 
the excessive oxidative burden that occurs upon acute smoke exposure [23]. Also, 
unlike in healthy smokers and patients with stable COPD, patients with acute 
exacerbations have been reported to have reduced levels of GSH because of 
inhibited activity and transcription of the GCL catalytic subunit (GCLC) [23-25], 
predisposing the lung to injury due to overwhelming oxidative burden from reactive 
oxygen species released by neutrophils present at the time. The downregulation of 
GCLC in COPD patients might be related to a decreased Nrf2 activation in COPD 
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patients, which has been reported to be due to the loss of its positive regulator DJ-
1 [26]. 
 
Cysteine oxidation 
 
 Cysteine residues in proteins are the amino acids most susceptible to 
oxidative modification and therefore their functional implications and importance in 
cellular signaling pathways have been well characterized compared to other 
oxidized amino acids, including methionine, tyrosine and tryptophan [27]. It is the 
thiol group in a cysteine that can provide it with a low pKa, depending upon the 
amino acids in the environment surrounding the cysteine and make it more prone 
to post-translational modifications. In the presence of oxidative stress factors like 
ROS or reactive nitrogen species (RNS), the reduced cysteine in a protein can be 
oxidized to a thiyl radical (RS
.
) that has high reactivity with oxygen, leading to 
further cysteine oxidation (Figure 1). The oxidized cysteine (RS.) can undergo 
numerous redox-based modifications, including sulfenic acid (PSOH), nitrosylation 
(PSNO), palmitoylation (PSPalm), glutathionylation (PSSG) and the formation of 
inter- and intramolecular disulphides (S-S), with each modification having the 
potential to modify not only protein structure but also function in diverse fashion 
[28-32].  These aforementioned redox-based cysteine modifications are all 
reversible, but cysteines are also targeted by alkylating agents such as acrolein 
and prostaglandins, which are generated both endogenously and through 
environmental exposure and are irreversible [33, 34]. Also, cysteine amino acids in 
proteins can be oxidized to sulfenic (SOH), sulfinic (-SO2H) or sulfonic (-SO3H) 
acids. In numerous classes of proteins throughout species free cysteines are found 
to be highly conserved within a protein’s primary sequence and often play an 
important role in protein function, highlighting the specificity and tight regulatory 
measurements that have been acquired by cell organisms to control post-
translational modifications of these low pKa cysteines and their importance in cell 
physiology.  
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Figure 1: ROS induced protein S-glutathionylation and deglutathionylation [adapted with permission 
from S.Aesif] 
 
S-glutathionylation and its mediators 
 
 The direct addition of GSH to low pKa cysteines upon mild oxidative stress 
creates an S-glutathionylated residue, with an increase in molecular weight of 305 
and a net increase in negative charge, due to the glycine residue of GSH. As 
described, cysteines are among the most vulnerable with regard to oxidative 
modification and the conjugation of GSH to oxidized cysteines serves to protect 
against over oxidation. S-glutathionylation is a reversible post-translational 
modification, making it a potential biological switch for a number of critical oxidative 
signaling events. The added molecular weight of GSH to the thiol can change a 
proteins three dimensional conformation as well as alter its function. Pathways 
described to be altered by S-glutathionylation upon mild oxidation are involved in a 
wide variety of crucial cell functions, including energy metabolism, calcium 
homeostasis, inflammation, cell death and protein folding [35, 36]. Recently, it has 
been suggested that protein thiols may be a more accurate indicator of total 
cellular redox status, since they represent a potentially larger redox active pool that 
free GSH [37]. To gain more insight in these protein thiols and their oxidation, 
5 
 
antibodies directed towards specific thiol oxidations have been developed. 
Combining mass spectrometry with affinity purification protocols has provided 
identification and quantification of S-glutathionylated proteins. For example, 
nitrosative and oxidative stress have been shown to be responsible for S-
glutathionylation of GSTP on Cys47 and Cys101 [38] and haemoglobin A has been 
found to be S-glutathionylated on Cys 93 through a cysteine sulfenic  acid  
intermediate [39].  
Protein S-glutathionylation has been compared to phosphorylation with regard to 
its impact on protein function and structure and its ability to reversibly alter 
signaling pathways [40, 41]. Much like phosphorylation, where kinases and 
phosphatases respectively govern its formation and resolution in a regulated 
manner, a handful of proteins have been suggested to play a similar part in forward 
and reverse reactions in the S-glutathionylation cycle.  
 
 Glutathione S-transferase Pi (GSTP) 
 
Although binding of GSH to proteins can be achieved non-enzymatically, 
there is some evidence that glutathione-S-transferase P1 (GSTP1) can catalyse 
this reaction [38, 42]. GSTP1 is a member of the GST superfamily that catalyses 
the conjugation of GSH to various hydrophobic and electrophilic compounds to aid 
in detoxification. The P isoform is expressed highly in lung tissue and was found to 
be increased in patients with mild COPD [43]. In fibroblasts, deletion of GST-P1 
has been shown to lead to apoptosis [44] while overexpression was protective 
against cigarette smoke extract induced cell death [45]. Polymorphisms in GSTP1 
have been linked to COPD, and suggested to be due to a lack of sufficient 
detoxification of, and antioxidant protection against cigarette smoke and associated 
products. However, to date none of these polymorphisms have been considered in 
the context of their impact on S-glutathionylation. Lastly, GSTP1 can contribute to 
pathogenesis through  interacting with proteins such as c-jun-N-terminal kinase 
(JNK) and tumor necrosis factor receptor-associated factor (TRAF) 2 [36, 46, 47]. 
 
 Glutaredoxins 
 
Glutaredoxins (Grx) are part of the oxidoreductase class of enzymes and 
are found in virtually all organisms [48]. Several isoforms of glutaredoxin have 
been identified, but glutaredoxin 1 (Grx1) is the most extensively described and 
characterized.  Grx1 was first discovered as a GSH-dependent electron donor for 
ribonucleotide reductase in E.Coli [49]. Later Grx1 has been described as 
catalyzing the removal of GSH from cysteines, known as deglutathionylation, 
unders physiological conditions [50], thereby liberating this reservoir of GSH.  
Changes in expression of Grx1 can result in differential protein S-gluathionylation 
and can thus impact function of proteins influenced by altered cysteine oxidation. 
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Grx1 localizes primarily to the cytosol, whereas Grx2 is present in the 
mitochondria and nucleus. Grx2 exists as an inactive dimer with a 2Fe(iron)-
2S(sulfur) cluster which can be released in active enzyme monomers upon 
increased GSSG or oxidative stress. Grx3 is an isoform that does not exhibit 
deglutathionylating activity, but is reported to be altered in lung cancer [51]. Grx5 is 
located in the mitochondria and functions through a monothiol mechanism to 
reduce mixed protein disulfides. A role for Grx5 in heme synthesis and Fe-S cluster 
formation has been described [52]. 
 
The NF- κB pathway 
 
The transcription factor, Nuclear Factor kappa B (NF-κB) is an important 
regulator of cell survival as well as immune and inflammatory responses. The 
canonical NF-κB pathway is activated following stimulation of various receptors 
including toll like receptors and cytokine receptors and results in activation of the 
Inhibitory kappa B kinase (IKK) complex which consists of the catalytic subunits 
IKKα, IKKβ and IKKγ. Activation of IKKβ triggers phosphorylation of the NF-κB 
inhibitor IκBα, resulting in its proteasomal degradation and the release of RelA to 
the nucleus for activation of transcription of target genes. Non canonical NF- κB 
signaling is activated by agonists such as CD40 and B cell activating factor 
receptor and is responsible for stabilizing NF-kB inducing kinase, which in turn 
phosphorylates and activates homodimers of IKKα, leading to nuclear translocation 
of RelB and gene transcription of target genes [53, 54]. (Figure 2) 
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Figure 2:  Canonical and non-canonical NF-κB pathways [adapted with permission from S.Aesif] 
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Multiple members of the NF-κB pathway can be dynamically regulated through 
reversible cysteine oxidations, which include S-nitrosylation, sulfenic acid 
formation, disulfide formation, and S-glutathionylation [55]. S-glutathionylation of 
IKKβ, RelA, and p50 have been documented and resulted in inhibition of the NF-κB 
pathway [56, 57]. We previously demonstrated that ablation of Grx1 enhances S-
glutathionylation of IKKβ-Cys179 induced by hydrogen peroxide and inhibits 
cytokine-induced NF-κB activation and pro-inflammatory mediators. 
Overexpression of Grx1 on the other hand, decreases S-glutathionylation of IKKβ-
Cys179 and enhances NF-κB activation following oxidation by hydrogen peroxide. 
These data demonstrate that the cellular content of Grx1 regulates the extent to 
which NF-κB becomes activated [57]. Upon activation of NF-κB increased Grx1 
levels have been reported in retinal glial cells [58], suggesting reciprocal regulation 
of Grx1 and NF- κB.  
 
Thesis outline 
 
We started off investigating into more detail this reciprocal regulation of 
NF-kB and glutaredoxin in lung epithelial cells in chapter 2 because overall little 
information is available on the mediators of glutaredoxin expression and activity. 
Next to investigating whether NF-kB indeed is involved in transcriptional regulation 
of grx1, we tried to tie these findings back into the role of S-glutathionylation of the 
NF-κB mediator IKKβ to the inflammatory response to LPS. In chapter 3 we 
investigated whether CSE could be responsible for the downregulation of grx1 that 
was previously shown in patients with COPD. Secondly, we investigated if this 
downregulation impacted total protein PSSG and mediated sensitivity to CSE 
induced death of lung epithelial cells. Grx and PSSG were next also investigated in 
lung tissue of mice exposed to cigarette smoke for four weeks in chapter 4. In this 
chapter, another reversible cysteine oxidation, S-nitrosylation and its mediators 
ADH5 and iNOS were examined to establish a broader insight in the effects of 
cigarette smoke on reversible cysteine oxidations. The role of glutaredoxin 1 in 
cigarette smoke induced inflammation in mice was then assessed by using a 
glutaredoxin 1 knock out mouse  in a four week exposure study. In chapter 5 a 
comprehensive study was set up to evaluate Grx in conjunction with PSSG in lung 
tissue and sputum and of COPD patients and to examine their relation to lung 
function and inflammatory parameters. As COPD also manifests itself by systemic 
inflammation and oxidative stress, PSSG of plasma proteins was assessed in 
COPD patients compared to controls in the next chapter, including the positive and 
negative enzyme mediators GSTP1 and glutaredoxin 1 respectively. Correlations 
between S-glutathionylation, its mediators, as well as systemic inflammatory 
markers and lung function were investigated. Lastly, in research previously 
conducted by our laboratory, Grx1 was reported to be increased in a mouse model 
for allergic airways disease. However, data on Grx and PSSG in asthma were 
lacking. We therefore measured levels of S-glutathionylation and glutaredoxin 1 in 
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sputum of asthmatic patients compared to controls and investigated correlations 
between the Grx1-PSSG axis, lung function and inflammation. 
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Abstract 
 
The transcription factor, Nuclear Factor kappa B (NF-κB) is a critical regulator of 
inflammation and immunity, and is negatively regulated via S-glutathionylation. The 
ihibitory effect of S-glutathionylation is overcome by glutaredoxin-1 (Grx1), which 
under physiological conditions catalyses deglutathionylation and enhances NF-κB 
activation. The mechanisms whereby expression of the Glrx1 gene is regulated 
remain unknown. Here we examined the role of NF-κB in regulating activation of 
Glrx1. Transgenic mice which express a doxycyclin-inducible constitutively active 
version of inhibitory kappa B kinase-beta (CA-IKKβ) demonstrate elevated 
expression of Grx1. Transient transfection of CA-IKKβ also resulted in significant 
induction of Grx1. A 2kb region Glrx1 promoter that contains two putative NF-κB 
binding sites was activated by CA-IKKβ, RelA/p50, and lipopolysaccharide (LPS). 
Chromatin immunoprecipitation experiments confirmed binding of RelA to the 
promoter of Glrx1 in response to LPS. Stimulation of C10 lung epithelial cells with 
LPS caused transient increases in Grx1 mRNA expression, and time-dependent 
increases in S-glutathionylation of IKKβ. Overexpression of Grx1 decreased S-
glutathionylation of IKKβ, prolonged NF-κB activation, and increased levels of pro-
inflammatory mediators. Collectively, this study demonstrates that the Glrx1 gene 
is positively regulated by NF-κB, and suggests a feed forward mechanism to 
promote NF-κB signaling by decreasing S-glutathionylation.  
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Introduction  
 
The transcription factor, Nuclear Factor kappa B (NF-κB) is a cardinal regulator of 
cell survival, and immune and inflammatory responses. Its activation has been 
linked to a wide variety of chronic inflammatory, and immune diseases, as well as 
cancer [1]. NF-κB is comprised of diverse subunits of NF-κB/Rel proteins and 
inducibly regulates transcription of over 100 target genes. The canonical NF-κB 
pathway is activated following stimulation of various receptors including toll like 
receptors and cytokine receptors and results in activation of the Inhibitory kappa B 
kinase (IKK) complex which consists of the catalytic subunits IKKα and IKKβ, and 
the regulatory protein, IKKγ. The catalytic activity of IKKβ mediates 
phosphorylation of the NF-κB inhibitor IκBα, leading to its proteasomal degradation. 
Non canonical signaling is activated by agonists such as CD40 and B cell 
activating factor receptor, stabilization of NF- κB inducing kinase, which in turn 
phosphorylates and activates homodimers of IKKα (Fig. 1A). IKKα and IKKβ also 
mediate additional phosphorylation events and collectively lead to enhanced 
transcriptional activation of target genes [2-4].  
Redox-based regulation of cell signaling is receiving increased attention as a result 
of the demonstration that diverse pathways and transcription factors, including NF-
κB can be dynamically regulated through reversible cysteine oxidations [5, 6]. 
Reactive, low pKa, cysteines in the thiolate state can be reversibly oxidized in 
diverse manners, which include S-nitrosylation, sulfenic acid formation, disulfide 
formation, and S-glutathionylation [5]. Protein S-glutathionylation (also referred to 
as S-glutathiolation or mixed disulfides) causes functional alterations in target 
proteins, and both activation and inhibition of physiological function has been 
observed [7-10]. We and others have previously demonstrated that the NF-κB 
pathway is inhibited via S-glutathionylation, and S-glutathionylation of IKKβ, RelA, 
and p50 have been documented [10-12]. However, the exact proportion of S-
glutathionylation of NF-κB members that occurs in intact cells, and impact for the 
strength of NF-κB signaling remains unknown to date. Steady state levels of S-
glutathionylated proteins are controlled by glutaredoxins, members of the 
thioredoxin family of oxidoreductases. Glutaredoxins (Grx) under physiological 
conditions act to efficiently, and specifically deglutathionylate proteins [13]. We 
previously demonstrated that ablation of Grx1 enhances S-glutathionylation of 
IKKβ-Cys179 induced by hydrogen peroxide (H2O2), and inhibits cytokine-induced 
NF-κB activation and pro-inflammatory mediators, while overexpression of Grx1 
decreases S-glutathionylation of IKKβ-Cys179 and enhances NF-κB activation 
following oxidation by H2O2, collectively demonstrating that the cellular content of 
Grx1 regulates the extent to which NF-κB becomes activated under conditions of 
oxidative stress [10] (Fig. 1B).  
We recently demonstrated that the cellular content of Grx1 is modulated by diverse 
pro-inflammatory stimuli. In mice with allergic airway inflammation, Grx1 content 
was increased in bronchial epithelial cells [14], which also show activation of NF-κB 
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[15]. Upregulation of Grx1 has also been observed in retinal glial cells cultured in 
high glucose medium, concomitant with activation of NF-κB [16]. These findings 
suggest that NF-κB and Grx1 may be regulated in a coordinate fashion. In the 
present study we sought to determine whether the glutaredoxin (Glrx1) gene is 
regulated via the NF-κB pathway, and to determine the functional implications of 
such regulation.  
 
A 
 
B 
 
Figure 1. Overview of the NF-κB activation pathways and the impact of S-glutathionylation. A) 
Schematic representation of activation of classical (top) and alternative (bottom) NF-κB activation 
pathways, and outcomes. The classical pathway is activated by diverse ligands, such as LPS, Tumor 
Necrosis Factor-alpha (TNFα), Interleukin 1-beta (IL-1β), among many others, which results in the 
activation of Inhibitory kappa B kinase beta (IKKβ) which in turn mediates degradation of IκBα, resulting 
in the nuclear translocation and activation of RelA/p50 NF-kB subunits. The alternative NF-κB pathway 
is activated by distinct subsets of ligands, such as B cell Activating Factor (BAFF), CD40 ligand 
(CD40L) etc. which result in NF-κB Inducing Kinase (NIK) dependent activation of I kappa B kinase 
alpha (IKKα) which phosphorylates p100, and resultant proteolytic processing to p52. RelB/p52 dimeric 
complexes then are translocated to the nucleus, to activate transcription of unique sets of genes. Note 
that this schematic is an oversimplification, as additional regulatory post-translational modifications, and 
chromatin remodeling events occur to enable transcriptional activation of genes. Cross talk between 
classical and alternative NF-κB pathways also occurs, and is not illustrated here. B) Impact of H2O2 of 
IKKβ and NF-κB signaling. Stimulation of cells with LPS or TNFα leads to activation of IKKβ, and 
downstream NF-κB signaling. In the presence of H2O2 (100-200 μM) or following overexpression of 
NOX1, IKKβ is inhibited via S-glutathionylation (PSSG) of Cys179. Overexpression of glutaredoxin-1 
(Grx1) reverses S-glutathionylation of IKKβ (P-SH), and permits NF-κB signaling in the presence of 
H2O2. This schematic is a summary of previously published data [10].  
 
Materials and methods  
 
Plasmids and reagents  
Constitutively active IKKβ (CA-IKKβ) in which serines 177 and 181 are mutated to 
glutamic acid residues, dominant negative IκBα (dnIκBα) in which serines 32 and 
36 are mutated to alanines, and flag tagged glutaredoxin-1 (Grx1) constructs were 
used as previously described [9, 17, 18]. All transfections were performed using 
the DharmaFECT reagent (Thermo Scientific) according to the manufacturer’s 
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instructions. Grx1 targeting SiRNA, and SiRNA controls (Invitrogen) were used as 
previously described, with modification [19]. Herein we will refer to glutaredoxin 1 
using the commonly used abbreviation, Grx1. When referring to the mouse 
glutaredoxin 1 gene, we will use the Glrx1 as the abbreviation.  
 
Cell culture  
Murine type two lung epithelial (C10), and macrophage (RAW 264.7) cell lines 
were propagated in CMRL medium (C10), or Dulbecco’s minimal essential medium 
(RAW 264.7), supplemented with 10% fetal bovine serum and 100 U/ml 
penicillin/streptomycin. For stimulation experiments, RAW 264.7 cells were plated 
and allowed to adhere for 1 h prior to treatment. Cells were stimulated with 5 
ng/mL IL-1β (Axxora), 10 ng/mL TNF-α (Calbiochem), or 0.5-10 μg/mL LPS (List 
Biological Laboratories) for the times indicated.  
 
Immunoblotting  
Cells were lysed in buffer containing 137 mM Tris·HCl (pH 8.0), 130 mM NaCl, and 
1% NP-40. Proteins were resolved by SDS-PAGE and blotted onto PVDF 
membranes (Millipore) prior to immunoblotting. In selected experiments, nuclear 
extracts were prepared according to previously published procedures [20], and 
nuclear proteins resolved by SDS-PAGE. The following antibodies were used for 
Western Blotting, Grx1 (American Diagnostica), β-actin (Sigma), IKKβ (Santa 
Cruz), RelA (Santa Cruz), and Histone H3 (Millipore). 
 
Glutaredoxin-1 activity assay  
Cells were lysed in buffer containing 137 mM Tris·HCl (pH 8.0), 130 mM NaCl, and 
1% NP-40, lysates were then cleared by centrifugation, and 100 μg of protein 
incubated with reaction buffer containing 137 mM Tris-HCl, pH 8.0, 0.5 mM 
glutathione (Roche), 1.2 U glutathione disulfide reductase (Roche), 0.35 mM 
NADPH (Sigma), 1.5 mM EDTA, and 2.5 mM cysteine-SO3 (Sigma) for 10 min. 
Consumption of NAPDH was determined spectrophotometrically at 340 nm and 
data are expressed as Units, in which 1 Unit equals the oxidation of 1 μmol 
NADPH/min/mg protein. 
 
Assessment of protein-S-glutathionylation (PSSG)  
Protein S-glutathionylation in cells was determined using the 
glutathione/glutathione reductase/NADPH/ 5,5’-dithiobis (2-nitrobenzoic acid) 
recycling assay, according to procedures as described elsewhere [21] with minor 
modifications. Cells were lysed in 137 mM Tris-HCl, pH 8.0, 130 mM NaCl, and 1% 
NP-40. Protein content was determined, and samples equalized for protein 
content. 200 μg of protein was precipitated with acetone. The pellet was 
resuspended in 0.1% Triton-X100, 0.6% sulfosalicylic acid containing buffer, and 
freeze thawed twice. Protein-associated glutathione was released with sodium 
borohydride, and GSH determined. The sodium borohydride sensitive fraction of 
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GSH was calculated, and expressed as nmol GSH/mg of protein. S-
glutathionylation of IKKβ was assessed in cells lysed in buffer containing 50 mM 
Tris, pH 7.4, 150 mM NaCl, 0.25% SDS, 1% NP-40, 0.5% CHAPS, and 20 mM N-
ethylmaleimide with protease inhibitor cocktail (Sigma-Aldrich), via 
immunoprecipitation using and antibody directed against GSH (Virogen). As a 
reagent control, lysates were incubated in the presence of 1 mM DTT to 
decompose S-glutathionylated proteins prior to immunoprecipitation [9].  
 
Chromatin Immunoprecipitation (ChIP)  
ChIP assays were carried out as described elsewhere with minor modifications 
[22]. Briefly, at the appropriate times of harvest, formaldehyde (Sigma) was added 
to the culture medium to a final concentration of 1% and cells were incubated for 
10 min. Glycine was then added to a final concentration of 125 mM. Cells were 
washed with ice cold PBS and scraped into buffer containing 25 mM Hepes (pH 
7.8), 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, and protease inhibitor (Sigma). A 
Dounce homogenizer was used to isolate nuclei, which were then resuspended in 
buffer containing 50mM Hepes pH (7.8), 140 mM NaCl, 1 mM EDTA, 1% SDS, and 
protease inhibitor (Sigma). Isolated nuclei were sonicated (VibraCell Sonicator) to 
produce chromatin fragments of 200-1000 nucleotides in length. Following 
sonication, isolated chromatin was diluted 1:10 and precleared with protein-G 
linked magnetic Dynabeads (Invitrogen). Immunoprecipitations were performed 
using 2 μg anti-RelA antibody (Millipore), 2 μg anti-RNA Polymerase 2 antibody 
(Millipore), 2 μg Acetylated histone H4 antibody (Millipore), or IgG isotype control 
antibody, at 4°C overnight with constant agitation. Protein-G linked magnetic 
Dynabeads (Invitrogen) were added and immunoprecipitates isolated using a 
DynaMag (Invitrogen) magnet rack and washed four times according to protocol. 
Isolated chromatin was then incubated with 20 μg of Proteinase K (Roche) for 2 h 
at 55°C, and then 65°C overnight to reverse the cross-links. Isolated DNA was then 
purified by QAIquick column (Qiagen) purification according to the manufacturer’s 
protocol, prior to PCR analysis. Primer sequences used for PCR were as follows, 
forward 5’-aacaggagtggcaaatattgaga-3’ and reverse 5’-ctttctggcaaccttctgatg-3’.  
 
Glutaredoxin Promoter Analysis  
The online promoter mining algorithm PROMO3.0 was used to analyze the 2kb 
sequence upstream of the Glrx1 locus derived from the NCBI MGI build 37 of the 
Mus musculus genome [23]. Forward primer, 5’-ctcgagtaggagagcttggctattccatgt 
and reverse primer 3’-agatctgctgacaggctgcagcttctccag, were designed using NCBI 
MGI build 37 to clone the genomic sequence 2kb upstream of the Glrx1 locus, 
introducing an Xho1 site 5’ and Bgl2 site 3’. The resultant amplicon was inserted 
into the pGL4.0 (Promega) vector to create Glrx1-luc. C10 cells were transfected 
with Glrx1-luc, β-galactosidase (β-gal), in the presence or absence of CA-IKKβ. 24 
h post transfection, cells were lysed in luciferase lysis buffer (Promega), and 
luciferase (Promega) and β-gal (Applied Biosystems) activity measured according 
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to the manufacturer’s instructions. Luciferase units were expressed as relative light 
units (RLU) after correction for β-gal. In select experiments, cells pRL-TK was 
employed to correct for differences in transfection efficiency, and cells were 
analyzed with the dual-luciferase reporter assay system (Promega) according to 
manufacturer’s protocol instructions.  
 
Mice 
Bi-transgenic mice that inducibly express constitutively active IKKβ (CA-IKKβ) 
under the control of the rat clara cell secretory protein, 10 kDa promoter were 
used. In these mice, expression of the CA-IKKβ transgene is induced in non-
ciliated bronchiolar epithelial cells of the lung, upon administration of doxycycline, 
as previously described [18]. For all experiments, two month old CA-IKKβ 
transgenic mice, or transgene negative littermates were maintained on doxycycline 
containing chow (6g/kg) (Purina Diet Tech) for 1 week prior to analyses. All studies 
were approved by the Institutional Animal Care and Use Committee at the 
University of Vermont.  
 
mRNA analyses  
Total RNA was isolated from C10 cells or lung tissue using the RNeasy mini-kit 
(Qiagen, Valencia, CA), subjected to reverse transcription and DNase treatment to 
produce cDNA for Taqman gene analysis using SYBR green (Biorad, Hercules, 
CA) or Assays on Demand for the individual target genes (Applied Biosystems, 
Foster City, CA). Results were normalized to house keeping genes, cyclophilin, or 
HPRT. Primer sequences are: Glutaredoxin-1: forward; TTT ACA ACA GCT CAC 
CGG AG, reverse; TCA CTG CAT CCG CCT ATG (accession number: NM 
053108.4) Cyclophilin: forward; TTC CTC CTT TCA CAG AAT TAT TCC A, 
reverse; CCA GTG CCA TTA TGG (accession number: NM 008907.1), HPRT: 
forward; AGA ATG TCT TGA TTG TGG AAG A, reverse; ACC TTG ACC ATC TTT 
GGA TTA (accession number NM 13556.2)  
 
Scratch assays  
Scratch assays were performed as previously described with modifications [24]. On 
Day 1 C10 were transfected with pcDNA or CA-IKKβ expression plasmid, on Day 2 
cells were transfected with Grx1 SiRNA or control SiRNA, on Day 3 medium was 
changed and cells were allowed to recover for 24 h. On Day 5 cells were scratched 
in a linear fashion using a p1000 micropippette tip, immediately following the 
scratch a photograph was taken of the cells using an Olympus IX70 inverted light 
microscope with QImaging Retiga 2000R digital camera. Twenty four h later, an 
identical photograph was taken of the same location to assess scratch closure. 
Scratch closure analysis was performed using ImageJ software 
(http://rsb.info.nih.gov/ij). All experiments were performed in triplicate, with 
additional samples prepared simultaneously for biochemical analysis of gene over 
expression and SiRNA knockdown.  
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Statistics 
Analyses of all data were performed using the Graph Pad Prism software 
(Graphpad, Inc.) by one way ANOVA or Student’s t test where appropriate. Data 
from each experiment is presented plus/minus the standard error of the mean 
(SEM). All experiments were repeated twice. Analyses with resultant p values of < 
0.05 were accepted as significant. 
 
Results  
 
Activation of the NF-κB pathway in lung epithelial cells in vitro and in vivo results in 
enhanced Grx1 expression  
Previous reports have demonstrated that within the lung, Grx1 is highly expressed 
in airway epithelial cells, in addition to macrophages [14, 25], and in mice with 
allergic airway inflammation, NF-κB activation and increases in Grx1 are apparent 
in lung epithelium [14, 15]. In order to determine whether Glrx1 is regulated by NF-
κB, we took advantage of a transgenic mouse model wherein NF-κB activation is 
selectively induced in lung epithelial cells, following doxycyclin-inducible 
expression of CA-IKKβ [18]. Results in Fig. 2A demonstrate that Grx1 content was 
increased in homogenized lung tissue of mice that express the CA-IKKβ transgene, 
while in the absence of doxycyclin, Grx1 expression was equal to controls (not 
shown). Increases in Grx1 content were accompanied by increases in Grx1 mRNA 
(Fig. 2B). Since CA-IKKβ-expressing mice display marked neutrophilic 
inflammation [18], it is difficult to ascertain whether increases in Grx1 expression 
are the direct result of NF-κB activation, or a consequence of the inflammatory 
process. In order to directly determine whether Grx1 expression in epithelial cells is 
regulated by NF-κB activation, we over expressed CA-IKKβ in a line of mouse type 
II alveolar epithelial cells (C10). In pcDNA vector-transfected cells, Grx1 content 
increased over time in culture (Fig. 2C). Following expression of CA-IKKβ, Grx1 
content and mRNA levels were further increased (Fig. 2C and D). In CA-IKKβ 
expressing lung epithelial cells, the overall content of protein-S-glutathionylation 
was decreased (Fig. 2E), consistent with the observed increases in Grx1 content, 
and the physiological role of Grx1 in catalyzing protein-deglutathionylation. 
Lipopolysaccharide (LPS) is a well known activator of NF-κB, and administration of 
LPS to airways results in activation of NF-κB in lung epithelium, and consequently 
neutrophilic inflammation. Moreover, in response to administration of LPS, 
increases in Grx1 content were observed in the lung [26]. We therefore assessed 
whether LPS also increased Grx1 expression in C10 cells. Results in Fig. 2F 
demonstrate that LPS induced transient increases in Grx1 mRNA expression after 
30 min and 2 h of exposure. At later time points, no increased in Grx1 mRNA were  
  
18 
 
 
 
 
Figure  2. Increases of Grx1 expression following activation of the NF-κB pathway in lung epithelial 
cells. (A) Transgenic mice that express CA-IKKβ within the conducting airways, in a doxycycline 
inducible manner, or transgene negative littermate controls were maintained on doxycycline for 1 week. 
Mice were euthanized, and whole lung homogenates prepared for assessment of Grx1 expression by 
immunoblot analysis. IKKβ blot is shown to verify expression of trangenic IKKβ. β-actin is shown as a 
loading control. (B) Assessment of Grx1 mRNA content by real time PCR is lung tissues from mice 
expressing the CA-IKKβ transgene, compared to C57B/6 littermates. Results were normalized to the 
housekeeping gene, HPRT, and expressed as fold increases compared to transgene negative littermate 
controls that were fed doxycycline containing food. Data reflect mean +SEM of 4 mice/group. * p < 0.05 
(ANOVA) compared to C57B/6 group. (C) Mouse alveolar type II cells (C10) were transfected with 1 μg 
or pcDNA3 or CA-IKKβ plasmids. After 24 and 48 h, whole cell lysates were evaluated for Grx1 
expression by immunoblot analysis. β-actin: loading control. (D) Assessment of Grx1 mRNA expression 
via real time PCR in C10 cells transfected with 1 μg or pcDNA3 or CA-IKKβ plasmids. Results were 
normalized to the housekeeping gene, cyclophilin, and expressed as fold increases compared to pcDNA 
controls. * p<0.05 (Student T Test) compared to pcDNA3 controls. (E) Assessment of protein S-
glutathionylation in C10 cells following expression of CA-IKKβ. 24 or 48 post transfection with PcDNA3 
or CA-IKKβ, cells were lysed and proteins precipitated for assessment of PSSG. The sodium 
borohydride dependent release of GSH was measured. Results are normalized to cellular protein 
content. * p<0.05 (ANOVA) compared to pcDNA3 controls. (F) Assessment of Grx1 mRNA expression 
in C10 cells exposed to 1 μg/ml of LPS for the indicated times. Results were normalized to the 
housekeeping gene, cyclophilin, and expressed as fold increases compared to pcDNA controls. * 
p<0.05 (ANOVA) compared to pcDNA3 controls.  
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apparent. Collectively, these findings demonstrate that Grx1 expression can be 
induced in an NF-κB-dependent mechanism.  
 
Stimulation of RAW264.7 cells with LPS induces expression of Grx1 in an NF-κB 
dependent manner  
In addition to lung epithelial cells, Grx1 expression is also robust in alveolar 
macrophages [26]. We therefore next determined the impact of pro-inflammatory 
cytokines on Grx1 content in RAW264.7 macrophage like cells. RAW264.7 cells 
were stimulated for 24 h with LPS, IL-1β, or TNF-α, agonists known to induce NF-
κB activation. Exposure to IL-1β or TNF-α, resulted in no or modest increases in 
Grx1 expression or activity. However, stimulation of cells with LPS resulted in a 
significant increase in Grx1 protein expression and activity (Fig. 3A-C).  
We next sought to determine whether NF-κB activity was directly involved in LPS-
induced increases in Grx1 content, by over expression of a dominant negative 
version of IκBα in RAW264.7 cells. As is demonstrated in Fig. 3D, over expression 
of dominant negative IκBα markedly inhibited LPS-induced increases in Grx1 
content. As was demonstrated earlier in C10 lung epithelial cells (Fig. 2C), 
overexpression of CA-IKKβ, also enhanced Grx1 expression in RAW264.7 cells in 
the presence or absence of LPS (Fig. 3D). Collectively these results demonstrate 
that LPS induces Grx1 expression in an NF-κB-dependent manner.  
 
Identification of NF-κB binding sites within the promoter of the Glrx1 gene locus  
In order to further examine the molecular mechanisms regulating Grx1 expression 
in RAW264.7 cells, we analyzed the 2 kb sequence of genomic DNA upstream of 
the Glrx1 start codon for potential NF-κB binding sites. This sequence of genomic 
DNA was previously described and determined to be a transcriptionally competent 
promoter sequence [27]. Using the PROMO3.0 promoter mining software revealed 
of two regions containing putative NF-κB (p50) binding sites at -1247-1256 kb and -
1307-1316 kb upstream of the transcriptional start site (Fig. 4A). We next assessed 
the transcriptional activity of the 2 kb region of the Glrx1 promoter containing the 
putative NF-κB sites, and assessed the impact of CA-IKKβ, RelA/p50, or LPS on 
Glrx1 promoter activation. Transfection of C10 cells with Glrx1-luc resulted in 
enhanced luciferase expression over the PGL4 vector control (Fig. 4B). Co-
transfection of cells with constitutively active IKKβ resulted in a concentration 
dependent increase in luciferase compared to vector controls (Fig. 4B). Similarly, 
transfection of RelA/p50 or exposure to LPS increased Glrx1-luciferase activity 
(Fig. 4C). In order to determine whether NF-κB could directly bind to the Glrx1 
promoter, we next conducted chromatin immunoprecipitation analyses in 
RAW264.7 cells stimulated with LPS. Results in Fig. 4D demonstrate that binding 
of RelA to the Glrx1 promoter occurred between 4-24 h post stimulation of cells 
with LPS, which coincided with occupancy of the Glrx1 promoter with RNA 
polymerase II. In contrast, no RelA or RNA polymerase II was bound in 
unstimulated cells. Acetylated histone H4 was constitutively bound to the Glrx1 
20 
 
promoter, suggesting that this genomic site is competent with respect to 
transcription factor binding [28]. In aggregate, these findings demonstrate that the 
Glrx1 gene can be activated by canonical NF-κB signaling.  
 
 
hr PcDNA3 Flag GRX1 
RANTES 
- 207 ± 28 286 ± 46 
24 906 ± 97 1282 ± 114 
48 1210 ± 206 2079 ± 482* 
72 1375 ± 242 1787 ± 289 
IL-6 
- 16.1 ± 1.4 20.4 ± 3.9 
24 19.5 ± 3.4 33.5 ± 3* 
48 19.0 ± 4.1 33.5 ± 3* 
72 16.5 ± 2.4 26.6 ± 4* 
GM-CSF 
- 2.2 ± 0.1 2.3 ± 0.4 
24 4.0 ± 1.0 3.4 ± 1.1 
48 6.2 ± 0.9 10.9 ± 1.7* 
72 2.9 ± 0.9 9.9 ± 2.3* 
KC 
- 386 ± 12 369.7 ± 98 
24 927 ± 121 941.0 ± 67 
48 3179 ± 297 3261.2 ± 265 
72 3471 ± 492 4644.4 ± 401* 
*p < 0.05, ANOVA, compared to pcDNA3 group at the same time. 
 
Table 1. Impact of overexpression of Grx1 on content of NF-κB dependent pro-inflammatory cytokines 
in C10 cells stimulated with LPS. C10 cells were transfected with 1 μg of Flag-Grx1 plasmid, or PcDNA3 
control, and 24 h later stimulated with 10 μg/ml of LPS for 24, 48 or 72 h. Cytokine content in medium 
was assessed via ELISA assays, * p< 0.05, ANOVA, compared to PcDNA group at the same time. 
 
 
Expression of Grx1 promotes LPS-induced NF-κB signaling in lung epithelial cells 
Activation of IKKβ is the pre-requisite signal in NF-κB activation by LPS, and 
previously we determined that H2O2- induced S-glutathionylation of IKKβ inhibits is 
activity [10]. We next determined whether exposure of lung epithelial cells to LPS 
leads to S-glutathionylation of IKKβ. Indeed, results in Fig. 5A demonstrate that 
stimulation of C10 cells with LPS results in increases of S-glutathionylation of IKKβ. 
Incubation of cell lysates with 1 mM dithiotreitol prior to immunoprecipitation with 
anti-glutathione antibody resulted in a complete loss of immunoprecipitation of 
IKKβ (data not shown). S-glutathionylation of IKKβ occurred at protracted time 
points relative to phosphorylation of RelA, degradation of IκBα, and increases in 
nuclear RelA content, which are all reflective of activation of IKKβ. We next 
assessed whether Grx1 overexpression would reverse increases in S-
glutathionylation of IKKβ in response to LPS, and the impact for NF-κB activation. 
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Consistent with its physiological role in de-glutathionylation, overexpression of 
Grx1 prevented LPS-induced increases in S-glutathionylation of IKKβ (Fig. 5, top 
panel). Assessment of IκBα content, which is degraded upon IKKβ-induced 
phosphorylation in response to LPS (Fig. 1A), demonstrated a second wave of 
IκBα degradation in cells overexpressing Grx1, in particular at the 4 and 6 h time 
points. Prolonged degradation of IκBα corresponded with increases in 
phoshorylation of RelA and nuclear content of RelA at those times, in Grx1 
expressing cells, compared to pcDNA3 control cells exposed to LPS (Fig. 5). The 
content of LPS-induced NF-κB dependent pro-inflammatory cytokines, interleukin-6 
(Il-6), keratinocyte-derived chemokine (KC), granulocyte monocyte-colony 
stimulating factor (GM-CSF), and Regulated on Activation Normal T Cell 
Expressed and Secreted (RANTES) in supernatants was markedly enhanced in 
Grx1 overexpressing cells, comparison to pcDNA3-transfected vector controls, in 
particular at the later time points (Table 1), demonstrating that increased 
expression of Grx1 enhances LPS-induced NF-κB dependent pro-inflammatory 
signaling.  
In addition to its role in inflammation, activation of NF-κB has been demonstrated 
to be important in wound healing [29]. We recently demonstrated that S-
glutathionylation is prominent in cells at the leading edge of a wound [19]. We 
therefore conducted scratch assays to determine the impact of CA-IKKβ 
expression of wound closure in lung epithelial cells, and the role of Grx1 therein. 
Results of Fig. 6 demonstrate that CA-IKKβ expressing cells showed an enhanced 
ability to close the wound area. However, following siRNA-mediated knock down of 
Grx1, the enhanced ability of CA-IKKβ expressing cells to close the wound area 
was completely abolished. These results suggest that Grx1 induction following CA-
IKKβ mediated activation of NF-κB is critical in promoting wound repair.  
In aggregate, these findings suggest that NF-κB-dependent induction of Grx1 
represents a feed forward regulatory mechanism to promote NF-κB signaling, by 
decreasing levels of protein-S-glutathionylation, which inhibit the NF-κB pathway 
(Fig. 7). 
 
Discussion  
 
NF-κB has been considered a prototypic redox-sensitive transcription factor that is 
induced following oxidative stress. While convincing studies exist which document 
activation of NF-κB following activation of NADPH oxidases or oxidative stress [30, 
31], other studies have demonstrated that NF-κB is inhibited following oxidative 
insults [32]. The exact oxidative events that regulate the activity of NF-κB have 
remained elusive. Our laboratory recently demonstrated that canonical NF-κB 
signaling is inhibited via S-glutathionylation. Specifically we demonstrated that S-
glutathionylation of cysteine 179 of the IKKβ following exposure to hydrogen 
peroxide (H2O2, 100-200 μM) resulted in the reversible inactivation of IKKβ [10].  
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Figure 3. Expression of Grx1 in RAW264.7 macrophage like cells following stimulation with known NF-
κB agonists. (A) RAW264.7 cells were stimulated with IL-1β (5ng/mL), TNF-α (10 ng/mL), or LPS 
(1μg/mL) for 24 h. Whole cell lysates were resolved by SDS-PAGE and immunoblotted for Grx1, and β-
actin. (B) Assessment of Grx1 activity RAW264.7 cells, 24 h post stimulation with agonists, as in A. 
Data are expressed as mean (±SEM) units. * p < 0.05 (ANOVA) compared to sham controls. (C) Dose 
dependent modulation of Grx1 content in RAW264.7 cells 24 h after stimulation with LPS. RAW264.7 
cells were stimulated with the indicated concentrations of LPS, and after 24 h, whole cell lysates were 
prepared for Western Blot analysis. (D) RAW264.7 cells were transfected with vector control 
(pcDNA3.0), constitutively active IKKβ (CA-IKKβ), or dominant negative IκBα (dn-IκBα). 24 h later, cells 
were exposed to LPS (1 μg/ml) for an additional 24 h before immunoblot analysis for Grx1. Actin is 
shown as a loading control.  
 
Importantly, the thioltransferase Grx1 effectively reversed the H2O2-induced S-
glutathionylation of IKKβ, and permitted activation of NF-κB in the presence of 
H2O2 [10]. Other members of the NF-κB pathway have also been identified as 
targets for S-glutathionylation, including p50 and RelA (p65), in association with 
impaired DNA binding and transcriptional activation [11, 12]. A consensus cysteine 
has been identified in rel homology domains of all members of the NF-κB family 
[33], suggesting that other members of the NF-κB family also may be susceptible 
to redox modification.  
The present study expands upon previous observations in that we demonstrate 
that a physiological ligand of NF-κB, LPS, results in S-glutathionylation of IKKβ. S-
glutathionylation of IKKβ occurred at relatively protracted times relative to IKKβ-
mediated phosphorylation, suggesting that S-glutathionylation may be a negative 
feedback mechanism in order to decrease kinase activity. We were not able to 
accurately determine this using in vitro kinase assays due to the requirement of 
reducing agents in these assays which reverse S-glutathionylation, and additional 
studies are needed to determine the exact mechanism whereby S-glutathionylation 
inhibits the activity of IKKβ. Additional studies are also needed to elucidate the 
exact stoichiometry of S-glutathionylation of NF-κB family members in intact cells,  
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Figure 4. Assessment of activation of the glrx1 promoter by NF-κB. (A) Schematic depiction of the glrx1 
promoter highlighting two putative NF-κB1 (p50) binding sites at -1250 base pairs (bp) and -1310 bp. 
Arrows indicate the primer sequences used for ChIP analysis. (B) C10 cells were transfected with vector 
encoding β-galactosidase, empty PGL4.0 vector, or PGL4.0 vector containing the 2000 bp sequence up 
stream of the glrx1 gene locus (Glrx1-luc), in the presence or absence of increasing amounts of 
PcDNA3, or CA-IKKβ. Cells were incubated 24 h prior to luciferase activity analysis. All data are 
expressed as mean (±SEM) relative light units (RLU) normalized to β-galactosidase activity. * p < 0.05 
(ANOVA) compared to Glrx1-luc controls. (C) Cells were transfected with Glrx1-luc and renilla luciferase 
(pRL-TK), and where either co-transfected with 1 μg, pcDNA3, CA-IKKβ, or 0.5 μg RelA plus 0.5 μg 
p50. After 24 h, pcDNA3-transfected cells were stimulated with 1 μg/ml LPS. All cells were harvested 24 
h later using the dual-luciferase reporter assay system (Promega) according to manufacturer’s 
instructions. Data are expressed as mean (±SEM) relative light units (RLU) normalized to Renilla 
activity. * p < 0.05 (ANOVA) compared to PcDNA3 controls. (D) Assessment of RelA binding to the 
Glrx1 promoter via ChIP analysis. RAW264.7 cells were stimulated with 1 μg/ml of LPS for the indicated 
times. Chromatin was crosslinked, sheared, and precipitated with antibodies recognizing RelA, RNA 
polymerase II (Pol II), or aceylated Histone H4. Pre-immune IgG antibody was used at a control. 
Immmunoprecipitated DNA was subjected to PCR analysis, using primer sequences indicated in Fig. 
3A.  
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Figure 5. Assessment of the impact of over expression of Grx1 on LPS-induced NF-κB activation and 
S-glutathionylation of IKKβ (IKKβ-SSG) in C10 lung epithelial cells. Top panel: S-glutathionylation of 
IKKβ. At the indicated times, S-glutathionylated proteins were immunoprecipitated (IP) with anti-GSH 
antibody, and subjected to Western Blotting to detect IKKβ. No immunoreactivity occurred in IgG control 
immunoprecipitations or following decomposition of protein-S-glutathionylation with DTT (data not 
shown). Whole cell lysates (WCL); Assessment of IKKβ content as a control in samples used for IP, and 
IκBα content, and phoshorylation of RelA at serine 536 (pRelA) as measures of NF-κB activation. Total 
RelA: loading control, Grx1: confirmation of Grx1 overexpression. Bottom panels: Assessment of 
nuclear content (Nucl) of RelA in response to LPS in cells transfected with PcDNA3 (left), or Grx1 
(right). H3: histone H3 as a loading control.  
 
 
Figure 6. Enhanced wound closure in CA-IKKβ expressing cells requires the presence of Grx1. C10 
cells were transfected with control SiRNA, or Grx1 SiRNA, and 24 h thereafter transfected with PcDNA3 
or CA-IKKβ. 24 h later, a scratch was made with a pipet tip, and 24 h thereafter, the % closure of the 
wound area quantified. Results are representative of 6 observations conducted in two separate 
experiments. * p < 0.05 (ANOVA) compared to the pcDNA group; ‡ p < 0.05 (ANOVA) compared to the 
control siRNA, CA-IKKβ-transfected group.  
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with consideration of formation of IKK signalsomes, subcellular localization, and 
unique pools of NF-κB complexes in those settings. The link between S-
glutathionylation of IKKβ and activation of NADPH oxidases also needs further 
study. Furthermore, the specificity of S-glutathionylation of IKKβ also will need to 
be unraveled, in light of the existence of many proteins with reactive cysteines that 
are potential targets for oxidation. Nonetheless, it is worthy of mention that 
glutathione S-transferase P was recently unraveled as a catalyst of S-
glutathionylation reactions [34, 35], and could be a major determinant for which 
proteins constitute biologically relevant targets for S-glutathionylation, together with 
Grx enzymes.  
In C10 cells, which transiently increased Grx1 mRNA expression in response to 
LPS, overexpression of Grx1 largely prevented the LPS-induced increases in S-
glutathionylation of IKKβ, and prolonged degradation of IκBα, phoshorylation of 
RelA, nuclear localization of RelA, and led to further increases in expression of 
diverse NF-κB dependent pro-inflammatory cytokines. In addition to its role in 
inflammation, NF-κB also plays a role in wound healing [29]. Results from our 
present study indeed demonstrate enhanced wound closure in epithelial cells 
expressing active IKKβ, and that the ability of IKKβ to facilitate wound closure 
required the presence of Grx1, findings which suggest a role for Grx1 in wound 
healing. Using a technique of Grx1-based cysteine derivatization, we previously 
demonstrated that S-glutathionylation was preferentially apparent in cells at the 
leading edge of the wound [19], which potentially is due to activation of NADPH 
oxidases [36]. We did not unravel whether NF-κB subunits or IKKβ are S-
glutathionylated during wound healing nor do we know the functional implications 
of such events. Alternatively, S-glutathionylation of actin has been shown to occur 
and interferes with its ability to polymerize [37]. Grx1-catalysed de-glutathionylation 
may be required to facilitate actin remodeling, and cell migration.  
Given the functional significance of Grx1 in prolonging the activation of the NF-κB 
pathway, and its role in CA-IKKβ-induced wound closure we sought to further 
explore the molecular mechanisms by which Grx1 expression is regulated. The 
results of the present study demonstrate that Glrx1 expression is increased by 
activation of the canonical NF-κB pathway itself, through the direct interaction of 
the NF-κB subunit RelA (p65) with the glrx1 promoter. To date, little information 
exists regarding the transcriptional regulation of Glrx1. The human Glrx1 gene 
contains putative activator protein-1 (AP-1) sites in its promoter, which links 
expression of Glrx1 to signaling pathways that control Fos and Jun family members 
[27]. Indeed, the chicken Glrx1 gene was demonstrated to be a direct target of 
oncogenic Jun [38], and similarly, under conditions of oxidative stress, in lens 
epithelial cells the human Glrx1 gene was induced in an AP-1 dependent manner 
[39]. Results from the present study demonstrate that both in RAW 264.7 
macrophages and C10 lung epithelial cells, Grx1 protein expression was increased 
following activation of NF-κB through expression of CA-IKKβ. The present data 
also clearly demonstrate that Glrx1 induction is agonist specific. Despite its well-
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known ability to activate NF-κB,TNF-α failed to increase Grx1 expression or activity 
in RAW 264.7 macrophages (Fig. 2A and B). These data suggest that besides 
canonical NF-κB pathway activation, other pathways may either enhance or 
dampen Glrx1 gene activation. Computational analysis of the Glrx1 promoter, 
revealed a putative PU.1 binding site adjacent to the NF-κB binding sites. PU.1 is 
an ETS family transcription factor associated with hematopoietic differentiation and 
maturation, which has been described to antagonize NF-κB signaling in 
macrophages [40]. Of relevance to our findings, silencing of PU.1 using short 
interfering RNA resulted in enhanced NF-κB signaling following stimulation of 
RAW264.7 cells with LPS, while conversely, overexpression of PU.1 dampened 
NF-κB-dependent signaling [40]. Additional studies are necessary to formally 
determine the repressive role of PU.1 in the activation of the Glrx1 gene, and to 
unravel the other transcription factors or signaling events that either enhance or 
dampen activation of the Glrx1 gene in response to different ligands.  
Canonical NF-κB signaling is critical to the initiation of innate immune responses 
following exposure to bacterial toxins such as LPS. Our laboratory has 
demonstrated that over expression of a dominant negative version of IκBα 
specifically within the airway epithelium is sufficient to inhibit influx of neutrophils 
into the lung and block inflammatory cytokine production following exposure to LPS 
[17]. Furthermore, we and others have demonstrated that activation of canonical 
NF-κB signaling within the airway epithelium is sufficient to induce an inflammatory 
response in the lungs, which is associated with neutrophil influx and enhanced 
production of inflammatory cytokines [18]. Results from the present study suggest 
a direct link between Grx1 expression and a feed forward mechanism for the 
propagation of NF-κB signaling (Fig. 7). These results would suggest that under 
conditions wherein Grx1 expression is increased, inflammatory responses in the 
lung are potentiated, while conversely, in the absence of Grx1, NF-κB-dependent 
inflammatory responses would be attenuated. A recent study from our laboratory 
demonstrated that in Glrx1 deficient mice the ability of LPS to induce acute 
inflammation was identical to WT mice exposed to LPS. However, a clear trend 
toward more rapid resolution of LPS-induced inflammation was apparent in Glrx1-/- 
mice, which corresponded with time-dependent increases in protein-S-
glutathionylation [26]. Studies examining patients with chronic obstructive 
pulmonary disease have correlated increases in expression of Grx1 in alveolar 
macrophage with disease progression and decreased lung function. In contrast, 
patients with sarcoidosis and allergic alveolitis show decreased expression of Grx1 
in alveolar macrophages [25]. Based upon those observations, additional studies 
are needed to unravel the impact of Grx1 status in lung tissue on the extent and 
resolution of inflammatory responses, and to functionally link these associations 
with S-glutathionylation of NF-κB. Such endeavors will be important, given the 
documented roles of LPS, and Toll like receptor 4 signaling in the orchestration not 
only of acute inflammatory responses, and lung injury, but also in promoting 
allergic airways disease.  
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In summary, results from the present study demonstrate that activation of the Glrx1 
gene by canonical NF-κB signaling represents a feed forward mechanism to 
prolong NF-κB activation (Fig. 7). These findings suggest that Grx1-based control 
of protein-S-glutathionylation represents a post-translational mechanism to control 
the timing of the NF-κB activation, and point to Grx1 as a possible target to combat 
diseases characterized by NF-κB-driven chronic inflammation. 
 
 
 
Figure 7. Model depicting the potential impact of Grx1 on prolonging activation of NF-κB. In response to 
stimulation with LPS, S-glutathionylation (PSSG) of IKKβ is important to shut down the activity of NF-κB. 
Activation of the Glrx1 gene via canonical NF-κB activation prevents the accumulation of IKKβ-SSG, 
thereby prolonging activation of the NF-κB pathway, and the production of pro-inflammatory mediators. 
Note that Grx1-catalyzed deglutathionylation results in the formation of protein sulfhydryl groups (P-SH). 
It is plausible that in addition to IKKβ, other members of the NF-κB pathway are regulated via S-
glutathionylation and Grx1-catalyzed deglutationylation (not shown).  
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Abstract 
 
 It is established that cigarette smoke causes irreversible oxidations in lung 
epithelial cells and can lead to their death. However, its impact on reversible and 
physiologically relevant redox-dependent protein modifications remains to be 
investigated.  Glutathione is an important anti-oxidant against inhaled reactive 
oxygen species as a direct scavenger, but it can also covalently bind protein thiols 
upon mild oxidative stress to protect them against irreversible oxidation. This 
posttranslational modification, known as S-glutathionylation, can be reversed under 
physiological conditions by the enzyme glutaredoxin 1 (Grx1). The aim of this study 
was to investigate if cigarette smoke modifies Grx1 and if this impacts on protein S-
glutathionylation and epithelial cell death. Upon exposure of alveolar epithelial cells 
to cigarette smoke extract (CSE) a decrease in Grx1 mRNA and protein expression 
was observed, in conjunction with decreased activity and increased protein S-
glutathionylation. Using mass spectrometry, irreversible oxidation of recombinant 
Grx1 by CSE and acrolein was demonstrated, which was associated with 
attenuated enzyme activity. Furthermore, carbonylation of Grx1 in epithelial cells 
after exposure to CSE was shown. Overexpression of Grx1 attenuated CSE-
induced increases in protein S-glutathionylation and increased survival. 
Conversely, primary tracheal epithelial cells of mice lacking Grx1 were more 
sensitive to cigarette smoke-induce cell death with corresponding increases in 
protein S-glutathionylation.  
These results show that cigarette smoke can modulate Grx1 not only at the 
expression level, but can also directly modify Grx1 itself, decreasing its activity. 
These findings demonstrate a role for the Grx1/S-glutathionylation redox system in 
cigarette smoke induced lung epithelial cell death. 
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Background 
 
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of 
morbidity and mortality in the United States (1) that is mainly caused by cigarette 
smoking. Cigarette smoke (CS) contains 10
16
 free radicals per cigarette (2), 
including reactive oxygen (ROS) and reactive nitrogen species (RNS). Inhalation of 
these oxidants in combination with the production of ROS/RNS by macrophages 
and neutrophils leads to oxidative stress. Oxidants in CS can cause direct cellular 
damage by lipid peroxidation (3), DNA damage (4) and irreversible protein 
oxidations (5, 6).  
 
The pulmonary epithelium is equipped with lining fluid (ELF) that contains 
high concentrations of glutathione (GSH) (7), which is an important anti-oxidant 
against inhaled ROS. CS is known to acutely deplete GSH, thereby decreasing the 
lungs’ anti-oxidant capacity and making it vulnerable to oxidant-induced injury. As 
an adaptive response to oxidative stress, such as in smokers, GSH levels increase 
in the ELF due to up -
glutamylcysteine ligase (8). GSH in concert with its redox cycle partners serves to 
maintain the reduced state of protein thiol groups.  This can be achieved by direct 
scavenging of oxidants or by covalently and reversibly binding protein thiols. The 
latter formation of mixed disulfides between protein thiols and GSH occurs under 
physiological conditions and can be induced upon mild oxidative stress, and is 
known as S-glutathionylation or S-glutathiolation. S-glutathionylation is believed to 
protect its targeted protein thiols from further irreversible oxidations. Additionally, 
S-glutathionylation can modulate protein function. For instance, our laboratory 
previously described the inhibition of Inhibitory kappa B kinase β (IKKβ) activity, the 
enzyme responsible for NF- -inflammatory conditions, 
through S-glutathionylation of cysteine 179 after oxidative challenge of lung 
epithelial cells (9).  
 
Under physiological conditions, S-glutathionylation can be reduced by 
glutaredoxins (Grx) (10). Several mammalian Grxs have been identified. Grx1 
localizes primarily to the cytosol while Grx2 is present in mitochondria and the 
nucleus. Recently, Grx3 has gained interest for its altered expression in lung 
cancer, although this isoform does not exhibit deglutathionylation activity (11). 
 
In the lungs, Grx1 expression is predominant in macrophages and 
bronchial epithelium and has been shown to be altered in allergic airway disease 
(12), COPD (13) and after acute exposure to LPS (14). So far, little is known about 
the regulation of Grx expression. In the context of COPD for instance, it is unknown 
if CS itself influences Grx expression or can modify its activity. Moreover, the 
effects of CS on protein S-glutathionylation remain to be determined. The aim of 
this study was therefore to investigate the effects of CS on the Grx/protein S-
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glutathionylation axis in lung epithelial cells, and furthermore to investigate their 
role in CS induced-cell death.  
 
Materials and Methods 
 
Cell Culture 
A human transformed alveolar epithelial cell line, A549, was obtained from the 
American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 
1640 (Gibco, Grand Island, NY, USA) containing 10% FBS (Biochrome, Berlin, 
Germany), L-glutamine (2 mM) and penicillin/streptomycin (Invitrogen, Grand 
Island, NY,USA). Twenty-four hours before stimulation, cells were cultured in 
DMEM/F12 without phenol red and 0.5% FBS.  
Glrx1
-/-
 mice, a kind gift of dr. Ho (Wayne State University, Detroit, MI), and their 
littermate controls were used to isolate primary tracheal epithelial cells (MTE) as 
described previously (15) with minor modifications (16). Cells were cultured in full 
medium lacking phenol red for 24h prior to stimulation. The institutional Animal 
Care and Use Committee granted approval for all procedures. 
 
Cigarette smoke extract 
3R4F Research Cigarettes, from the University of Kentucky (Lexington, KT, USA), 
were removed from their filters and cigarette smoke extract (CSE) was made 
according to (17).  
 
Grx1 luciferase reporter assay 
Transient transfections were performed using Fugene (Roche) according to the 
manufacturer's instructions using 1.75 µg human grx1 promotor luciferase plasmid, 
kindly provided by Dr. Park (US Department of Agriculture). Co-transfection with 
0.25 µg pSV-β-galactosidase was employed to correct for differences in 
transfection efficiency. Luciferase (Promega) and β-galactosidase (Tropix) activity 
were measured according to the manufacturer’s instructions.  
 
Grx1 activity assay 
Grx1 activity assay was performed as described in (18). Data were expressed as 
µmol NADPH/minutes/mg
 
protein
 
(19). 
 
Grx1 catalyzed cysteine derivatization for in situ detection of S-glutathionylated 
proteins 
S-glutathionylated proteins were detected in cells as described earlier (16). 
 
Quantitative determination of protein S-glutathionylation using 5,5’-dithio-bis(2-
nitrobenzoic acid) (dTNB) 
Cells were lysed in 137 mM Tris-HCl, pH 8.0, 130 mM NaCl, and
 
1% NP-40 and 
cleared by centrifugation. 200 μg of protein was acetone precipitated for 20 min at -
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20°C and next resuspended and sonicated in extraction buffer. Furthermore the 
determination of protein S-glutathionylation was conducted as described in (20). 
 
Mass spectrometry 
Recombinant Grx1 was incubated for 24h at RT in the dark in 0.1% trifluoroacetic 
acid (TFA) with 2.5% or 5% CSE, or equimolar concentrations of acrolein. For 
mass spectrometric analysis, 1 µl of recombinant Grx1 (10 pmol/µl) and 1 µl matrix 
solution (10 mg/ml Sinapinic acid in 40% acetonitrile/ 0.1%TFA) were spotted on a 
384-well target plate of a MALDI-TOF/TOF (4800 MALDI TOF/TOF analyzer, 
Applied Biosystems). The instrument was operated in positive linear mode, mid 
mass range. Acquisition mass range was 10000-15000 Da.  
 
Detection of Grx1 carbonylation in vitro 
Grx1 was immunoprecipitated from A549 cells and carbonyls were derivatized 
using an oxyblot kit (Millipore). Carbonylation of Grx1 was visualized on an SDS-
PAGE gel using the DNP antibody.  
 
Assessment of cell viability 
Cells were harvested by trypsinization, pelleted and washed twice with PBS. Next 
propidium iodide (1 µg/ml) was added and cell viability assessed by flow cytometry. 
 
Results 
 
CSE downregulates Grx1 expression  
In order to investigate the effect of CS on Grx1 expression, we first exposed A549 
cells transiently expressing a human Grx1 promotor luciferase construct to CSE 
and measured Grx1 promoter activity using a luciferase assay. Results in Fig. 1A 
demonstrate that β-galactosidase corrected Grx1 luciferase activity was dose-
dependently inhibited by treatment with CSE for 48h. Significant attenuation of 
Grx1 promoter activity was also observed after 24h of exposure to 2.5% CSE, but 
not after 4h (Fig 1B). Grx1 mRNA (Fig. 1C) was negatively affected by 5% CSE 
after both 24 and 48h of exposure. In contrast, no significant alterations in the 
expression of Grx2 mRNA were observed (data not shown). Protein levels of Grx1 
were decreased upon CSE exposure in A549 cells (Fig. 1D, left) as well as in MTE 
cells (Fig. 1D, right). 
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Fig. 1: CSE downregulates Grx1 expression. A549 cells were transiently transfected with a human Grx1 
promotor luciferase construct and β-galactosidase and exposed to CSE. (A) Cells were treated for 48h 
with indicated doses of CSE and luciferase activity was measured and corrected for β-galactosidase. 
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(B) Cells were control treated (black bars) or exposed to 2.5% CSE (grey bars). After 4, 24 and 48h 
luciferase activity was measured and corrected for β-galactosidase. (C) A549 cells were control treated 
(black bars) or exposed to 5% CSE (grey bars) and expression of Grx1 mRNA was measured by QPCR 
and corrected for HPRT. Data are expressed as fold-change over control treated cells at 24h. (D) 
Protein expression of Grx1 was determined by Western blotting in A549 cells (left panel) and in primary 
MTE cells exposed to CSE (right panel). The level of β-actin was measured as a loading control. * p-
value < 0.05 compared to untreated controls, analyzed by ANOVA. 
 
Grx activity is attenuated and protein S-glutathionylation increased by CSE 
exposure 
 
Because of the observed attenuation of Grx1 expression by CSE, we next 
assessed Grx activity and protein S-glutathionylation in A549 and MTE cells. As 
expected, Grx activity was attenuated by 2.5 and 5% CSE in A549 cells after 24 
and 48h, although not significant (Fig. 2A, left), in agreement with results on mRNA 
and protein expression. In MTE cells Grx1 activity decreased as well after 48h, but 
not 24h of exposure to 0.5% CSE (Fig. 2A, right). We next assessed the impact of 
decreased Grx levels and activity on the overall content of cellular protein S-
glutathionylation. Results in the left panel of Fig. 2B demonstrate that protein S-
glutathionylation was augmented after CSE exposure in a dose and time 
dependent fashion in A549 cells. MTE cells showed a significant induction of S-
glutathionylated proteins only after 48h of CSE exposure (Fig. 2B, right), coinciding 
with the decreased activity at this time point. CSE-induced increases in protein S-
glutathionylation were corroborated by in situ detection of S-glutathionylated 
proteins using Grx1-catalyzed cysteine derivatization in MTE cells stimulated with 
0.5% CSE for 48h (Fig. 2C). Total free GSH in A549 cells was measured using the 
DTNB recycling method and showed 50% depletion of GSH upon stimulation with 
5% CSE for 24 and 48h (data not shown). This attenuation of free GSH levels 
occurs in conjunction with enhanced protein S-glutathionylation. 
 
Modulation of Grx1 protein by CS  
A recent study demonstrated that Grx1 can be oxidized and inhibited by a variety 
of oxidants (21). In order to investigate whether CS could directly modify the Grx1 
protein, we incubated recombinant human Grx1 with 2.5 and 5 % CSE for 24h and 
assessed mass modifications by MALDI-TOF mass spectrometry, as well as 
activity. Incubation of Grx1 with 2.5% CSE resulted in a mass addition of 
approximately 58 Da compared to untreated protein (Fig. 3A). This mass addition 
occurred in a concentration dependent manner as incubation with 5% CSE further 
increased the presence of the modified protein to 63.5% and was non-reversible by 
DTT (Table 1). Moreover, mass addition did not occur after pre-incubation of Grx1 
with the cysteine alkylating agent N-ethylmaleimide (NEM) (data not shown), 
implying that the mass addition occurs on a cysteine residue. Acrolein is a 58 Da 
highly oxidative component of CS, which is reactive towards cysteine residues. We 
next incubated recombinant Grx1 with an equimolar amount of acrolein to assess 
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Fig. 2: Grx activity is attenuated and protein S-glutathionylation increased by CS. A549 cells were 
control treated (black bars), exposed to 2.5% (grey bars) or 5% (white bars) CSE. After 24 and 48h Grx 
activity (Fig. 2A, left panel) and protein S-glutathionylation (Fig. 2B, left panel) were measured. MTE 
cells were control treated (black bars) or exposed to 0.5% CSE (grey bars) for 24 and 48h and Grx 
activity (Fig. 2A, right panel) and protein S-glutathionylation (Fig. 2B, right panel) were measured. (C) 
Protein S-glutathionylation was visualized using Grx1-catalyzed cysteine derivatization in primary MTE 
cells treated for 48h with 0.5% CSE.  –GSH: omission of glutathione in the Grx1 reduction mix as a 
negative control. * p-value < 0.05 compared to untreated controls, analyzed by ANOVA. 
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whether the mass addition observed by CSE could be due to acrolein present in 
CSE. Indeed, here we also detected a DTT irreversible mass addition of 58 Da 
(Table 1). Addition of 116 Da, indicative of oxidation of 2 cysteine residues by 
acrolein could also be found in Grx1 using higher concentration of CSE or acrolein 
(Table 1). Incubation of recombinant Grx1 with CSE dose dependently attenuated 
its activity in a DTT irreversible fashion and similar effects were observed following 
exposure to acrolein (Fig. 3B).  
 
 
 
Table 1: Percentage of recombinant Grx1 that is modified by either CSE or purified acrolein in an 
equimolar concentration of the recombinant protein. Both conditions show no changes when pre-
incubated with DTT. 
 
To investigate whether oxidation of Grx1 also occurs in cells, Grx1 was 
immunoprecipitated form A549 cells stimulated with CSE for 48h. Carbonylation of 
Grx1 was then investigated using an oxyblot kit. Results in Fig. 3C indicated that 
2,5 and 5% CSE exposure resulted in carbonylation of Grx1, demonstrating that 
Grx1 is not only oxidized by CSE in a cell free environment, but that oxidation of 
Grx1 also takes place in epithelial cells. As a positive control recombinant Grx1 
exposed to CSE was derivatized which showed carbonylation as well.  
 
Effect of Grx1 modulation on CS-induced protein S-glutathionylation and epithelial 
cell death  
We next sought to investigate whether the observed attenuation of Grx1 by CSE is 
linked to CSE-induced cell death. We therefore first exposed A549 cells that were 
transiently transfected with Flag-tagged Grx1 to CSE. In pcDNA transfected cells, 
CSE dose dependently induced cell death. After 24h, cells overexpressing Grx1 
demonstrated significant protection against CSE-induced cell death at high doses 
of CSE. Moreover, transfection with 1 µg Flag-Grx1 offered better protection 
compared to transfection with 0.5 µg (Fig. 4A). In agreement with Fig. 2B, CSE 
increased total protein S-glutathionylation in pcDNA transfected cells. Flag-Grx1 
overexpression however, provided protection against smoke-induced S-
glutathionylation in a dose dependent manner (Fig. 4B).  
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Fig. 3: Modulation of Grx1 protein by CS. (A) Recombinant human Grx1 control (left spectrum), or 
exposed to 2.5% CSE (right spectrum) for 24h at RT and analyzed by MALDI-TOF mass spectrometry. 
Numbers in spectra indicate the mass of the product. (B) Assessment of recombinant Grx1 activity after 
24h of treatments. (C) Carbonylation of immunoprecipitated Grx1 from lysates of A549 cells. Negative 
derivatization control for recombinant Grx1 (rGrx1) and Grx1 immunoprecipitated from lysates (IP Grx1) 
exposed to CSE. Derivatization of recombinant Grx1 exposed to CSE and control in the last two lanes. * 
p-value < 0.05 compared to untreated control, analyzed by ANOVA. 
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To further investigate the importance of Grx1 in CS-induced cell death MTE cells 
isolated from Glrx1
-/-
 mice were used. MTE cells in general were more sensitive to 
CSE-induced cell death compared to A549 cells as marked death was observed 
with concentrations as low as 1%. MTE cells lacking Glrx1 demonstrated 
significantly more cell death compared to cells isolated from littermate controls at 
all doses of CSE tested (Fig. 5A). Total protein S-glutathionylation was furthermore 
only increased in cells isolated from Glrx1
-/-
 mice using 1% CSE (Fig. 5B).  
Taken together, these data indicate that the decreased content and activity of Grx1 
after CSE exposure is indeed responsible for observed increases in total protein S-
glutathionylation and contributes to CSE-induced death of lung epithelial cells. 
 
Discussion 
 
Previous research regarding CS-induced oxidative stress has focused on 
irreversible oxidations linked to damage, while ignoring the effects of CS on 
physiologically relevant oxidations that can reversibly modify function. The 
objective of the present study therefore was to investigate whether CS can cause 
changes in protein S-glutathionylation, an oxidation which can be reversed by 
glutaredoxins, and if changes in this S-glutathionylation-Grx1 redox system play a 
role in epithelial cell death provoked by CS.  
This is the first report to demonstrate attenuation of Grx1 expression and Grx 
activity by CSE, in concert with increased protein S-glutathionylation in lung 
epithelial cells. In patients with COPD it has been shown that the number of Grx1 
positive macrophages was decreased in the lungs along with decreases in Grx1 
protein levels in whole lung homogenates. In contrast, in sputum supernatants 
more Grx1 was detected during acute exacerbations (13). Protein S-
glutathionylation was not investigated in the latter study, but elevated levels were 
reported in blood samples of smokers compared to non-smokers (22). The present 
study in cell culture models confirms the previous reports regarding the modulation 
of Grx1 expression and protein S-glutathionylation in patients with COPD and 
healthy smokers. However, CS probably did not directly affect mRNA expression of 
Grx1, since attenuated levels of Grx1 mRNA could only be observed after at least 
24h of exposure. It would appear more likely that CS acts on signaling pathways 
that modulate transcription factors that in turn regulate Grx1 mRNA expression. 
Interestingly, the decreased expression of Grx1 observed after TGFβ treatment 
also occurred only after 24h (mRNA, (12)) or 72h (protein, (23)). The signaling 
intermediates and transcription factors involved in the modulation of Grx1 mRNA 
remain to be investigated. There is only a single study regarding potentially 
important transcription factor binding sites and regulatory regions in the human 
Grx1 promoter (24), which need to be evaluated in detail in future research. CSE 
and TGFβ both downregulate Grx1 mRNA expression, which for TGFβ appears to 
fit into a general repressive effect on antioxidant genes, whereas this is not the 
case for smoke. No effects of CS on Grx2 mRNA were observed, which is in line  
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Fig. 4: Overexpression of Grx1 confers partial protection against CS-induced epithelial cell death and 
smoke-induced increases in protein S-glutathionylation. A549 cells were transiently transfected with 
PcDNA (black bars), 0.5 -Grx1 (grey bars) or 1 µg Flag-Grx1 (white bars) and treated with CSE 
for 24h. (A) Cell death was assessed by flow cytometry using PI uptake. The percentage of analyzed 
cells that did not take up PI was expressed as % survival. (B) Protein S-glutathionylation. * p-value < 
0.05 compared to pcDNA control exposed to CSE, analyzed by ANOVA. 
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with previous studies in which only levels of Grx1 were affected, but not of Grx2 
(12). It is however possible that the activity of Grx2 is altered by smoke exposure, 
as this isoform is actived when the active site is opened up upon monomerization, 
which can be accomplished by oxidation (25). The activity assay used here 
furthermore does not distinguish between the different isoforms. Together this 
could explain why the strong effects observed on Grx1 expression and on 
recombinant Grx1 activity after CSE exposure do not translate into equally strong 
effects on total cellular Grx activity.  
In addition to the attenuated expression of Grx1 in response to CSE exposure, we 
observed elevated levels of Grx1 mRNA, protein and activity in control cells over 
time in culture. Accordingly, protein S-glutathionylation levels were also decreased 
over time in culture. Some previous reports have linked Grx1 to cell proliferation. 
For instance, the enzyme was first discovered as an alternative electron donor for 
ribonucleotide reductase in E. coli, an enzyme essential to DNA synthesis in 
proliferating cells (26). In addition, Grx1 has been shown to control actin S-
glutathionylation and its polymerization status after growth factor stimulation, which 
was postulated to play a role in the formation of signal transduction scaffolds and 
the cellular response to growth factors (27). The increased levels of Grx1 in culture 
over time could potentially be linked to proliferation as the experiments were 
performed at subconfluency and minor proliferation could still be observed using 
0.5% FBS.  
In the present study we show that CS not only attenuated Grx1 expression, but that 
the Grx1 protein itself was modified by CSE, thereby decreasing its activity (Fig. 3A 
and C and table I). It was determined that CSE exposure resulted in Grx1 adduct 
formation through both alkylation by acrolein, and carbonylation.  Acrolein is the 
most highly oxidative compound in CS and is known to irreversibly bind proteins, 
probing them for rapid proteolytic degradation (6). It is therefore plausible that 
alkylation of Grx1 leads to proteolytic degradation, a scenario that needs to be 
formally tested. Nonetheless, results from the present study demonstrate that CS 
targets Grx1 via multiple mechanisms which have implications for cell survival.  
Cysteines with a low pKa are prone to S-glutathionylation upon mild 
oxidative stress, and when S-glutathionylation occurs at a critical cysteine, this can 
modify the activity and conformation of the targeted protein. In the present study 
we demonstrated that CS exposure enhanced total levels of protein S-
glutathionylation (Fig 2B and C). Further studies are needed to investigate which 
particular proteins are targeted by S-glutathionylation. The function of proteins 
potentially involved in disease pathogenesis such as IKKβ and NF-κB, AP-1 and 
matrix metalloproteases have been shown to be affected by S-glutathionylation 
and in some instances by alterations in Grx1  levels (9, 28). Variations in Grx1 and  
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S-glutathionylation of these proteins could therefore contribute to the 
pathophysiology of COPD. 
Some of the target proteins of S-glutathionylation are known to modulate cell death 
(18), a process that has gained interest as a mechanism in the development of 
COPD (29). Here we demonstrate that modulation of Grx1 expression, in 
conjunction with alterations in protein S-glutathionylation in lung epithelial cells 
affects their survival in response to CS. So far, Grx1 has been reported to have a 
cardioprotective role and reduce ROS production after ischemia and reperfusion in 
Glrx1 transgenic mouse hearts. Conversely, Glrx1
-/-
 mice and Grx1 inhibition by 
cadmium increased infarct size and ROS production (30). In addition, lens epithelial 
cells of Glrx1
-/-
 mice exhibited increased sensitivity to oxidative stress as they had 
a reduced ability to clear H2O2 and administration of recombinant Grx1 restored 
anti-oxidant capacity (31). In the present study, we show that primary MTE cells 
isolated from Glrx1
-/-
 mice were more sensitive to CS-induced cell death compared 
to wild type controls, in association with enhanced protein S-glutathionylation. 
Conversely, overexpression of Grx1 in an epithelial cell line was found to protect 
against CS-induced cell death, while attenuating the induction of S-
glutathionylation in response to CSE. Collectively, these data indicate that the 
decreased expression of Grx1 and attenuation of Grx activity after CSE exposure 
are indeed responsible for observed increases in total protein S-glutathionylation 
and contribute to CSE-induced death of lung epithelial cells. However, additional 
studies need to be conducted to unravel the target proteins for increased S-
glutathionylation that contribute to cell death after CS. Mediators of apoptosis and 
cell death shown to be modulated by the S-glutathionylation / Grx1 axis include 
procaspase-3 (32), multiple members of the NF-κB survival pathway (33), ASK1 
(34) and Fas (18).  
Taken together, there is increasing evidence for Grx1 as a potentially 
therapeutically relevant candidate for enhancing cell survival upon CS exposure. A 
previous study showed a similar protective effect using recombinant Thioredoxin-1, 
another member of the thioredoxin family, in the CS exposure model for COPD in 
mice (35). Restoring Grx1 content in the lungs after exposure to CS may therefore 
have implications in enhancing cell survival and therefore potentially help to 
prevent the development of emphysema.  
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Fig. 5: Increased smoke-induced cell death and protein S-glutathionylation in MTE cells from Glrx1
-/-
 
mice. MTE cells isolated from wild type (black bars) or Glrx1
-/-
 mice (gray bars) were treated with CSE 
for 24h. (A) Cell death was assessed by flow cytometry using PI uptake. (B) Protein S-glutathionylation. 
* p-value < 0.05 compared to cells from litter mate controls exposed to CSE, analyzed by ANOVA. 
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Abstract  
 
Cigarette smoke causes irreversible oxidations in lungs, but its impact on 
reversible and physiologically relevant redox-dependent protein modifications 
remains to be investigated.  
Here the effect of cigarette smoke exposure in mice was investigated on the 
covalent binding of glutathione to protein thiols, known as S-glutathionylation 
(PSSG), which can be reversed by glutaredoxins (Grx). Also, protein S-
nitrosylation (PSNO) which is the modification of protein thiols by NO and which is 
reversed by the enzyme alcohol dehydrogenase (ADH) 5 was examined. 
Both PSSG and PSNO levels in lung tissue were markedly decreased after four 
weeks of cigarette smoke exposure. This coincided with attenuated protein free 
thiol levels and increased protein carbonylation. The mRNA expression of oxidant 
generating enzyme NOX4, DHE sensitive oxidant production and iNOS mRNA and 
protein levels were induced by cigarette smoke, whereas Grx 1 mRNA expression 
and activity were attenuated. Free GSH levels were unaffected by smoke exposure 
and no alterations in protein expression or activity of ADH5 were observed.  
Taken together, smoke exposure decreases reversible cysteine oxidations PSSG 
and PSNO, and enhances protein carbonylation. These alterations are not 
associated with differences in some of the regulatory enzymes, but are likely the 
result of oxidative stress. It remains to be investigated which specific proteins are 
differentially modified, to what extent their function is affected and if this contributes 
to pathology. 
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Introduction 
 
1.3 billion people worldwide smoke tobacco, exposing themselves directly 
to a mixture of over 4000 hazardous chemicals and oxidative compounds 
associated with various pulmonary and cardiovascular diseases. Cigarette smoking 
is the most important risk factor for chronic obstructive pulmonary disease (COPD), 
which is characterized by chronic bronchitis and emphysema. Oxidative stress is 
an important hallmark of COPD, which is defined by an accumulation of oxidants 
that outweighs the anti-oxidant protective system present in the lung. Free radicals, 
reactive oxygen (ROS) and nitrogen (RNS) species are directly produced during 
cigarette smoking and their release is induced upon activation and infiltration of 
phagocytes into the lungs.  
Cellular damage by free radicals and oxidants includes lipid peroxidation 
(1), DNA damage (2) and irreversible protein oxidations (3, 4), which have been 
demonstrated in patients with COPD and in cigarette smoke exposed mice and are 
used as oxidative stress measures (5, 6). Less well studied are mild reversible 
protein oxidations that occur on specific cysteine residues and that have been 
shown to modulate protein function in a regulatable fashion. These oxidations that 
are therefore considered posttranslational modifications have furthermore been 
shown to protect against damaging, irreversible oxidations. In oxidative stress 
mediated diseases such as COPD these reversible oxidations could therefore play 
a very important role, through their protective as well as modulating effects. It 
should be noted that the modulating effects are not always protective and that a 
loss of these redox-dependent posttranslational modifications that are considered 
protective from the chemical perspective could actual not be beneficial with respect 
to altered protein function.  
The two most studied protein oxidations linked to protective redox signaling 
are S-nitrosylation and S-glutathionylation. S-nitrosylation is the attachment of NO 
to the thiol group of cysteine amino acids in proteins. Chemically, the thiol group 
needs to be oxidized first or NO needs to be activated to NO
+
 for protein S-
nitrosylation to occur. Alternatively, the NO group can be transferred between 
proteins or delivered by glutathione (GSH). S-nitrosylation can be reversed by non 
enzymatic pathways such as by metal ions, ascorbic acid and light. The major 
enzyme related to denitrosylation is alcohol dehydrogenase 5 (ADH5) which is also 
referred to as nitrosoglutathione (GSNO) reductase (7, 8).  
GSH serves to protect the reduced state of protein thiol groups by either directly 
scavenging oxidants or alternatively by covalently and reversibly binding to protein 
thiols. The latter formation of mixed disulfides occurs under physiological 
conditions, can be induced upon mild oxidative stress and is known as S-
glutathionylation. Under physiological conditions, S-glutathionylation can be 
reduced by glutaredoxins (Grx). Several mammalian Grx have been identified. 
Grx1 localizes primarily to the cytosol while Grx2 is present in the mitochondria and 
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nucleus (9). Recently, Grx3 has gained interest for its altered expression in lung 
cancer, although this isoform does not exhibit deglutathionylation activity (10). 
There is major overlap between the proteins targeted by S-nitrosylation and S-
glutathionylation. This is not surprising since S-nitrosylation can be considered an 
intermediate oxidation that can precede S-glutathionylation. Examples of target 
proteins whose function is altered by these oxidations include the transcription 
factors NF-κB and AP-1 and some of their regulatory enzymes (11-15), MMP9 (16, 
17) and caspase 3 (18, 19). 
Redox signaling can thus be manifested trough S-nitrosylation and S-
glutathionylation in a highly specific and regulated manner. Potential alterations in 
these posttranslational modifications and functional consequences should 
therefore be considered in addition to damaging oxidations in oxidative stress 
mediated diseases. In this paper, we thus investigated S-nitrosylation and S-
glutathionylation in mice exposed to cigarette smoke. It was hypothesized that 
smoke exposure would lead to a switch from protective to damaging oxidations, 
possibly through alterations in regulatory enzymes.   
 
Materials and methods 
 
Animals and smoke exposure 
Eight week old male C57BL/6 mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME, USA). They received food and water ad libitum and were 
exposed to cigarette smoke as described previously (20). Briefly, a group of 7 mice 
were exposed whole body to the tobacco smoke of five cigarettes (Cigarette 3R4F, 
without filter, University of Kentucky, Lexington, KY) four times a day with 30-min 
smoke-free intervals, 5 days a week for 4 weeks, leading to a serum level of 
carboxyhemoglobin of 8.3 ± 1.4%, which is similar to the level observed in 
smokers. The control group was exposed to air. The local Ethics Committee for 
animal experimentation of the Faculty of Medicine and Health Sciences of Ghent 
University approved the in vivo manipulations. 
 
Grx1 catalyzed cysteine derivatization for in situ detection of S-Glutathionylated 
proteins 
Frozen tissue sections were thawed and washed twice with PBS before being fixed 
with 4% paraformaldehyde (PFA) for 10 minutes at RT. After three washes with 
PBS slides were permeabilized and free thiol groups
 
were blocked using 25 mM 
Hepes, pH 7.4, 0.1 mM EDTA, pH 8.0, 0.01 mM neocuproine (Sigma),
 
40 mM N-
ethylmaleimide (Sigma) and 1% Triton (Sigma) for
 
30 minutes. After three washes 
with PBS, S-glutathionylated cysteine groups were reduced by incubation
 
with 13.5 
µg/ml human Grx1 (Lab Frontiers), 35 µg/ml
 
GSSG reductase (Roche), 1 mM GSH 
(Sigma), 1 mM NADPH
 
(Sigma), 18 µmol EDTA and 137 mM Tris,
 
pH 8.0, for 20 
minutes. As a control GSH was left out of this mix. After three washes with PBS, 
newly reduced
 
cysteine residues were labelled with 1 mM N-(3-
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maleimidylpropionyl)
 
biocytin (MPB) (Roche) for 1 hour, after which excess MPB 
was removed by
 
three washes with PBS. Next, tissue was incubated with
 
0.5 µg/ml 
streptavidin-conjugated Alexa Fluor 568 for
 
30 minutes and nuclei were stained 
using 0.5 µg/ml DAPI Blue. Tissue was mounted, coverslipped and analyzed
 
by 
fluorescent microscopy using a Nikon Eclipse E800 microscope.
 
All conditions 
were scanned using identical instrument settings
 
that did not result in saturation of 
pixel intensities.  
 
Quantitative determination of S-Glutathionylated proteins and free GSH using 5,5’-
dithio-bis(2-nitrobenzoic acid) (DTNB) 
Lungs were lysed in 137 mM Tris-HCl, pH 8.0, 130 mM NaCl, and
 
1% NP-40 and 
cleared by centrifugation. A portion of the lysate was used to determine free GSH 
and 200 μg of protein was acetone precipitated for 20 minutes at -20°C. Pellets 
were resuspended and sonicated in 200 μl of ice-cold extraction buffer containing 
0.2 % Triton-X 100 and 0.6 % sulfosalicyclic acid in 0.1 M potassium phosphate 
buffer with 5mM EDTA disodium salt (KPE), pH 7.5. After 2 freeze-thaw cycles, 
samples were centrifuged at 3000xg for 4 min at 4°C. To remove glutathione 
(GSH) from proteins, the pellet was treated with 100 μl of 1% NaBH4 and 
neutralized with 40 μl of 30% metaphosphoric acid. Samples were centrifuged at 
1000xg for 15 min and the GSH content in the supernatant was determined using 
the DTNB GSSG reductase recycling method (21). To this end 20 μl of KPE, GSH 
standards and samples were pipetted into a 96-well microtiter plate and freshly 
prepared, equal volumes of DTNB and GSSG reductase were added in the dark. 
After 30 seconds, β-NADPH was added to start the conversion of DTNB to TNB 
and the absorbance at 412 nm was read every 30 seconds for 2 minutes. A 
standard curve was performed using a concentration range of GSH. NaBH4 was 
omitted for each sample, as a negative control. 
 
Visualisation of S-glutathionylated proteins using GSH IP and Coommassie blue 
staining 
S-Glutathionylated proteins were immunoprecipitated from lung lysates using a 
GSH antibody (Virogen) as reported previously (22). After SDS-PAGE separation, 
proteins were visualized by Coommassie blue staining of the gel. As a loading 
control, a GAPDH Western blot was performed on pre-IP lysates. 
 
In situ detection of S-nitrosylated proteins 
The procedure was identical to the visualization of PSSG, except that S-
nitrosothiols were reduced using 1 mM vitamin C. Vitamin C was omitted for each 
tissue section, as a negative control (23). 
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Figure 1: Decreased levels of reversible cysteine oxidations PSSG and PSNO in lung tissue of smoke 
exposed mice. Protein S-glutathionylation (PSSG) in lung tissue of control and smoke exposed mice 
was assessed biochemically using DTNB (A), by immunoprecipitation of S-glutathionylated proteins 
using a GSH antibody and SDS-PAGE combined with Coommassie blue staining and control Western 
blot on pre-IP samples using a GAPDH antibody (B)  or visualized using Grx1 catalyzed cysteine 
derivatization in red, nuclei in blue (C). As a negative control, GSH was omitted from the reduction mix 
(-GSH). Protein S-nitrosylation (PSNO) was visualized in lung tissue of control and smoke exposed 
mice using chemical derivatization in red, nuclei in blue (D). Vitamin C was omitted as a negative control 
(-vitC). 
 
Measurement of free thiols in tissue lysate 
Lungs were lysed as described above and 12mM DTNB was added to 100 μg of 
protein lysate. Free thiols groups were measured at 405 nm and GSH was used as 
a standard (24). 
 
Oxyblot 
Lung protein carbonyls were derivatized using an oxyblot kit (Millipore). 
Carbonylation was visualized on an SDS-PAGE gel using the DNP antibody.  
 
DHE staining 
Oxidant production was visualized by incubating frozen sections for 5 min with 5 
µM dihydroethidium (DHE). After washing sections with PBS, nuclei were 
counterstained with DAPI, tissue mounted, coverslipped and analyzed
 
by 
fluorescent microscopy using a Nikon Eclipse E800 microscope. Semi-quanititative 
assessment of the intensity of DHE reactivity in bronchial epithelium and 
parenchymal regions was conducted by evaluating mean red fluorescence intensity 
(DHE) in each region of interest and divided by the mean blue fluorescence 
intenstiy (nuclear DAPI staining) present in the same region using Image J 
software. Mean relative fluoresence intensity (RFI) values and SEM were obtained 
by evaluating images obtained from 7 different animals in each group. 
 
Grx1 activity assay 
Lungs were lysed in 137 mM Tris-HCl, pH 8.0, 130 mM NaCl, and
 
1% NP-40. 
Lysates were cleared by centrifugation and 100 μg of protein was incubated with 
reaction buffer (137
 
mM Tris-HCl, pH 8.0, 0.5 mM glutathione, 1.2 U glutathione 
disulfide
 
reductase (Roche), 0.35 mM NADPH, 1.5 mM EDTA, pH 8.0, and 2.5
 
mM 
cysteine-SO3). Consumption of NAPDH was followed
 
spectrophotometrically over 
10 minutes at 340 nm. The specific enzymatic reaction rate was obtained by 
subtracting the enzymatic rate omitting the substrate cysteine-SO3 from the 
enzymatic rate including the substrate in the reaction mixture (25). 
 
Alcohol dehydrogenase 5 (ADH5) activity assay 
Lungs were lysed as described above and NADH and freshly prepared GSNO 
were added at a final concentration of 100μM to 100 μg of protein. NADH 
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consumption was measured for 2 minutes at 340 nm (8). The non specific NADH 
consumption obtained in the absence of the substrate GSNO was subtracted for 
each sample.  
 
Quantitative Polymerase Chain Reaction 
Total RNA was isolated from lungs using the RNeasy Mini kit (QIAGEN,
 
California, 
USA) and an equal amount was reverse transcribed into cDNA using the Reverse-
iT
 
1st strand Synthesis Kit (Abgene, Epsom, UK). Primers for mouse HPRT (FW: 
TGGATATGCCCTTGACTATAATGAGTAC; REV: 
AGGACTCCTCGTATTTGCAGATTC), Grx1 (FW:TTTACAACAGCTCACCGGAG; 
REV:TCACTGCATCCGCCTATG), Grx2 (FW:AAATCTTCTTGGCCATGGAA; 
REV:AACAGCACATCGTCGTTTTG), non-phagocytic NADPH oxidase 4 (NOX4, 
FW: TGTTGGGCCTAGGATTGTGTT; REV:AGGGACCTTCTGTGATCCTCCT) 
and iNOS (FW: GCAGCTACTGGGTCAAAGACA; REV 
TCTCTGCCTATCCGTCTCGT) were used. PCR reactions were performed on an 
iCycler iQ Real-Time PCR
 
system (BioRad, Hercules, California, USA) using 
SYBRgreen (BioRad). Relative mRNA expression of genes was calculated using 
the standard curve method. 
 
Western Blot 
Lung lysates were loaded onto a 10% polyacrylamide gel and transferred onto a 
nitrocellulose membrane. The membrane was blocked at RT for 1h in 5% BSA or 
milk in Tris-buffered Saline (TBS) containing 0.05% Tween 20 (TBST). After two 
washes in TBST, the membrane was incubated overnight at 4°C with primary 
antibody against ADH5 (Abnova, Heidelberg, Germany), GAPDH (Cell Signaling) 
and iNOS (Millipore). After three washes, peroxidase-conjugated secondary 
antibody was incubated for 1h at RT. After three washes with TBST, conjugated 
peroxidase was detected by chemiluminescence using the Pierce ECL Western 
Blotting Substrate (Thermo Scientific, Rockford, IL, USA). 
 
Statistical analysis 
Data were analyzed by the Mann-Whitney U test (SPSS 17). Data were expressed 
as mean values ± SEM. Differences were considered significant when p< 0.05, 
indicated by * symbol.  
 
Results 
 
Decreased PSSG and PSNO after smoke exposure in mice 
We first investigated the reversible cysteine oxidations S-glutathionylation and S-
nitrosylation in mice exposed to cigarette smoke for 4 weeks. Using the 
biochemical determination of glutathione bound to proteins we found that cigarette  
 
 
54 
 
Figure 2
F
re
e
 t
h
io
ls
 (
m
M
 G
S
H
/m
g
 p
ro
te
in
)
0
5
10
15
20
25
Air Smoke
*
Figure 3
Air Smoke   -DNPH
A
0
5
10
15
20
25
30
Air Smoke
P
ro
te
in
 c
a
rb
o
n
y
la
ti
o
n
 (
A
U
)
*
B
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Decreased levels of protein free thiol groups in lung tissue of smoke exposed mice. Protein 
free thiol levels were assessed in lung tissue of control and smoke exposed mice using DTNB.  
 
smoke exposure significantly decreased protein S-glutationylation in lung tissue 
(Fig. 1A). Also, using an immunological approach performing an 
immunoprecipitation of S-glutathionylated proteins, we found that this trend was 
observed for most all targeted proteins as visualized on the Coommassie stained 
gel in Fig. 1B. Lastly, this finding was corroborated using Grx1 catalysed 
derivatisation which demonstrated that this decrease occurred in airways as well 
as in the alveolar compartment (Fig. 1C). When we visualized protein S-
nitrosylation, an attenuation of this oxidation was also observed, in airways as well 
as alveolar regions (Fig. 1D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Increased protein carbonylation in lung tissue of smoke exposed mice. Protein carbonylation 
in lung tissue was examined from air and smoke exposed mice by oxyblot. As a control, DNPH 
derivatization was omitted from the procedure in a smoke exposed lung sample (-DNPH). Quantification 
on the right in arbitrary units (AU). 
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Increased carbonylation, DHE sensitive oxidant production and expression of 
NOX4 and iNOS  
We next asked whether the loss of these reversible modifications was associated 
with chemical or enzymatic reduction to free thiols. As expected however, results in 
Fig. 2 show that cigarette smoke exposure causes a decrease in protein free thiol 
levels. Since free thiol levels are decreased after smoke exposure and also PSSG 
and PSNO are attenuated, protein thiols are likely in an overoxidized state. With 
respect to overoxidation, cigarette smoke exposure has been shown to lead to 
protein carbonylation which can also target cysteine amino acids. Fig. 3A indeed 
demonstrates that protein carbonylation is enhanced in lungs of mice exposed to 
cigarette smoke. A minimal signal was detected when the derivatization solution 
was omitted in a smoke-exposed lung lysate as a negative control. The mRNA 
expression of the superoxide generating enzyme NOX4 was found to be enhanced 
by smoke exposure and also DHE sensitive oxidant production in lung tissue of 
mice exposed to smoke was increased (Fig. 4B and C).  Cigarette smoke exposure 
was furthermore found to increase the mRNA as well as protein expression of 
iNOS (Fig 4D and E). 
 
Regulatory enzymes Grx and ADH5 
Both PSSG and PSNO are reversible oxidations, for which the reverse reactions 
are catalyzed by specific enzymes. The attenuation of both modifications could 
thus be due to increased expression and/or activity of these enzymes. The 
expression of glutaredoxin 1, which catalyses deglutathionylation under 
physiological conditions, was however found to be decreased. The mRNA levels of 
the other isoform, glutaredoxin 2 were unaffected (Fig. 5A). When assessing total 
lung Grx activity this was found to be significantly decreased in lung tissue of 
smoke exposed mice (Fig. 4B). Since protein S-glutathionylation levels and Grx 
activity can also be affected by GSH levels, these were also assessed. Results in 
Fig. 5C demonstrate however, that free GSH levels in lung tissue were not affected 
by smoke exposure. GSSG levels could not be determined as they were found to 
be below the detection limit of the assay. With respect to PSNO, the protein levels 
as well as activity of ADH5 were not affected by cigarette smoke exposure (Fig. 6A 
and B). 
 
Discussion 
 
In this paper, we show a decrease in reversible cysteine oxidations S-
glutathionylation and S-nitrosylation in lungs of mice exposed to cigarette smoke 
for 4 weeks, in conjunction with an increase in irreversible protein carbonylation. 
With respect to irreversible protein oxidations, cigarette smoke extract in vitro has 
been reported to increase carbonylation of proteins in alveolar macrophages in a 
concentration and time dependent manner (26). Examples of specific proteins 
targeted by irreversible post-translational modifications induced by smoke include 
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Figure 4: Increased NOX4 expression and oxidant production and increased iNOS expression in lung 
tissue of smoke exposed mice. (A) mRNA levels of NOX4 in lung tissue of air and smoke exposed mice, 
using HPRT as a reference gene. (B) Oxidant production in situ visualized using DHE in red and nuclei 
counterstained using DAPI in blue. As a negative control, DHE was omitted. (C) The mean red 
fluorescence intensity in each region of interest was divided by the mean blue fluorescence intensity 
present in the same region to obtain mean relative fluoresence intensity (RFI) values. 
(D)  iNOS mRNA levels in lung tissue of air and smoke exposed mice, using HPRT as a reference gene. 
(E) iNOS protein levels by Western blotting of lung tissue of mice exposed to air or cigarette smoke. 
GAPDH was used as a loading control. Quantification in bottom panel. AU: arbitrary units.  
 
Sirtuin 1, for which adducts with 4-Hydroxy-2-nonenol and nitration of tyrosine 
residues have been demonstrated (27) and Grx1 which was shown to contain 
acrolein and carbonyl adducts (28). Furthermore, plasma protein carbonylation was 
increased in smokers and COPD patients (29), indicating that irreversible oxidation 
of proteins is increased upon smoking. Fewer reports can be found on effects of 
cigarette smoke on reversible protein oxidations. We previously revealed increased 
protein S-glutathionylation in lung epithelial cells upon exposure to cigarette smoke 
extract, together with decreased expression and activity of Grx1 (28). In this study 
however, we report that, although Grx1 expression and total Grx activity are 
decreased in lung tissue of smoke exposed mice, a significant decrease in protein 
S-glutathionylation was measured following four weeks exposure. These 
alterations in PSSG levels moreover likely did not arise from differences in free 
GSH levels as these were unaffected by smoke exposure as shown in Fig 5C. 
These data are in contrast with a paper by Chung et al that reported increased 
protein S-glutathionylation in the lungs of mice exposed to smoke for 3 days (30). 
Grx1 levels were decreased in this acute model, as in our sub-acute study. The 
primary difference in experimental protocols is the duration of exposure. S-
glutathionylation is induced by relatively mild oxidative stress which is in agreement 
with our published in vitro findings and the 3 day exposure in mice. A further 
increase in oxidative stress by prolonged exposure to smoke could however lead to 
the reaching of a tipping point that results in depletion of protein S-glutathionylation 
to increase free GSH levels to combat oxidative stress, leaving protein thiols 
vulnerable to overoxidation. This hypothesis is also in line with the gradation of 
oxidative cysteine modifications outlined in (7). 
 
Enhanced nitrosative stress has been reported in patients with COPD by 
measurement of elevated nitrosothiols and NO in exhaled breath condensate (31) 
and NO derivatives in sputum (32).  To our knowledge, we are the first to report on 
the influence of cigarette smoke exposure on protein S-nitrosylation in lung tissue. 
We observed a significant decrease in S-nitrosylation in situ following smoke 
exposure for four weeks, in the bronchial and alveolar compartment. This appears 
to be in contrast with the reported increased levels of nitrosothiols in exhaled 
breath condensate of COPD patients. In asthma however, nitrosothiols are also 
exhaled in higher levels compared to healthy controls, whereas pulmonary levels 
are decreased (8, 31, 33). As nitrosothiols and nitrosoglutathione in   
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Figure 5: Decreased expression and activity of glutaredoxin, no alterations in free GSH levels in lung 
tissue of smoke exposed mice. (A) mRNA levels of Grx1 (black bars) and Grx2 (white bars) in lung 
tissue of air and smoke exposed mice, using HPRT as a reference gene. (B) Total lung Grx activity in 
air and smoke exposed mice, expressed as µmol NADPH per minute and per mg protein. (C) Free GSH 
levels in lung tissue of air and smoke exposed mice, expressed as µmol per mg protein. 
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particular represent an important pool of NO activity and nitrosoglutathione acts as 
a potent bronchodilator (33), this depletion of nitrosothiols could have important 
pathophysiological consequences in COPD as well. A major difference is the fact 
that in asthma the enzyme AHD5 appears to be responsible for the decreased 
levels of nitrosothiols (8, 34), whereas at least in this subacute exposure model, 
cigarette smoke does not appear to influence ADH5 expression or activity.  
 
ROS in cigarette smoke are reported to deplete free thiols in alveolar epithelial 
cells in vitro (24). In this manuscript we extend these findings to show that cigarette 
smoke has a similar effect in mouse lungs as well. The levels of free thiols and 
reversible cysteine oxidations in the lungs after four weeks of cigarette smoke 
exposure appear to be declined in favor of irreversible oxidations. This was indeed 
measured in the form of enhanced protein carbonylation in lungs of smoke 
compared to air exposed mice. Carbonylation result from direct reactions of 
acrolein or aldehydes present in cigarette smoke or of secondary formation of 
carbonyl species. It occurs on cysteine, lysine, arginine, proline and threonine 
amino acids (35), and carbonylation is therefore not specific for thiol oxidation. 
Although protein carbonylation is typically regarded as an irreversible oxidation, 
there is some evidence that a detoxification system could exist (36). Since Grx1 
levels and total Grx activity were decreased and ADH5 levels and activity remained 
unaltered, the switch from reversible oxidations to carbonylation is likely due to 
oxidative stress per se. Next to oxidative stress from smoke itself, DHE sensitive 
oxidant production and the expression of the oxidant producing enzymes NOX4 
and iNOS were found to be increased in the lungs of smoke exposed mice. NOX4 
is an NAPDH oxidase that generates superoxide in non-phagocytic cells. It has 
been shown to be induced by TGFβ 
responses to this growth factor. This is the first report on the increased expression 
of this enzyme in response to cigarette smoke exposure. 
 
Irreversible oxidations can cause protein degradation through proteasomal 
targeting by ubiquitination or damaged proteins can accumulate. Cigarette smoke 
can on the other hand also induce protein ubiquitination such as in Akt (37) and 
HDAC2 (38) and in lungs of COPD patients, an accumulation of ubiquitinated 
proteins in conjunction with oxidative stress and aberrant proteasomal degradation 
have recently been shown and were hypothesized to contribute to the development 
of emphysema (39). Reversible oxidations on the other hand, are known to protect 
proteins from further irreversible oxidations, and they can regulate protein function 
due to the highly conserved and functionally important nature of the cysteine 
residues they target. Mediators of cell death and inflammation including 
procaspase-3 (18), multiple members of the NF-κB survival pathway (reviewed in 
(9)), ASK1 (40) and Fas (41), have been shown to be regulated by S-
glutathionylation and S-nitrosylation, as were matrixmetalloproteases (16). 
Inhibition has been shown for caspase 3, as well as NF-κB, whereas the Fas  
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Figure 6: ADH5 protein and activity levels in lung tissue are unaffected by smoke exposure in mice. (A) 
ADH5 protein levels by Western blotting of lung tissue of mice exposed to air or cigarette smoke. 
GAPDH was used as a loading control. AU: arbitrary units. (B) ADH5 activity in lung tissue of mice 
exposed to air or cigarette smoke, expressed as µmol NADH per minute and per mg protein. 
 
 
pathway and MMP9 have been shown to be activated by these redox 
modifications. Given the impact of S-glutathionylation and S-nitrosylation on these 
important regulatory pathways and the insight we provide in this manuscript 
regarding decreases of these reversible oxidations, further study is needed to 
elucidate the overall impact of reported changes in cysteine oxidations in the 
development of cigarette smoke induced lung disease. In addition, restoration of 
these reversible oxidations might be a more promising therapeutic strategy over 
the use of general antioxidants that have been tested to date. 
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Abstract  
 
Glutaredoxins (Grx) are redox enzymes that remove glutathione bound to protein 
thiols, know as S-glutathionylation (PSSG). PSSG is a reservoir of GSH and can 
affect the function of proteins. It inhibits the NF-κB pathway and LPS aspiration in 
Grx1 KO mice decreased inflammatory cytokine levels. In this study we 
investigated whether absence of Grx1 similarly repressed cigarette smoke-induced 
inflammation in an exposure model in mice.  
Cigarette smoke exposure for 4 weeks decreased lung PSSG levels, but increased 
PSSG in lavaged cells and lavage fluid (BALF). Grx1 KO mice had increased 
levels of PSSG in lung tissue, BALF and BAL cells in response to smoke compared 
to wt mice. Importantly levels of multiple inflammatory mediators in the BALF were 
decreased in Grx1 KO animals following cigarette smoke exposure compared to wt 
mice, as were levels of neutrophils, dendritic cells and lymphocytes. Macrophage 
numbers on the other hand were higher in Grx1 KO mice in response to smoke. 
Although cigarette smoke in vivo caused inverse effects in inflammatory and 
resident cells with respect to PSSG, primary macrophages and epithelial cells 
cultured from Grx1 KO mice both produced less KC compared to cells isolated 
from WT mice after smoke extract exposure.  
In this manuscript, we provide evidence that Grx1 has an important role in 
regulating cigarette smoke induced lung inflammation which seems to diverge from 
its effects on total PSSG. Secondly, these data expose the differential effect of 
cigarette smoke on PSSG in inflammatory versus resident lung cells. 
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Introduction 
 
The lung continuously encounters oxidants from inhalation and is therefore 
well equipped with a high concentration of the antioxidant glutathione (GSH). GSH 
acts as an electron donor and is used by glutathione peroxidase to reduce 
peroxides, resulting in oxidized glutathione (GSSG) (1). Cigarette smoke is known 
to acutely deplete GSH, for instance by directly reacting with GSH to form non-
reducible glutathione-aldehyde derivatives (2), thereby decreasing the lungs’ anti-
oxidant capacity and making it vulnerable to oxidant-induced injury. On the other 
hand, as an adaptive response to oxidative stress, such as upon chronic smoking, 
levels of GSH increase in the epithelial lining fluid due to upregulation of the rate 
limiting enzyme in GSH synthesis, γ-glutamylcysteine ligase (3).  
Besides being oxidized itself, glutathione can in conditions of mild oxidative 
stress, also bind to cysteine residues in proteins. This posttranslational 
modification is known as S-glutathionylation and protects proteins from irreversible 
oxidations.  Glutaredoxins (Grx) or thioltransferases are redox enzymes that, under 
physiological conditions, can reverse S-glutathionylation. S-glutathionylation does 
not only protect the targeted protein thiol groups from further irreversible 
oxidations, but also has been shown to modulate protein function when the 
targeted cysteine residue is critical to its function (4). Examples include mediators 
of cell death and inflammation such as procaspase-3 (5), multiple members of the 
NF-κB pathway (reviewed in (6)), and matrix metalloproteases (7). Inhibition has 
been shown for caspase 3, as well as NF-κB, whereas MMP9 has been shown to 
be activated by this redox modification. Therefore glutaredoxins play an important 
role in redox-modulated protein function by regulating S-glutathionylation. Several 
mammalian Grxs have been identified. Grx1 localizes primarily to the cytosol and 
Grx2 is present in the mitochondria and nucleus (8). 
In many pulmonary diseases, including COPD, the importance of 
glutathione homeostasis is described (3), whereas S-glutathionylation and Grxs 
have hardly been investigated. Grx1 expression in the lungs has been found to be 
predominantly localized in macrophages and bronchial epithelium. In a mouse 
model of allergic airway disease and after acute exposure to LPS Grx1 expression 
was increased (9-11). In patients with COPD on the other hand, Grx1 was 
decreased and specifically the number of Grx1 positive macrophages was found to 
be positively correlated with lung function (10). In line with these clinical findings, 
we have previously reported that cigarette smoke extract downregulated Grx1 
levels, which was associated with increased protein S-glutathionylation in lung 
epithelial cells.  Moreover, primary epithelial cells from Grx1 knock out mice were 
more prone to smoke-induced cell death and displayed higher levels of protein S-
glutathionylation compared to controls (12). In vivo on the other hand, we found 
smoke exposure to decrease protein S-glutathionylation, while also decreasing 
Grx1 levels and total Grx activity (13).  
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Targeted S-glutathionylation is described to inhibit multiple members of the 
pro-inflammatory NF-κB pathway, including IKKα, IKKβ and Rel A (14, 15). We 
have previously described that LPS exposure in the context of ablation of Grx1 
failed to activate NF-κB and decreased inflammatory cytokine levels (11). In the 
current study we set out to investigate whether absence of Grx1 similarly represses 
cigarette smoke-induced inflammation in a subacute exposure model in mice. 
Rather than focusing on individual NF-κB members, we investigated the differential 
inflammatory response of mouse lungs as well as primary epithelial cells and 
macrophages to cigarette smoke. 
 
Material and methods 
 
Mice and primary cell culture 
Male Grx1
-/-
 mice, a kind gift of Dr. Ho (Wayne State University, Detroit, MI), and 
WT C57BL/6 controls (n =10 per group) were exposed to cigarette smoke for four 
weeks as described previously (16). Briefly, mice were exposed whole body to the 
tobacco smoke of 5 Reference Cigarettes 3R4F without filter (University of 
Kentucky, Lexington, KY) four times a day with 30 min smoke-free intervals, 5 days 
a week for 4 weeks. During the exposure an optimal smoke to air ratio of 1:6 was 
obtained. The control groups were exposed to room air. Additional unexposed mice 
were used to isolate primary tracheal epithelial cells (MTE) as described previously 
(17) with minor modifications (18) and pulmonary macrophages by saline lavage. 
Cells were cultured in full medium lacking phenol red for 24h prior to stimulation. 
The local ethics committee for animal experimentation of the faculty of medicine 
and health sciences (Ghent University, Belgium) granted approval for all in vivo 
procedures. 
 
Bronchoalveolar lavage (BAL) 
5 days after the last exposure mice were euthanized with an overdose of 
pentobarbital and a cannula was inserted into the trachea. Three times 300 µl 
HBSS, free of Ca
2+
 and Mg
2+
 and supplemented with 1% BSA, followed by 3 times 
1 ml HBSS supplemented with 0.05 mM EDTA, was instilled through the cannula 
and recovered by gentle aspiration. All lavage fractions were pooled, centrifuged 
and the cell pellet washed twice and resuspended in 1 ml HBSS. Total and 
differential cell counts were performed in a Bürker chamber and cytocentrifuged 
preparations stained with May-Grünwald-Giemsa respectively. Flow cytometric 
analysis of BAL cells was performed as described previously to enumerate 
dendritic cells, macrophages, neutrophils and T-lymphocyte subsets (19). 
 
Lung tissue processing and cell counts 
After rinsing of the pulmonary and systemic circulation, the left lung was used for 
histology by intratracheal infusion of 4% PFA and embedding in paraffin. Single cell 
suspensions were prepared from the right lung by mincing thoroughly, digesting 
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and RBC lysis. Cell counts were performed with a Beckman Coulter counter and 
flow cytometric analysis was performed as described previously to enumerate 
dendritic cells, macrophages, neutrophils and T-lymphocyte subsets (19). The 
other part of the right lung was snap frozen in liquid nitrogen for biochemical 
assessments.  
 
Cigarette smoke extract 
3R4F Research Cigarettes, from the University of Kentucky (Lexington, KT, USA), 
were removed from their filters and cigarette smoke extract (CSE) was made fresh 
before every experiment according to (20). 
 
Quantitative determination of S-Glutathionylated proteins using 5,5’-dithio-bis(2-
nitrobenzoic acid) (dTNB) 
200 μl of BAL fluid or 200 μg of lung protein homogenate was acetone precipitated 
for 20 minutes at -20°C and spun down for 5 minutes at 3000xg. Pellets were next 
resuspended and sonicated in 200 μl of ice-cold extraction buffer containing 0.2 % 
Triton-X 100 and 0.6 % sulfosalicyclic acid in 0.1 M potassium phosphate buffer 
with 5mM EDTA disodium salt (KPE), pH 7.5. After 2 freeze-thaw cycles, samples 
were centrifuged at 3000xg for 4 min at 4°C. To remove glutathione (GSH) from 
proteins, the pellet was treated with 100 μl of 1% NaBH4 in water and neutralized 
with 40 μl of 30% metaphosphoric acid. Samples were centrifuged at 1000xg for 15 
min and the supernatant was used to determine the GSH content using the dTNB 
GSSG reductase recycling method (21). 20 μl of KPE, GSH standards and 
samples were pipetted into a 96-well microtiter plate and freshly prepared, equal 
volumes of dTNB and GSSG reductase were added in the dark. After 30 seconds, 
β-NADPH was added to start the conversion of dTNB to TNB and the absorbance 
at 412 nm was read every 30 seconds for 2 minutes. A standard curve was 
performed using a concentration range of GSH. NaBH4 was omitted for each 
sample, as a negative control. Values were corrected for protein content and data 
are expressed as nmol GSH per milligram of protein. 
 
Grx1 catalyzed cysteine derivatization for in situ detection of S-glutathionylated 
proteins 
Frozen cytospins were thawed and washed twice with PBS before being fixed with 
4% paraformaldehyde (PFA) for 10 minutes at RT. After three washes with PBS 
slides were permeabilized and free thiol groups
 
were blocked using a buffer 
containing 25 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
 
acid, pH 7.4, 
0.1 mmol/L EDTA, pH 8.0, 0.01 mmol/L neocuproine,
 
40 mmol/L N-ethylmaleimide 
(Sigma) and 1% Triton (Sigma) for
 
30 minutes to an hour. After three washes with 
PBS, S-glutathionylated cysteine groups were reduced by incubation
 
with 13.5 
µg/ml human Grx1 (Lab Frontiers), 35 µg/ml
 
GSSG reductase (Roche), 1 mmol/L 
GSH (Sigma), 1 mmol/L NADPH
 
(Sigma), 18 µmol EDTA and 137 mmol/L Tris · 
HCl,
 
pH 8.0, for 20 minutes. As a control GSH was left out of this mix. After three 
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 Figure 1: BAL fluid cell counts and differentials in wild type versus Grx1 KO mice exposed to air and 
smoke. Total BAL fluid cells (A), total numbers of macrophages (B), neutrophils (C), dendritic cells (D), 
CD3+ cells (F), CD4+ cells (G) and CD8+ cells (H) in BAL fluid represented as mean ± SD. * represents 
p<0.05 between air and smoke exposed mice, # represents p<0.05 between WT smoke and KO smoke. 
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washes with PBS, newly reduced
 
cysteine residues were labelled with 1 mmol/L N-
(3-maleimidylpropionyl)
 
biocytin (MPB) (Roche) for 1 hour, after which excess MPB 
was removed by
 
three washes with PBS. Next, cells were incubated with
 
0.5 µg/ml 
streptavidin-conjugated Alexa Fluor 568 for
 
30 minutes. Nuclei were stained using 
0.5 µg/ml DAPI Blue. Cells were then mounted, coverslipped and analyzed
 
by 
fluorescent microscopy using a Nikon Eclipse E800 microscope. All conditions 
were scanned using identical instrument settings
 
that did not result in saturation of 
pixel intensities. Semi-quanititative assessment of the staining intensity was 
conducted by dividing mean red fluorescence intensity (PSSG staining) by the 
mean blue fluorescence intensity (nuclear DAPI staining) using Image J software. 
Mean relative fluorescence intensity (RFI) values and SEM were thus obtained.   
 
Grx1 staining  
Macrophages were fixed with 4% PFA for 10 min at RT. After permeabilization and 
blocking non-specific binding sites using 0.1%triton, 1% BSA in PBS, primary 
antibody against Grx1 (Imco) was incubated for 1 h followed by Alexa fluor 488 
labelled secondary anti-goat antibody for 1h. Nuclei were counterstained with DAPI 
and cells were coverslipped. Semi-quanititative assessment of the staining 
intensity was conducted by dividing mean green fluorescence intensity (Grx1 
staining) by the mean blue fluorescence intenstiy (nuclear DAPI staining) using 
Image J software. Mean relative fluoresence intensity (RFI) values and SEM were 
thus obtained.   
 
Multiplex for cytokine measurement 
To quantify concentrations of 23 cytokines and chemokines in BALF we used a 
Bio-Plex mouse cytokine 23-plex Panel (IL-1a, IL-1β, IL-2, IL-3, IL-4, IL-5. IL-6, KC, 
IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN- γ, 
MCP-1(MCAF), MIP-1α, MIP-1β, RANTES and TNF-α). Assays were performed as 
described by the manufacturer’s instructions. The analysis was done with a 
Luminex 100 IS 2.3 system using the Bio-Plex Manager 4.1.1. software. 
 
KC ELISA 
KC levels in cell culture medium were measured using a commercially available 
ELISA kit (R&D systems, Inc. Minneapolis, USA) according to the manufacturer’s 
instructions.  
 
QPCR 
Total RNA was isolated from lungs or cells using the RNeasy Mini kit (QIAGEN,
 
California, USA) and an equal amount was reverse transcribed into cDNA using 
the Reverse-iT
 
1st strand Synthesis Kit (Abgene, Epsom, UK). Primers for human 
HPRT (FW:AGAATGTCTTGATTGTGGAAGA; 
REV:ACCTTGACCATCTTTGGATTA), Grx1 (FW:TTTACAACAGCTCACCGGAG; 
REV:TCACTGCATCCGCCTATG) and KC (Fw: CACTGCACCCAAACCGAAG; 
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 Figure 2: Lung tissue differential cell counts in wild type versus Grx1 KO mice exposed to air or smoke. 
Total lung cells (A), total numbers of lung macrophages (B), dendritic cells (C), CD3+ cells (D), CD4+ 
CD69+ cells (E) CD8+ CD69+ cells (F) and GR1 cells (G), represented as mean ± SD. * represents 
p<0.05 between air and smoke exposed mice. 
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REV: TCAGGGTCAAGGCAAGCC) were used. PCR reactions were performed on 
an iCycler iQ Real-Time PCR
 
system (BioRad, Hercules, California, USA) using the 
SYBRgreen dye
 
(BioRad). Relative mRNA expression of genes was calculated 
using the standard curve method. 
 
Statistical analyses 
Between-group comparisons were analyzed using the Kruskal-Wallis test, followed 
by Mann-Whitney U test (SPSS 17). Unless indicated otherwise, data are 
expressed as mean and standard deviation. A p-value <0.05 was considered 
statistically significant. 
 
Results 
 
BAL fluid cell counts and differentials in wild type versus Grx1 KO mice exposed to 
air and smoke 
When analyzing lavaged cells, the total number of BALF cells was found to be 
significantly elevated in wild type and Grx1 KO mice due to cigarette smoke 
compared to respective air exposed controls. The level of increase in total cell 
numbers in the BALF did not differ between the two mouse strains (Figure 1A). 
Macrophage cell counts in BALF also increased with cigarette smoke compared to 
respective air exposed controls, but significantly more so in Grx1 KO mice than in 
WT (Figure 1B). The smoke-induced increase in the number of neutrophils, 
dendritic cells, CD8+, CD4+ and CD3+ cells on the other hand was significantly 
dampened in Grx1 KO compared to WT mice (Figure 1 C-G). 
 
Lung tissue differential cell counts in wild type versus Grx1 KO mice exposed to air 
or smoke 
Next, we investigated total and differential cell numbers in lung tissue of the wild 
type and Grx1 KO mice. Figure 2A shows that there is no significant difference in 
total cell numbers of the lung tissue between the Grx1 KO and wild type mice, 
under basal conditions and after exposure to cigarette smoke.  
Although the numbers of macrophages tended to be higher in lung tissue of Grx1 
KO mice compared to wild type controls, this was not statistically significant (Figure 
2B). In addition, the numbers of lung dendritic cells (Figure 2C), lung CD3+ cells 
(Figure 2D), lung CD8+CD69+ (Figure 2F) and GR1+ cells (Figure 2G) were not 
affected by smoke exposure in the WT animals, or in the Grx1 KO mice. The 
numbers of lung CD4+CD69+ cells on the other hand was significantly increased in 
wild type mice exposed to cigarette smoke. This increase was however not present 
in the Grx1 KO mice after cigarette smoke exposure (Figure 2E).  
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Figure 3: BAL fluid cytokines in wild type versus Grx1 KO mice exposed to air and cigarette smoke. 
Measurement of cytokines in the BAL fluid by multiplex:  IL 12 (A), GCSF (B), MCP1 (C), KC (D), 
RANTES (E) and MIP1α (F) expressed in pg/ml and represented as mean ± SD. * represents p<0.05 
between air and smoke exposed mice, # represents p<0.05 between WT smoke and KO smoke and $ 
represents p<0.05 between WT air and Grx1 KO air. 
 
BAL fluid cytokines in wild type versus Grx1 KO mice exposed to air and cigarette 
smoke 
We next assessed a broad panel of inflammatory mediators in BALF in order to 
determine a cause for the diminished influx of inflammatory cells into the lungs of 
Grx1 mice after smoke exposure. While analyzing the inflammatory mediators 
measured in the BAL fluid of wild type versus Grx1 KO mice, the general 
observation was that these are decreased in Grx1 KO mice after exposure to 
cigarette smoke compared to wild type controls exposed to cigarette smoke (Figure 
3). Specifically, cigarette smoke exposure significantly increased the BALF  
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Figure 4: S-glutathionylation in lungs and BAL fluid cells and BAL fluid of Grx1 KO compared to wild 
type mice exposed to cigarette smoke and air. S-glutathionylation of proteins quantified by the DTNB 
assay in lung tissue of Grx1 KO compared to wild type mice exposed to cigarette smoke and air, data 
shown in nmol GSH/mg protein and represented as mean ± SD (A). S-glutathionylation of proteins 
visualised by the biotin switch staining in BAL fluid cells of Grx1 KO compared to wild type mice 
exposed to cigarette smoke and air, the outer right panel shows the quantification of staining expressed 
as relative fluorescent intensity of red staining (S-glutathionylated proteins) compared to blue, nuclear 
DAPI staining and represented as mean ± SD (B). S-glutathionylation of proteins quantified by the 
DTNB assay in BAL fluid of Grx1 KO compared to wild type mice exposed to cigarette smoke and air, 
data shown in nmol GSH/μg protein and represented as mean ± SD (C). * represents p<0.05 between 
air and smoke exposed mice, # represents p<0.05 between WT smoke and KO smoke. 
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concentration of IL12(p40), GCSF, MCP-1, KC, RANTES and MIP-1alpha in wild 
type mice. In the Grx1 KO, the cigarette smoke-induced upregulation of these 
cytokines was significantly impaired, compared to the wild type controls. Moreover, 
the baseline levels of IL12(p40), GCSF, RANTES, MIP-1a, TNFα (data not shown) 
and IFNγ (data not shown) were found to be lower in the BAL fluid of Grx1 KO 
mice compared to wild type mice.   
 
S-glutathionylation in lungs and BAL fluid cells of Grx1 KO compared to wild type 
mice exposed to cigarette smoke and air 
Since the major function of Grx1 is to catalyze deglutathionylation under 
physiological conditions, we next investigated the levels of total protein S-
glutathionylation in lung tissue. As demonstrated in Figure 4A, exposure to 
cigarette smoke for four weeks lead to a significant decrease in S-glutathionylation 
of proteins in the lung tissue of wild type mice as reported previously. In the Grx1 
KO mice, the smoke-induced decrease in protein S-glutathionylation did not reach 
statistical significance, but the levels observed after smoke exposure were 
significantly elevated compared to those in the wild type mice exposed to smoke. 
The levels of free GSH were decreased after smoke exposure as well, but no 
differences were observed between Grx1 KO and wild type mice (data not shown). 
When previously visualizing protein S-glutathionylation in whole lung tissue, we 
noted that this was not decreased in inflammatory cells after smoke exposure (13). 
We therefore analyzed protein S-glutathionylation in cells obtained by BAL using 
the biotin-switch approach and found that protein S-glutathionylation in these BAL 
fluid cells of mice exposed to smoke was increased compared to BAL fluid cells 
from air exposed mice. Moreover, S-glutathionylation in BAL fluid cells of Grx1 KO 
mice was higher after cigarette smoke exposure than in the wild type controls 
(Figure 4B-C). As expected, most of the cells in the cytospins had the 
morphological characteristics of macrophages. In cell free BALF, similar trends 
were observed with increased protein S-glutathionylation after smoke exposure 
and heightened levels in Grx1 KO mice compared to wt controls (Fig. 4D). At 
baseline, no differences were observed between WT and Grx1 KO mice.  
 
Grx expression in lung tissue and macrophages of mice exposed to cigarette 
smoke  
We have previously shown that exposure of pulmonary epithelial cells to cigarette 
smoke extract (CSE) leads to decreased expression of Grx1 mRNA and protein. In 
Figure 5A we first confirmed these data in lung tissue of smoke exposed mice. 
Indeed, Grx1, but not Grx2 (data not shown) mRNA levels are significantly 
decreased after four weeks of cigarette smoke exposure compared to air exposed 
controls in wild type mice. Given the differential response of structural and 
inflammatory cells to smoke with respect to protein S-glutathionylation, we also  
assessed the effects of CSE on Grx expression in primary macrophages isolated  
76 
 
Figure 5
A
B
C
0
0.2
0.4
0.6
0.8
1
1.2
Air Smoke
R
e
la
ti
v
e
 G
rx
1
 m
R
N
A
 
e
x
p
re
s
s
io
n
 i
n
 l
u
n
g
 t
is
s
u
e
 
*
Control                        0.5% CSE
*
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Control 0.5% CSE
R
F
I 
G
rx
1
 S
ta
in
in
g
 
Figure 5: Grx1 expression in lung tissue and primary macrophages of mice exposed to cigarette smoke. 
(A) Grx1 mRNA expression corrected for HPRT mRNA expression in lung tissue of mice exposed to air 
and cigarette smoke, represented as mean ± SD. (B) Fluorescent Grx1 staining in primary 
macrophages after 24 hours of control or 0.5% cigarette smoke extract exposure. The green staining 
represents Grx1 protein expression, whereas blue represents the nuclear DAPI staining. Quantification 
of fluorescent Grx1 staining is expressed as RFI in (C). 
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from mice by fluorescent staining for Grx1 (represented in figure 5B and C) and 
confirm that smoke exposure also represses Grx1 protein levels in these cells. 
 
KC in primary macrophages versus primary epithelial cells from wild type and Grx1 
KO mice after exposure to cigarette smoke extract 
Protein S-glutathionylation appears thus to be differentially regulated in structural 
and inflammatory cells after smoke exposure, albeit independently from Grx1. We 
therefore asked whether this would differentially impact inflammatory mediator 
production in these cell types in response to cigarette smoke, given that we have 
previously shown that the Grx1-PSSG axis is important in determining the extent of 
NF-κB activation and the levels of cytokines and chemokines such as KC in 
response to pro-inflammatory stimuli. When performing an ELISA for KC on culture 
supernatants of macrophages isolated from wild type mice, we found a significant 
increase in KC after exposure to CSE. In contrast, the Grx1 KO macrophages 
displayed decreased KC concentrations in their medium after exposure to CSE 
(Figure 6A). Also in MTECs the production of this chemokine was increased by 
cigarette smoke from both WT and Grx1 KO mice. Moreover, this response to CSE 
was significantly decreased in the Grx1 KO MTECs compared to the cells from wild 
types (Figure 6B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: KC in primary macrophages versus primary epithelial cells from wild type and Grx1 KO mice 
after cigarette smoke extract exposure. KC in medium of primary macrophages (B) and of mouse 
tracheal epithelial cells (D) from wild type and Grx1 KO mice exposed to air or 0.1% cigarette smoke 
extract for 24 hours expressed in pg/ml. 
78 
 
Discussion 
 
It is becoming increasingly clear that GSH and its associated enzymes and the 
redox state of cells in general do not only play a role in protection against oxidative 
stress and damage, but also determine the outcome of discrete receptor-induced 
ROS-mediated signaling events involved in immune responses. Specifically shown 
here is that Grx1 and PSSG are key modulators of the in vivo response to cigarette 
smoke. Although there was no difference in the total amount of BAL fluid and lung 
cells between wild type and Grx1 KO mice after smoke exposure, the pattern of 
inflammatory cells found in the BAL fluid was different. The Grx1 KO mice actually 
accumulate macrophages in the BAL fluid after 4 weeks of cigarette smoke 
exposure, while in contrast to the wild type mice the increase of neutrophils, 
dendritic cells and CD3+, CD4+ and CD8+ T-cells was significantly impaired. This 
altered pattern of inflammatory cells in the BALF was mirrored by significant 
differences in the levels of chemokines and cytokines. After four weeks of cigarette 
smoke exposure the BALF of Grx1 KO mice contained significantly less KC, 
RANTES, MCP-1, IL12, GCSF and MIP1α compared to the wild type controls 
exposed to the same amount and duration of cigarette smoke. The decreased 
levels of inflammatory mediators in the BAL fluid of Grx1 KO mice can be caused 
by the diminished levels of inflammatory cells other than macrophages. On the 
other hand, it could be attributed to the immaturity of these macrophages as we 
reported previously that alveolar macrophages isolated from Grx1 KO mice are 
smaller, express lower levels of the hematopoietic cell specific transcription factor 
PU.1 and displayed decreased phagocytosis capacity in vitro compared to alveolar 
macrophages from wild type animals (11). Also, LPS-induced NF-κB activation and 
inflammatory mediator production were found to be attenuated in the Grx1 KO 
macrophages as well as primary tracheal epithelial cells.  
 
The Grx1 KO mice have been used by others to investigate the role of Grx1 in 
cigarette smoke induced lung inflammation. This study however employed a three 
day smoke exposure protocol and showed a much different outcome compared to 
the results obtained here. After a three day exposure regimen, the number of 
neutrophils were reported to be elevated in the Grx1 KO mice, in conjunction with 
increased levels of KC and MCP-1 compared to wild type controls (15). The main 
difference between studies is the length of exposure and might indicate that the 
role of Grx1 is opposite in an acute versus a more chronic exposure to cigarette 
smoke. This is also supported by the early increase in KC levels observed after 
LPS exposure in the Grx1 KO mice, compared to the attenuation of other 
mediators at more protracted time points (11). Not only the role of Grx1 in smoke-
induced inflammation was found to be different, but in our model smoke exposure 
was found to decrease protein S-glutathionylation compared to the increase 
observed in the acute three day model of cigarette smoke exposure. We did not 
observe a difference in basal level of protein S-glutathionylation between WT and 
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Grx1 KO mice, but smoke failed to affect PSSG in Grx1 KO mice.  The level of 
PSSG in the lungs of Grx1 KO mice was significantly higher after smoke compared 
to the wild type animals. The differential response in S-glutathionylation of proteins 
in the two models might thus be involved in the discrepancies found in lung 
inflammation between acute and chronic smoke exposure. It has been reported by 
our laboratory that upon oxidative stress, targeted S-glutathionylation of IKKβ 
inhibits its activity and thus inhibits Rel A nuclear translocation. Binding of NF-κB to 
its consensus sequence has also been shown to be negatively affected by S-
glutathionylation (14). Secondly, we have previously shown that Grx1 KO mice and 
primary epithelial cells isolated from these mice, show a markedly diminished 
response to LPS with respect to NF-κB activation and inflammatory mediator 
production (11).  Since the Grx1 KO mice have more overall S-glutathionylation in 
the lung and in the BAL cells after smoke exposure, this might, through the 
inhibition of nuclear Rel A translocation, contribute to the decreased inflammatory 
cytokine production observed in the Grx1 KO mice after four weeks of cigarette 
smoke exposure, compared to wild type mice. So it is likely that the differential 
response in PSSG levels in the acute versus the more chronic cigarette smoke 
exposure causes the difference in phenotype in the mouse lung. 
 
When we assessed PSSG in lavaged cells and fluid from smoke compared to air 
exposed mice, we found increased S-glutathionylation of proteins in contrast to the 
observed decrease in whole lung tissue. In lung tissue, S-glutathionylation was 
decreased despite a decrease in Grx1 mRNA expression. When we isolated 
primary macrophages from mice and exposed them to cigarette smoke extract, 
there was a decrease in Grx1 protein levels. These findings in macrophages are in 
line with our previously published data showing decreased Grx1 levels in various 
pulmonary epithelial cells after smoke exposure (12).  Together these data indicate 
that overall protein S-glutathionylation can alter independently of differences in 
Grx1 and that the patterns of S-glutathionylation depend on cell type as well as 
stimuli and duration of stimulation.  
 
It should be noted that the alteration in the overall protein S-glutathionylation 
pattern does not mean that all individually targeted proteins would be affected in 
the same direction. Although we did not investigate individual targets, in figure 6 of 
this manuscript we demonstrate that a differential effect on overall S-
glutathionylation of proteins in response to smoke observed in different cell types, 
can still result in the same outcome. In particular, we demonstrate that smoke-
induced KC production is decreased in both tracheal epithelial cells and 
macrophages isolated from Grx1 KO mice, irrespective of the effect on total protein 
S-glutathionylation.   
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Taken together, we demonstrate in this manuscript that by using a knock out 
mouse model for glutaredoxin 1, this redox mediating enzyme has an important 
role in regulating cigarette smoke induced lung inflammation.  
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Abstract 
Oxidative stress is a hallmark of COPD and alterations in glutathione levels and its 
associated enzymes are thought to contribute to the oxidant-anti-oxidant 
imbalance. Not investigated so far is the pool of glutathione bound to proteins, 
which is a sink of the important antioxidant and protects proteins against 
irreversible oxidative damage. This post-translational modification, S-
glutahionylation is reversed by the enzyme glutaredoxin. We therefore measured 
protein S-glutathionylation, glutaredoxin 1 protein levels and total glutaredoxin 
activity in sputum and lung tissue of controls and COPD patients. 
In induced sputum of patients experiencing an acute exacerbation, the level of 
glutathione bound to protein was found to be significantly decreased and Grx1 
protein as well as total Grx activity were increased compared to stable disease. No 
differences in all three parameters were found between healthy smokers and 
stable COPD patients. Glutathione bound protein levels negatively correlated with 
sputum neutrophil percentages as well as IL8 and IL1α levels and positively with 
lung function. Grx1 protein levels in contrast positively correlated with IL8 and IL1β 
and negatively with lung function. 
In lung tissue the inverse trends were observed; glutathione bound to proteins was 
increased and Grx1 protein levels and total Grx activity were decreased in stable 
patients. Grx1 positively correlated with lung function in lung tissue. 
In conclusion, this study highlights the importance of this new redox axis in COPD, 
both in stable condition and during acute exacerbations. Future research should 
examine in more detail the intricate relation with lung function and inflammation. 
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Introduction 
 
COPD, hallmarked by pulmonary inflammation and emphysema, is mainly 
caused by smoking. Cigarette smoke contains 10
16
 free radicals per cigarette [1] 
and is responsible for activation and recruitment of macrophages and neutrophils 
into the lungs. These inflammatory cells secrete more oxidants, leading to oxidative 
stress. Because of the lungs’ high risk of oxidative injury, they are equipped with a 
lining fluid containing high concentrations of glutathione (GSH)[2]. The ratio 
between GSH and its oxidized form GSSG provides information on the redox 
status of cells and tissues. Cigarette smoke acutely depletes GSH, but as an 
adaptive response to oxidative stress, such as upon chronic smoking, levels of 
GSH increase due to upregulation of the rate limiting enzyme in GSH synthesis, γ-
glutamylcysteine ligase [3]. GSH, together with its redox cycle partners serves to 
maintain the reduced state of protein thiol groups by direct scavenging of oxidants 
or by the covalent reversible binding of GSH to these protein thiols. The latter 
formation of mixed disulfides occurs under physiological conditions, is induced 
upon mild oxidative stress and is known as S-glutathionylation [4]. S-
glutathionylation also has the ability to modulate protein function. For instance, the 
kinase activity of Inhibitory kappa B kinase β (IKKβ), the enzyme responsible for 
NF-κB activation under pro-inflammatory conditions, was shown to be inhibited 
through S-glutathionylation after oxidative challenge of lung epithelial cells [5]. 
Also, DNA binding of both NF-κB and AP-1 has been shown to be inhibited by S-
glutathionylation of their respective p50 and c-jun subunits [6, 7]. 
 
Glutaredoxins (Grx) or thioltransferases are redox enzymes that reverse S-
glutathionylation of proteins under physiological conditions and are therefore  
important modulators of redox-mediated protein function [4]. Several mammalian 
Grxs have been identified. Grx1 localizes primarily to the cytosol and Grx2 is 
present in the mitochondria and nucleus. Grx3 is an isoform that does not exhibit 
deglutathionylating activity, but is reported to be altered in lung cancer [8]. 
 
With respect to COPD, the number of Grx1 positive alveolar macrophages 
was found to be decreased in patients versus healthy controls and importantly 
positively correlated with lung function. Additionally, increased levels of Grx1 were 
observed in sputum during exacerbations [9]. However, in this study Grx1 
expression was not linked to Grx activity or the level of protein S-glutathionylation. 
We recently reported that cigarette smoke exposure decreased Grx1 expression 
and modified its activity through direct oxidation of the enzyme in lung epithelial 
cells. Moreover this was shown to be associated with increased protein S-
glutathionylation and implicated the Grx1/S-glutathionylation axis in modulation of 
sensitivity to smoke-induced epithelial cell death [10].  
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Given these reports, the aim of the current study was to investigate the 
Grx1/S-glutathionylation axis in lung tissue and induced sputum of COPD patients 
compared to controls and to investigate the correlation thereof with measures of 
lung function and inflammation. 
 
Table 1: Subject demographics and lung function for sputum study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p<0.05  vs control smokers , **p<0.05 vs non-smokers 
 
Note pack years not available from 1 stable patient and 8 healthy smokers 
CS: corticosteroids; SABA: short acting beta 2 agonist; LABA: long acting beta 2 agonist 
 
 
13 14 LABA (n) 
12 11 Anticholinergic (n) 
3 2 GOLD IV 
800 (0 - 1600) 1600 (0 - 1600) Inhaled CS ( eq 
budesonide /day) 
10 10 SABA (n) 
Healthy non - 
smokers  
Control  
smokers  
Stable COPD  
patients  
COPD  
exacerbations  
Number of  
subjects 
12 12 16 13 
Age 49.8  ± 10.3 53.9  ± 10.7 58.6  ± 9.6 63.9  ± 8.8 ** 
Sex, M/F 6/6 7/5 12/4 11/2 
Smoking status  
(ex/current) 
9/3 13/3 8/5 
Pack years 19.9  ± 18.3 44.5  ± 11.1* 39.3  ± 17.2 * 
BMI 26  ± 5.1 24.8  ± 3.1 26.3  ± 4.5 28.0  ± 5.1 
FEV 1 % predicted 101.4  ± 17.6 95.5  ± 17.8 49.2  ± 14.5*,** 43.2  ± 18.4 
*,** 
FVC % predicted 105.4  ± 13.8 107.7  ± 21.2 82.6  ± 22.3*,** 69.9  ± 22.2 *,** 
FEV 1 /FVC, %  
predicted 
80.0  ± 6.2 75.6  ± 9.6 49.9  ± 9.5*,** 47.5  ± 9.8 *,** 
GOLD II 10 6 
GOLD III 4 4 
Oral CS 0 3 
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Methods 
 
Study design and subject characteristics 
We studied induced sputum obtained from 16 stable COPD patients and 14 COPD 
patients on day 1 or 2 during an acute exacerbation and compared them to 25 
healthy subjects. Demographic and functional characteristics of these subjects are 
given in Table 1. All of the COPD patients fulfilled the criteria proposed by the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines [11]. 
Stable patients did not have an upper respiratory tract infection or any 
exacerbations requiring a change in maintenance treatment or oral corticosteroid 
and antibiotic prescription for at least 12 weeks prior to the study. Four patients 
with an exacerbation were recruited from consultations and 9 were hospitalized 
patients, admitted at the service of pneumology of CHU of Liège.  Acute 
exacerbation of COPD is defined as an event in the natural course of
 
the disease 
characterized by a change in the patient's baseline
 
dyspnoea, cough and/or 
sputum that is beyond normal day-to-day variations, is acute in onset, and may 
warrant a change in regular medication. These patients were treated according to 
good clinical practice. Control subjects never had asthma or chronic bronchitis, nor 
had they experienced any bronchial or respiratory tract infection during the 8 
weeks preceding the study. Their pulmonary function was within the normal range.  
Human lung tissue was obtained from 20 stable COPD patients and 8 control 
subjects. 10 patients with GOLD stage 4 COPD were admitted to the pulmonary 
rehabilitation centre CIRO Horn, Horn, the Netherlands before undergoing lung 
volume reduction surgery (LVRS). Lung tissue was also obtained from 10 GOLD 2 
patients and control subjects with normal lung function who underwent a lobectomy 
or pneumectomy for lung cancer at the University Hospital Maastricht. 
Demographic and functional characteristics of these subjects are given in Table 5. 
Tissue was snap frozen in liquid nitrogen for biochemical analyses. The study was 
approved by the medical ethical committees of the University Hospital Maastricht. 
All subjects gave their informed consent in writing. 
 
Sputum induction and processing 
Sputum was induced by inhalation of hypertonic saline (NaCl 5%) when FEV1 post-
salbutamol was ≥65% predicted and isotonic saline (NaCl 0.9%) when FEV1 was 
<65% predicted. The whole sputum was collected in a plastic container, weighed, 
and homogenized by adding three volumes of phosphate-buffered saline, vortexed 
for 30 s, and centrifuged at 800 g for 10 min at 4°C. Supernatant was separated 
from cell pellet, in which squamous cells, total cell counts, and cell viability were 
checked by trypan blue exclusion. The differential cell count was performed on 
cytospins stained with Diff-Quick after counting 400 cells.  
Grx activity assay 
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100 μl of sputum or 100 μg protein of lung homogenate in 100 μl of lysis buffer 
(137 mM Tris-HCl, pH 8.0, 130 mM NaCl, and
 
1% NP-4) was incubated with an 
equal volume of reaction buffer (137
 
mM Tris-HCl, pH 8.0, 0.5 mM glutathione, 1.2 
U glutathione disulfide
 
reductase (Roche), 0.35 mM NADPH, 1.5 mM EDTA, pH 
8.0, and 2.5
 
mM cysteine-SO3). Consumption of NAPDH was followed
 
spectrophotometrically over 10 minutes at 340 nm. The specific enzymatic reaction 
rate was obtained by subtracting the enzymatic rate omitting the substrate 
cysteine-SO3 from the enzymatic rate including the substrate in the reaction 
mixture. Data are expressed as µmol NADPH/minute for induced sputum and as 
µmol NADPH/minute/mg protein for lung homogenates
 
 [12]. 
 
Western Blotting for Grx1  
Laemmli sample buffer containing DTT was added to 25 μl of sputum or, to 25 μg 
of lung homogenate and boiled for 10 minutes. Samples were loaded onto a 16,5% 
polyacrylamide gel and transferred onto a nitrocellulose membrane. The 
membrane was blocked at RT for 1h in 5% BSA in Tris-buffered Saline (TBS) 
containing 0.05% Tween 20 (TBST). After two washes in TBST, the membrane 
was incubated overnight at 4°C with primary antibody against Grx1 (Imco). After 
three washes, peroxidase-conjugated secondary antibody was incubated for 1h at 
RT. After three washes with TBST, conjugated peroxidase was detected by 
chemiluminescence using the Pierce ECL Western Blotting Substrate (Thermo 
Scientific, Rockford, IL, USA). Quantification of films was done using a Biorad 
scanner and was expressed as arbitrary units relative to diluted human Grx1 
recombinant standard (Labfrontier) on each gel for the induced sputum samples 
and as arbitrary units compared to GAPDH protein levels on the same blot for lung 
homogenates. 
 
Table 2: Correlations between the Grx1-PSSG axis in induced sputum and lung 
function in COPD from the whole group of subjects 
 
All subjects PSSG Grx activity  Grx1 protein 
FEV1% predicted 0.372 (0.007) n.s. -0.336 (0.015) 
FVC% predicted 0.372 (0.008) n.s. -0.436 (0.001) 
FEV1/FVC% predicted 0.336 (0.016) n.s. -0.273 (0.051) 
 
R (p-value) 
n.s. non significant 
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Figure 1: The Grx1-PSSG axis in induced sputum of healthy non-smokers, control smokers, stable 
COPD patients and COPD exacerbators. (A) Level of protein S-glutathionylation (PSSG) in induced 
sputum expressed as nmol GSH released per mg protein and represented as mean ± SD. (B) Total Grx 
activity in induced sputum expresssed as mol NADPH per minute and represented as mean ± SD. (C) 
Grx1 protein level in induced sputum assessed by Western blot. Data are expressed in arbitrary units 
(AU) where Grx1 levels were corrected for a sample of recombinant human Grx1 on each gel and 
represented as mean ± SD. The insert is a representative Western blot. * represents p < 0.05 vs stable 
COPD and ** represents p < 0.05 vs healthy non-smokers. 
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Quantitative determination of S-Glutathionylated proteins using 5,5’-dithio-bis(2-
nitrobenzoic acid) (dTNB) 
200 μl of sputum or 200 μg of lung homogenate was acetone precipitated for 20 
minutes at -20°C and spun down for 5 minutes at high speed. Pellets were next 
resuspended and sonicated in 200 μl of ice-cold extraction buffer containing 0.2 % 
Triton-X 100 and 0.6 % sulfosalicyclic acid in 0.1 M potassium phosphate buffer 
with 5 mM EDTA disodium salt (KPE), pH 7.5. After 2 freeze-thaw cycles, samples 
were centrifuged at 3000xg for 4 min at 4°C. To remove glutathione (GSH) from 
proteins, the pellet was treated with 100 μl of 1% NaBH4 in water and neutralized 
with 40 μl of 30% metaphosphoric acid. Samples were centrifuged at 1000xg for 15 
min and the supernatant was used to determine the GSH content using the dTNB 
GSSG reductase recycling method [13]. 20 μl of KPE, GSH standards and samples 
were pipetted into a 96-well microtiter plate and freshly prepared, equal volumes of 
dTNB and GSSG reductase were added in the dark. After 30 seconds, β-NADPH 
was added to start the conversion of dTNB to TNB and the absorbance at 412 nm 
was read every 30 seconds for 2 minutes. A standard curve was performed using a 
concentration range of GSH. NaBH4 was omitted for each sample, as a negative 
control. Values were corrected for protein content and data is expressed as nmol 
GSH per milligram of protein. 
 
Luminex analyses 
27 cytokines and chemokines in sputum supernatants were quantified using a Bio-
Plex human cytokine 27-plex Panel according to the manufacturer’s instructions. 
The analysis was done with a Luminex 100 IS 2.3 system using the Bio-Plex 
Manager 4.1.1. software. 
 
Statistical analyses 
SPSS (version 15) was used for data analyses. Unless indicated otherwise, data 
are expressed as mean and standard deviation. Between-group comparisons were 
analyzed using the Kruskal-Wallis test, followed by the Mann-Whitney U test. 
Correlations between variables were determined using Spearman’s rho. A p-value 
<0.05 was considered statistically significant. 
 
 
Results 
 
The Grx1-PSSG axis in induced sputum samples  
Healthy smokers and non-smokers, stable COPD patients and patients with an 
exacerbation were well matched for age and BMI (Table 1).  Patients had smoked 
more pack years compared to controls and were significantly older compared to 
healthy non-smokers. As expected, COPD patients exhibited poorer lung function 
compared to healthy non smokers and healthy smokers.  
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Table 3 : Sputum cell differentials and inflammatory cytokines 
 
  Healthy non- smokers Control smokers Stable COPD COPD 
Exacerbation 
Total cells 0.4 (0.05-1.74) 0.4 (0.07-3.60) 0.98 (0.04-35.00) 6 (1.14-83.4)*** 
%macrophages 60 (13-96) 28.7               (14-74.8) 11.3 (0.4-77.5) 8.4  (0-32) 
%neutrophils 17.8 (0-84)            55.5               (7.6-75.8) 82.05 (3-95)** 83.5 (25.5-99.5) 
%epithelial cells 5.4 (1.75-67) 
 
7.3                 (1.2-66.2) 4.8 (0-59) 3.2 (0-31) 
%eosinophils 0 (0-3.2) 0 (0-5.8) 
 
1.8 (0-5) 0.75 (0-23.3) 
%lymphocytes 1.8 (0-3.4) 1.6 (0-10) 0.5 (0-3) 1.62 (0-6.3) 
%squamous cells 33.1 (6-78.4) 32.5 (2-72.7) 28 (0-68) 7 (0-35)*** 
%viable cells 59 (27.3-80.6) 64.5 (22.2-88) 52.0 (0.97-81) 79 (45-99)*** 
IL1β 1.18 (0.43-8.58) 1.4 (0.43-2.37) 1.34 (0.41-31.24) 3.3 (0.64-602.6)*** 
IL8 25.7 (7.32-131.6) 74.7 (15.51-243.9) 186.7 (12.06-3989) 237 (60.1-1990) 
IL10 0.88 (0.23-1.59) 1.6 (0.67-2.74)* 0.91 (0.35-2.91) 2.01 (0.63-4.2)*** 
IL12 3.99 (1.06-7.22) 6.3 (4.48-16.33)* 1.51 (0.76-7.07)** 6.8 (2.52-14.99)*** 
 
Median (range), pg/ml for inflammatory cytokines 
* p<0.05 smokers vs non-smokers, ** p<0.05 stable COPD vs smokers, *** p<0.05 exacerbation vs 
stable COPD 
 
PSSG levels in induced sputum were not different between the healthy smokers 
and non-smokers, and also not between stable COPD patients and healthy 
smokers. However, PSSG levels in induced sputum of COPD patients 
experiencing an acute exacerbation were significantly decreased compared to 
stable patients (Fig. 1A). Total Grx activity in sputum was increased in healthy 
smokers compared to non-smokers and also in COPD patients with an 
exacerbation compared to stable patients (Fig.1B). There was also no significant 
difference in sputum Grx activity between healthy smokers and stable patients. The 
observed alterations in total Grx activity were reflected by altered Grx1 protein 
levels in induced sputum, where an increase in Grx1 protein was observed in 
healthy smokers compared to non-smokers and in COPD patients with an 
exacerbation compared to stable COPD (Fig. 1C). Again, the Grx1 protein level 
was not different between healthy smokers and stable patients. Interestingly, in all 
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COPD patients with an exacerbation an extra band was observed below that of 
Grx1 which could indicate a degradation product (Fig 1C, insert).   
Importantly, in agreement with the function of Grx to remove GSH from proteins, 
negative correlations were observed between PSSG and Grx1 protein levels (Fig. 
2A), and between PSSG and total Grx activity (Fig. 2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Correlations between Grx and PSSG. Negative correlations between PSSG and the Grx1 
protein level (A) and total Grx activity (B) in induced sputum in the whole study group.  
 
Correlations between the Grx1-PSSG axis in induced sputum and lung function  
When assessing the relations between the Grx1-PSSG axis and lung function 
parameters, we found PSSG levels positively correlated with FEV1, FVC, and 
FEV1/FVC in all subjects (Table 2). Grx1 protein levels on the other hand were 
negatively correlated with FVC and FEV1/FVC. No significant correlations were 
found for Grx activity. 
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Correlations between the Grx1-PSSG axis in induced sputum and age and pack 
years smoked  
We next assessed the possible relations between the Grx1-PSSG axis and age 
and pack years smoked. PSSG levels were negatively correlated with pack years 
smoked (r=-0.344, p=0.018), as well as with age (r=-0.570, p<0.001), whereas a 
positive correlation was observed between pack years smoked and Grx activity 
(r=0.365, p=0.015), and Grx1 protein levels (r=0.298, p=0.039). Lastly, Grx1 
protein levels were also found to be positively correlated with age (r=0.401, 
p=0.003).  
 
Sputum cell counts, inflammatory cytokines and their relation with the Grx1-PSSG 
axis 
Minor significant differences were observed in cell profiles in induced sputum 
between groups, likely due to the large variability (Table 3). A positive correlation 
was however observed between sputum PSSG levels and the percentage of 
macrophages, epithelial and squamous cells in the whole study group. Moreover, 
the percentage of neutrophils and viable cells negatively correlated with PSSG in 
the whole study group. These correlations remained significant when considering 
stable patients alone (Table 4). Grx1 protein negatively correlated with squamous 
cells in the whole study group and in stable patients. On the other hand, Grx1 
positively correlated with the percentage of viable cells in the whole study group. 
Grx activity was not found to correlate with sputum cells. 
 
With respect to inflammatory mediators, only the reported molecules showed 
significant differences between groups (Table 3). IL8 was increased and IL12 
decreased in stable patients compared to healthy smokers, although the difference 
in IL8 levels failed to reach statistical significance due to a large variability. In 
COPD patients with an acute disease exacerbation, increased levels of IL10, IL12 
and IL1β were found compared to patients with stable disease. IL10 and IL12 
levels were also increased in healthy smokers compared to non-smokers. 
Grx1 protein levels were significantly and positively correlated with IL1α
p=0.003), IL8 (r=0.427, p=0.009), IL10 (r=0.349, p=0.043) and IL12 (r=0.363, 
p=0.032) in the whole study group. PSSG levels on the other hand negatively 
correlated with IL1β (r=-0.484, p=0.003) and IL8 (r=-0.475, p=0.003). 
 
The Grx1-PSSG axis in lung homogenates  
Control subjects and COPD patients in which the Grx1-PSSG axis was assessed 
in lung tissue were well matched for age, gender and BMI. Patients had smoked 
more pack years compared to controls and exhibited poorer lung function (Table 
5). 
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Table 4: Correlations between the Grx-PSSG axis in induced sputum and sputum 
cell counts in COPD 
    All subjects Stable COPD COPD 
Exacerbation 
PSSG %macrophages 0.535 (<0.001) 0.733 (0.001) n.s. 
  %neutrophils -0.534  (<0.001) -0.709 (0.002) n.s. 
  %epithelial cells 
 
%eosinophils 
0.446 (0.002) 
 
n.s. 
0.699 (0.003) 
 
n.s. 
n.s. 
 
n.s. 
 
  %lymphocytes n.s. n.s. n.s. 
  %squamous cells 0.383 (0.006) n.s. n.s. 
  %viable cells -0.395 (0.005) n.s. n.s. 
  total cells -0.643 (<0.001) -0.652 (0.006) n.s. 
Grx1 %macrophages n.s. n.s. n.s. 
  %neutrophils 0.286 (0.052) n.s. n.s. 
  %epithelial cells 
 
%eosinophils 
n.s. 
 
n.s. 
n.s. 
 
n.s. 
n.s. 
 
n.s. 
  %lymphocytes n.s. n.s. n.s. 
  %squamous cells -0.400 (0.004) -0.603 (0.013) n.s. 
  %viable cells 0.380 (0.006) n.s. n.s. 
  total cells 0.543 (<0.001) 0.570 (0.021) n.s. 
r (p-value) 
n.s. non significant 
 
In contrast to the sputum findings, pulmonary PSSG levels were significantly 
increased in COPD patients compared to controls (Fig. 3A). No significant 
difference was observed when assessing GOLD 2 and GOLD 4 patients 
separately. Grx activity on the other hand was decreased in COPD patients 
compared to controls, as well as in GOLD 4 patients compared to controls (Fig 3B). 
Accordingly, Grx1 protein levels were also decreased significantly in all patients 
compared to controls, as well as in GOLD 2 and GOLD 4 patients separately. Grx1 
levels in GOLD 4 patients however, were significantly higher compared to Grx1 
levels in GOLD 2 patients (Fig. 3C). 
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Table 5: Subject demographics and lung function for lung tissue study 
 
  controls COPD patients 
Number of subjects 8 20 
Age 62.1 ± 6.9 61.0 ± 10.5 
Sex, M/F 5/3 12/8 
Pack years 16.9 ± 17.0 34.2 ± 17.2* 
BMI (kg/m
2
) 26.1 ± 3.1 25.5 ± 4.7 
FEV1 % predicted 113.0 ± 17.6 45.3 ± 24.1* 
FVC % predicted 112.8 ± 19.1 83.5 ± 15.8* 
FEV1/FVC, % predicted 81.1 ± 4.5 41.9 ± 18.3* 
GOLD II-IV   10/10 
 
*represents p<0.05 vs healthy controls 
 
Table 6: Correlations between the Grx1-PSSG axis in lung homogenates and lung 
function and age in COPD from the whole group of subjects 
 
All subjects PSSG Grx activity  Grx1 protein 
FEV1% predicted n.s. 0.438 (0.02) 0.388 (0.041) 
FVC% predicted n.s. 0.430 (0.022) n.s. 
FEV1/FVC% predicted n.s. 0.407 (0.032) 0.398 (0.036) 
Age n.s.  n.s. -0.389 (0.045) 
 
r (p-value) 
n.s. non significant 
 
Correlations between the Grx1-PSSG axis in lung homogenates and age and lung 
function  
In contrast to the findings in sputum, no correlations of PSSG with lung function 
parameters or age were found. On the other hand, Grx activity was positively 
correlated with FEV1, FVC as well as FEV1/FVC in the whole subject group. Only 
the correlation with FVC remained significant when only considering the patients 
(r=0.486, p=0.043). Grx1 protein levels were also positively correlated with FEV1 
and FEV1/FVC in the whole subject group, but not in the patients alone and 
negatively with age in the whole group (Table 6) and patients alone (r=-0.476, 
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p=0.039). No correlations with pack years smoked were found, but Grx1 levels 
were found to be higher in ex smoking COPD patients compared to currently 
smoking patients (0.81±0.48 vs 0.35±0.21 arbitrary units, respectively). Lastly, 
Grx1 protein levels positively correlated with total Grx activity in lung tissue in the 
whole study group (r= 0.421, p=0.026). 
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Figure 3: The Grx1-PSSG axis in lung tissue of control subjects and COPD patients. (A) Level of 
protein S-glutathionylation (PSSG) in lung tissue expressed as nmol GSH released per mg protein and 
represented as mean ± SD. (B) Total Grx activity in lung tissue expresssed as mol NADPH per minute 
and per mg protein, represented as mean ± SD. (C) Grx1 protein level in lung tissue assessed by 
Western blot. Data are expressed in arbitrary units (AU) where Grx1 levels were corrected for GAPDH 
and represented as mean ± SD. The insert is a representative Western blot. * represents p < 0.05 vs 
control and # represents p < 0.05 vs GOLD 2. 
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Discussion 
 
We here show decreased PSSG levels in conjunction with increased Grx1 
protein and total Grx activity in induced sputum of COPD patients experiencing an 
acute exacerbation compared to stable patients. Despite the lack of differences in 
sputum between healthy smokers and stable patients, Grx1 protein levels and total 
Grx activity were decreased in lung tissue of patients compared to controls. 
Moreover, pulmonary PSSG levels were increased.  
Data on Grx1 protein levels are fully in line with a previous publication on a 
smaller sample size  [9]. This study also found increased Grx1 protein in sputum of 
patients with an exacerbation, albeit only compared to controls and not to stable 
disease. We extend these findings here by reporting increased total Grx activity 
and decreased protein glutathionylation. Also, in healthy smokers Grx1 levels were 
increased compared to non-smokers which was mirrored by increases in total Grx 
activity. Importantly, in line with the function of Grx1 PSSG levels negatively 
correlated with GRX1 protein levels and with total Grx activity. The observed extra 
band below the expected molecular weight of Grx1, in particular in exacerbation 
sputa is intriguing and could represent a degradation product. This hypothesis 
remains to be tested, but we previously demonstrated that caspase 3 and 8 are 
able to cleave human Grx1 to a product of about 8 kDa in response to Fas ligand 
stimulation [14]. The fact that Grx1 levels positively correlated with the percentage 
of viable cells in the sputa fits the proposed non-classical export mechanism of the 
enzyme [9]. Grx1 levels were positively correlated with the pro-inflammatory 
cytokines IL1β, IL8 and IL12, but also with the anti-inflammatory cytokine IL10. It 
should be further investigated if these inflammatory mediators or triggers of 
exacerbations modulate Grx1 expression or induce its export. This seems likely 
since it was shown that aspiration of LPS in mice enhanced Grx1 protein levels 
and Grx activity in BALF [15]. On the other hand, cigarette smoke might induce 
export of Grx1 since Grx1 and Grx activity positively correlated with pack years 
smoked and both were increased in healthy smokers. Cigarette smoke extract was 
found to decrease Grx1 expression in lung epithelial cells, but we did not 
investigate levels in culture medium [10]. Another question is from which cell types 
Grx1 originates. Macrophages and epithelial cells are the most likely candidates, 
although no significant correlations with these cell proportions in sputa were 
detected. A study that examined extracellular Grx1 found that it was mostly 
detected from non-adherent cells compared to adherent cells, making the 
macrophage a likely origin of sputum Grx1 [16].  
 
In contrast to the sputum data, we observed decreased Grx1 protein levels and 
total Grx activity in lung homogenates of COPD patients compared to controls. 
These findings are in line with decreased Grx1 in lung tissue in COPD patients 
published previously [9]. No correlations with pack years smoked were observed, 
but Grx1 levels were found to be higher in COPD patients that were ex smokers 
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compared to current smokers. This finding is confounded by the fact that most ex 
smokers were GOLD 4 patients. However, we did recently report that cigarette 
smoke extract reduces Grx1 mRNA and protein expression as well as total Grx 
activity in lung epithelial cells [10]. Importantly, we also demonstrated that Grx1 
protected epithelial cells against cigarette smoke-induced cell death. It remains to 
be investigated whether decreased Grx1 levels in COPD patients are associated 
with increased death of resident cells.  
When considering Grx as an antioxidant enzyme, the lower levels in 
patients with COPD fit with the general trend of decreased levels of this class of 
enzymes which include heme oxygenase 1, NAD(P)H quinine oxidoreductase 1 
and glutamate-cysteine ligase modifier [17]. In lung tissue, Grx1 levels were also 
found to be negatively associated with age, which is in line with the oxidant theory 
of aging.  
Pulmonary Grx1 levels and total Grx activity were positively correlated with 
the lung function parameters FEV1, FVC and their ratio. In contrast, sputum Grx 
activity was negatively correlated with FVC and FEV1/FVC.  A better lung function 
seems thus associated with higher levels of Grx and activity in the lungs, but less 
in sputum. 
 
PSSG is a reservoir of GSH, which can be liberated under conditions of 
oxidative stress by Grx to increase the antioxidant potential. Data obtained in 
sputum could be interpreted as such to attempt to scavenge the high levels of ROS 
during an exacerbation by increasing extracellular Grx. The fact that PSSG levels 
are attenuated in this condition strengthens this hypothesis. However, PSSG also 
protects protein thiols from further oxidations and decreased PSSG levels could 
thus negatively affect the proteins involved, leading to irreversible damage and 
accumulation or degradation [18-20]. PSSG levels in sputum were positively 
correlated with lung function, supporting this protective function. Interestingly, 
sputum PSSG levels were also negatively associated with age, which could be 
interpreted as diminished protection in ageing. Thirdly, the function of certain 
proteins, especially ones with conserved and functionally important cysteine 
residues, is modified by the binding of GSH. Examples include mediators of cell 
death and inflammation such as procaspase-3 [21], multiple members of the NF-κB 
pathway (reviewed in [22]), and matrix metalloproteases [23]. Inhibition has been 
shown for caspase 3, and NF-κB, whereas MMP9 was shown to be activated by 
this redox modification.  
Positive correlations of sputum PSSG were found with macrophages, epithelial and 
squamous cells, indicating these cells as possible sources of extracellular GSH or 
PSSG. Epithelial cells are a known prominent source of extracellular GSH [24] and 
GSH regulation in macrophages has been shown to play a role in their functionality 
[25]. In contrast, the increased level of oxidative stress associated with neutrophils 
and dying cells [26-28] might underlie the negative association of PSSG with the 
percentage of these cells in sputum. Also, PSSG levels were negatively associated 
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with the pro-inflammatory cytokines IL1β and IL8. The relation between the Grx-
PSSG axis and inflammation is apparent from the literature and is mostly centred 
on NF-κB. In general, S-glutathionylation of IKKβ, p50 and p65 inhibits activation of 
NF-κB dependent gene transcription, which is in accordance with the observed 
negative association between PSSG and inflammation in sputum. The positive 
correlation of Grx1 with inflammatory mediators in sputum is also in line with our 
previous publications that shows that LPS-induced NF-κB activation and cigarette 
smoke induced inflammation are repressed in mice lacking Grx1 [15, 29]. In 
contrast, a 3 day exposure to cigarette smoke was found to cause exaggerated 
NF-κB activation and inflammation in Grx1 k.o. mice compared to wild type 
controls. Smoke exposure in wild type mice decreased Grx1 and increased PSSG 
levels [30]. Our data in lung tissue with respect to the Grx-PSSG axis in lung tissue 
from COPD patients confirm the effects of acute smoke exposure in vitro and in 
mice. Unfortunately, it was not possible to perform an in depth analysis of in situ 
PSSG staining or inflammation. 
In conclusion, this study highlights the importance of this new redox axis in 
COPD, both in stable condition and during acute exacerbations. Future research 
should examine in more detail the intricate relation with lung function and 
inflammation. 
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Abstract 
 
Background: Glutathione directly scavenges free radicals and protects protein 
thiols from irreversible oxidation by binding them. This post translational 
modification, S-glutathionylation (PSSG) is induced by mild oxidative stress or 
promoted by glutathione S-transferase P1 (GSTP1) and can be reversed by 
glutaredoxins (Grx). Importantly, PSSG can also alter protein function and has 
been shown to inhibit inflammation through S-glutathionylation of NF-κB pathway 
members. In lung tissue of COPD patients Grx1 levels were shown to be 
decreased.  
Methods: Since COPD can also manifest itself systemically through increased 
inflammatory mediator levels and oxidative stress, this study set out to investigate 
the levels PSSG, Grx1 and GSTP1 in plasma of 47 COPD patients versus 29 
healthy controls and associations of these parameters with lung function and 
inflammation.  
Results: PSSG was decreased in plasma of patients compared to controls and 
was positively correlated with lung function and negatively associated with the 
inflammatory markers CRP and IL-6. Also Grx1 protein levels in plasma and mRNA 
expression in blood were decreased in COPD, whereas GSTP1 protein levels and 
mRNA expression were unaltered. Total GST activity on the other hand was 
decreased in COPD patients compared to controls and was negatively associated 
with IL-6, and positively with lung function. 
Conclusions: This is the first study to report an attenuation of PSSG, Grx1 levels 
and GST activity in COPD patients, without effects on GSTP1. In addition, 
significant correlations between the PSSG-Grx1-GSTP1-axis and lung function and 
systemic inflammation are demonstrated which indicate a role for PSSG and its 
mediators in the pathogenesis of COPD.  
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Background 
 
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung 
disease pathologically identified as a mixture of obstructive bronchiolitis and 
emphysema which is associated with airflow limitation that is progressive and not 
fully reversible [1]. The airflow limitation is linked to an abnormal inflammatory 
response of the lungs to noxious particles and gases [2], characterized by a 
marked increase in neutrophils and inflammatory mediators in bronchoalveolar 
lavage fluid (BALF) and sputum, which correlates with disease severity [3, 4]. A so 
called low-grade systemic inflammation is also present in a subset of patients, 
comparable with chronic inflammatory diseases of other organs [5, 6]. Some of the 
systemic markers of inflammation, such as the acute phase protein C-reactive 
protein (CRP), are related to the systemic effects of COPD [7]. 
In addition, a myriad of studies has described oxidative stress in patients with 
COPD, locally in the lungs as well as in the systemic circulation [8]. Increased 
levels of both oxidants and oxidation products of proteins, lipids, DNA and sugars 
have been measured. Oxidative stress is generally correlated to inflammation, as 
inflammatory cells are the main source of oxidant production [9].  
One of the most important antioxidant defences is the tripeptide glutathione. It is a 
redox buffer of the cells that is oxidized preferentially over macromolecules. Blood, 
as well as the lining fluid of the lungs contain high levels of glutathione to protect 
these compartments from irreversible oxidations and damage. The ratio between 
reduced (GSH) and oxidized (GSSG) glutathione is often reported a measure of 
oxidative stress. In COPD, there are disturbances in glutathione as well as in the 
enzyme systems involved in synthesis and reduction of glutathione (for review see 
[10]). 
Oxidative stress can, in addition to direct oxidation of GSH to GSSG, induce the 
binding of glutathione to the sulfhydryl group of cysteine amino acids in proteins. 
This latter reaction is a posttranslational modification that is termed S-
glutathionylation. Glutathione binding to proteins has been proposed as a marker 
of oxidative stress and it has been shown to be increased in the blood of smokers 
[11]. On the other hand, protein S-glutathionylation (PSSG) is believed to protect 
proteins from further, irreversible oxidations. Targeted proteins can also be 
functionally influenced by the binding of GSH, such as for instance enzymes with 
catalytically important cysteines, cytoskeletal proteins and transcription factors, 
such as nuclear factor kappa B and AP-1 and upstream kinases. A strong link 
between protein S-glutathionylation and the response to inflammatory stimuli exists 
[12-14]. Importantly, S-glutathionylation is a reversible oxidation for which the 
removal of GSH is catalyzed by glutaredoxin (Grx) enzymes under physiological 
conditions [15], thereby liberating this reservoir of GSH.  Grx1 expression in the 
lungs has been found to be predominantly localized in macrophages and bronchial 
epithelium. In patients with COPD, Grx1 was decreased and specifically the 
number of Grx1 positive macrophages was found to be positively correlated with 
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lung function [16]. In line with these clinical findings, we have previously reported 
that cigarette smoke extract downregulated Grx1 levels, which was associated with 
increased protein S-glutathionylation in lung epithelial cells.  In vivo on the other 
hand, we found smoke exposure to decrease protein S-glutathionylation, while also 
decreasing Grx1 levels and total Grx activity [17]. Importantly, primary epithelial 
cells from Grx1 knock out mice were more prone to smoke-induced cell death and 
displayed higher levels of protein S-glutathionylation compared to controls [18]. 
Although binding of GSH to proteins can be achieved non-enzymatically, there is 
some evidence that glutathione-S-transferase P1 (GSTP1) can catalyse this 
reaction [19, 20]. GSTP1 is a member of the GST superfamily that catalyses the 
conjugation of GSH to various hydrophobic and electrophilic compounds to aid in 
detoxification. The P isoform is expressed highly in lung tissue and was found to be 
increased in patients with mild COPD [21]. Functionally, in fibroblasts, deletion of 
GSTP1 has been shown to lead to apoptosis [22] while overexpression was 
protective against cigarette smoke extract induced cell death [23]. Polymorphisms 
in GSTP1 have been linked to COPD, and suggested to be due to a lack of 
sufficient detoxification of, and antioxidant protection against cigarette smoke and 
associated products. However, it is also plausible that GSTP1 can contribute to 
pathogenesis through its effects on S-glutathionylation, but also independent of its 
catalytic activities by interacting with proteins such as c-jun-N-terminal kinase 
(JNK) and tumor necrosis factor receptor-associated factor (TRAF) 2 [24-26]. 
However, no functional studies have been performed to date. 
In this study we investigated whether protective plasma protein S-glutathionylation 
(PSSG) is decreased in patients with COPD and whether this is related to 
alterations in its regulatory enzymes glutaredoxin 1 and GSTP1.  Also their relation 
to lung function was studied as well as correlations with markers of systemic 
inflammation given the intricate links of PSSG and the regulatory enzymes with 
inflammation.  
 
 
Methods 
 
Study population plasma measurements 
For the present study, a subgroup from a larger cohort [27] was selected: 47 
patients with clinically stable mild-moderate and severe COPD (Center of expertise 
for chronic organ failure (Ciro), Horn, the Netherlands) and 29 control subjects that 
are matched for age, gender and pack years smoked.  Clinical history of COPD 
and the degree of disease severity were assessed according to the published 
Global Initiative for Chronic Obstructive disease (GOLD) guidelines. Research was 
carried out in accordance with the Declaration of Helsinki of the World Medical 
Association and the ethical review board of the University Hospital Maastricht 
approved the study, and all subjects gave their written informed consent. Patient 
information can be found in table 1.  
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Table 1. Characteristics of COPD patients and healthy controls 
 
BMI = body mass index, CRP = C-reactive protein, FEV1 = forced expiratory volume in the first second, 
FVC = forced vital capacity, IL-6= interleukin-6. Continuous data are expressed as mean ± SD or 
median (inter quartile range). Categorical data are expressed as number of observations (%). Controls 
versus COPD patients calculated using a t-test or a Wilcoxon rank-sum test for continuous data and a 
χ²-test for categorical data. 
 
Clinical examination & blood collection  
FEV1 and FVC were calculated from the flow-volume curve using standardized 
spirometry. FEV1 was performed after inhalation of a β2-agonist via a metered dose 
inhaler. BMI was calculated as body weight divided by squared height (kg/m
2
). 
Blood was collected in an evacuated tube containing EDTA (Sherwood Medical, 
St.Louis, Missouri, USA) and immediately placed on melting ice. After 
centrifugation twice at 800xg for 5-10 min at 4 °C, plasma samples were 
subsequently stored at –80 °C until analysis.  
 
ELISAs 
GSTP1 (Argutus Medical. Dublin Ireland) and IL-6 (Sanquin, Amsterdam, the 
Netherlands) were assessed in plasma by commercially available ELISA kits 
according to the manufacturers’ instructions and C-reactive protein by high-
sensitivity particle enhanced immunoassay (CRP, COBAS Mira Radiometer, 
Copenhagen). Grx1 levels in plasma were determined by ELISA using antibodies 
(Imco, Stockholm, Sweden) as previously published [28]. 
 
Quantitative determination of S-Glutathionylated proteins using 5,5’-dithio-bis(2-
nitrobenzoic acid) (dTNB) 
Trait Controls COPD patients p 
n 29 47  
Age (yrs) 58.2 ± 7.6 59.8 ± 7.8 0.41 
Male  14(48.3%) 24 (51.1%) 0.81 
BMI (kg/m
2
) 27.3 ± 3.0 25.0 ± 5.0 0.02 
Current smoker  14 (48%) 19 (40%) 0.50 
Smoking history, pack years-smoked 34 (26-38) 40 (27-45) 0.21 
FEV1 (L) 3.1 ± 0.6 1.2 ± 0.6 <0.001 
FEV1 (%pred) 107.3 ± 13.1 43.6 ± 18.2 <0.001 
FVC (L) 3.9 ± 0.9 2.9 ± 1.0 <0.001 
FVC (%pred) 111.9 ± 15.4 84.7 ± 21.0 <0.001 
FEV1/FVC (%) 78.5 ± 5.4 43.4 ± 12.1 <0.001 
CRP (mg/ml) 1.6 (0.2-3.9) 4.7 (1.8-11.1) <0.001 
IL-6 (pg/ml) 0.6 (0.4-1.0) 2.3 (1.2-4.0) <0.001 
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200 μl of plasma was acetone precipitated for 20 minutes at -20°C. Pellets were 
next resuspended and sonicated in 200 μl of ice-cold extraction buffer containing 
0.2 % Triton-X 100 and 0.6 % sulfosalicyclic acid in 0.1 M potassium phosphate 
buffer with 5mM EDTA disodium salt (KPE), pH 7.5. After 2 freeze-thaw cycles, 
samples were centrifuged at 3000xg for 4 min at 4°C. To remove glutathione 
(GSH) from proteins, the pellet was treated with 100 μl of 1% NaBH4   in water and 
neutralized with 40 μl of 30% metaphosphoric acid. Samples were centrifuged at 
1000xg for 15 min and the supernatant was used to determine the GSH content 
using the dTNB GSSG reductase recycling method [29]. 20 μl of KPE, GSH 
standards and samples were pipetted into a 96-well microtiter plate and 120 μl of 
freshly prepared, equal volumes of dTNB and GSSG reductase were added in the 
dark. After 30 seconds, 60 μl of β-NADPH was added to start the conversion of 
dTNB to TNB and the absorbance at 412 nm was read every 30 seconds for 2 
minutes. Calculations were performed using a concentration range of GSH. NaBH4 
was omitted for each sample, as a negative control and protein concentration was 
measured to express data as nmol GSH/mg protein. 
 
GST activity Assay   
50 μl plasma was added to the reaction mixture containing 0.1 M phosphate buffer 
pH 6.5, CDNB 20 mM, 20 mM GSH. GST activities were assayed kinetically using 
1 minute interval readings for 5 minutes at 340 nm. Plasma GST activity was 
expressed as nmol GSH/min/mg protein. 
 
Statistical analysis 
SPSS (version 19) was used for data analysis. For continuous data, group 
differences were analysed using Student’s t-test or the Wilcoxon rank-sum test 
(when the distribution was skewed), while for categorical data a χ²-test was used. 
Correlations between variables were determined using spearman’s rho. A p-value 
<0.05 was considered statistically significant. 
 
Study population for the micro-array 
Twenty COPD patients were recruited through the outpatient clinic and pulmonary 
rehabilitation center (CHU, Sart-Tilman, Liege). All COPD patients fulfilled the 
criteria proposed by the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD): FEV1/FVC ratio less than 0.7 measured 20 minutes after the inhalation of 
400 µg of salbutamol. Healthy controls (n = 18) were recruited by advertisement 
among the hospital. Research was carried out in accordance with the Declaration 
of Helsinki of the World Medical Association. The protocol was approved by the 
local ethics committee and subjects gave written informed consent for participation. 
 
Micro-array 
All patients underwent blood collection and blood cells were kept in PAXgene 
blood RNA tube (PreAnalytix, Hombrechtikon, Switzerland) until RNA extraction. 
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RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany) for the 
blood, the Paxgene Blood RNA Kit (PreAnalytix, Hombrechtikon, Switzerland) in 
accordance with the manufacturer’s instructions. cDNA were synthesized using the 
High Capacity cDNA reverse transcription kit (Applied BioSystems, Foster city, 
CA). The expression of 95 genes implicated in oxidative stress and inflammation 
were analysed with TaqMan® Gene Expression Assays (Applied Biosystems) and 
amplification was detected on Taqman 7900HT (Applied Biosystems). Data were 
then analysed using SDS v2.2 software. The Ct value of each gene was 
normalized to 18S to obtain ∆Ct. Relative quantitation in gene expression were 
determined using the formula 2
−∆∆Ct
, where ∆∆Ct = median ∆ Ct of all COPD 
samples – median ∆Ct of all healthy subjects. A difference in gene expression level 
between groups was considered significant when i) the comparison of the medians 
by the Mann-Whitney test gave a p value <0.05 calculated according to the 
Benjamini and Hochberg Discovery Rate to reduce the chance of false positive, 
and ii) the fold change (median of all COPD/ median of all controls) expressed as 
median was > ±1.5 in the COPD group. In this manuscript only expression of Grx1 
and GSTP1 is reported. 
 
Results 
 
The characteristics of the study population in which plasma was analysed are 
outlined in Table 1. Patients were current or former smokers with moderate-to-
severe COPD. The control population which consisted of apparently healthy (ex)-
smoking volunteers was matched for age, gender, smoking status and pack years 
smoked. The BMI of healthy controls was slightly higher then that of COPD 
patients. FEV1 and FVC percent predicted, as well as their ratio were lower in the 
COPD patients compared to the controls (p<0.001). Based on GOLD criteria, 4 
patients were categorized as stage I, 13 patients as stage II, 16 patients as stage 
III and 14 patients as stage IV. Median levels of plasma CRP and IL-6 were found 
to be significantly higher in stable COPD patients than in healthy subjects, 
indicating the presence of systemic inflammation in this patient population. 
 
 
 
 
 
 
 
Figure 1: (Left) Plasma PSSG in healthy controls and patients with COPD. PSSG was determined 
biochemically, expressed in nmol GSH/mg protein and represented as mean ± SD. * represents p<0.05 
between controls and COPD patients.  
Figure 2:  (Right) Glutaredoxin 1 protein levels in plasma of healthy controls and COPD patients. 
Glutaredoxin levels were determined by ELISA, expressed in ng/ml and represented as mean ± SD. * 
represents p<0.05 between controls and COPD patients. 
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The PSSG level in plasma of COPD patients was decreased compared to that in 
healthy controls (Figure 1). Importantly, PSSG levels were not found to correlate 
with the number of pack years smoked or current smoking status (data not shown). 
In order to determine whether this decrease in PSSG could be attributed to 
alterations in the enzymatic regulators of PSSG, namely Grx and GSTP1, these 
were also assessed in plasma of patients and controls. Grx1 plasma levels in 
COPD patients were significantly lower than in healthy controls (Figure 2). GST 
activity was significantly decreased in COPD patients (Figure 3), while the GSTP1 
levels in plasma determined by ELISA showed no difference between COPD 
patients and controls (Figure 4). Peripheral blood mononuclear cells (PBMCs) can 
be a source of Grx1 and it has been shown that transcriptional regulation of Grx1 
within these cells can influence secreted levels. The gene expression data 
obtained from the second cohort indeed revealed a significantly reduced 
expression of Grx1 in whole blood of COPD patients compared to healthy controls 
(Figure 5A), confirming plasma protein data. Also in line with the plasma protein 
data from the first cohort, GSTP1 expression was not different between whole 
blood of COPD patients and controls (Figure 5B).  
PSSG and Grx1 levels as well as overall GST activity were not only 
significantly lower in plasma of COPD patients, they were also found to be 
positively correlated with the lung function parameters FEV1%, FVC% and 
FEV1/FVC (Table 2), independent of BMI, gender, age and pack years-smoked.  
Grx1 expression in blood furthermore also positively correlated with all three lung 
function parameters (Table 5). 
With respect to systemic inflammation, CRP and IL-6 were elevated in this 
patient population (Table 1) and importantly were both negatively correlated with 
PSSG levels and GST activity. These associations were independent of BMI, 
gender, age and pack years-smoked, but not independent of lung function. Grx1 on 
the other hand was positively correlated with IL-6 levels, but only in COPD patients 
(Table 3). Also, Grx1 expression in whole blood was found to be positively 
correlated with the total blood leukocyte count (r: 0.560; p=0.03) and the neutrophil 
percentage (r: 0.540; p=0.04). 
 
Table 2. Correlations between PSSG, Grx1, GST activity and GSTP1 and lung 
function  
  FEV1 (% pred) FVC (%pred) FEV1/FVC 
Whole group COPD Whole group COPD Whole group COPD 
PSSG 0.58 (<0.01) 0.46 (<0.01) 0.47 (<0.01) n.s. 0.55 (<0.01) 0.34 (<0.05) 
Grx1 0.44 (<0.01) n.s. 0.32 (<0.01) n.s. 0.45 (<0.01) n.s. 
GST activity 0.32 (<0.01) n.s. 0.24 (0.05) n.s. 0.34 (<0.01) n.s. 
GSTP1 n.s. n.s. n.s. n.s. n.s. n.s. 
 
FEV1: forced expiratory volume in the first second, FVC: forced vital capacity, Data are expressed as 
Spearman’s rank correlation coefficient (p-value). 
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Figure 3: (Left) Plasma GST activity in healthy controls and patients with COPD. GST activity was 
determined using CDNB as substrate, expressed in nmol GSH/min/mg protein and represented as 
mean ± SD. * represents p<0.05 between controls and COPD patients. 
Figure 4:  (Right) Plasma GSTP1 levels in healthy controls and COPD patients. GSTP1 levels were 
determined by ELISA, expressed in ng/ml and represented as mean ± SD. 
 
Figure 5: Glutaredoxin 1 and GSTP1 mRNA expression in whole blood of healthy controls and patients 
with COPD. Data are expressed as relative quantity (RQ) of Grx1 (A, Left) and GSTP1 (B, Right) 
mRNA. * represents p<0.05 between controls and COPD patients. 
 
 
Table 3. Correlations between PSSG, Grx1, GST activity and GSTP1 and 
inflammatory markers  
  CRP IL-6 
Whole group COPD Whole group COPD 
PSSG -0.23 (0.05) n.s. -0.36 (<0.01) n.s. 
Grx1 n.s. n.s. n.s. 0.32 (<0.05) 
GST activity n.s. n.s. -0.27 (<0.05) n.s. 
GSTP1 n.s. n.s. n.s. n.s. 
CRP = C-reactive protein, IL-6: interleukin-6. Data are expressed as Spearman’s rank correlation 
coefficient (p-value).  
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Discussion 
  
This study is the first to determine S-glutathionylation of proteins in plasma of 
healthy controls and COPD patients as well as to report on its association with 
GSTP1 and glutaredoxin 1, previously described as anti-oxidant enzymes 
responsible for pro- and deglutathionylation of proteins respectively under 
physiological conditions.  
S-glutathionylation of proteins in blood of smokers has previously been described 
to be elevated compared to non smokers [11]. We are the first to report decreased 
S-glutathionylation of proteins in plasma of patients with COPD. In this study, we 
have not found an association of pack years or current smoking status with PSSG. 
The decrease in S-glutathionylation of plasma proteins in COPD patients 
compared to controls reported here might appear counterintuitive since PSSG is a 
marker of oxidative stress as it is induced by oxidants and it has been established 
that COPD patients indeed display systemic oxidative stress [8]. However, since 
protein S-glutathionylation can also be interpreted as a defence mechanism 
against further irreversible oxidations and the release of GSH from this protein pool 
a mechanism to increase the free GSH pool to counteract oxidants, the observed 
decreased level of glutathionylation of plasma proteins in COPD can be interpreted 
as a defective defence mechanism. Importantly, the plasma PSSG level was found 
to be positively correlated with multiple lung function parameters, which provides 
further support for its protective role.  
 
Table 4. Characteristics of COPD patients and healthy controls used in microarray 
study 
 
BMI : body mass index, FEV1: forced expiratory volume in the first second, FVC: forced vital capacity. 
Continuous data are expressed as mean ± SD or median (inter quartile range). Categorical data are 
expressed as number of observations (%). Controls versus COPD patients calculated using a t-test or a 
Wilcoxon rank-sum test for continuous data and a χ²-test for categorical data. 
 
Trait Controls COPD patients p 
n 18 20  
Age (yrs) 58 ± 7 64 ± 11 0.054 
Male  10 (55%) 12 (60%) 0.78 
BMI (kg/m
2
) 26 ± 4 25 ± 5 0.68 
Current smoker  2 (11%) 4 (20%) 0.45 
Smoking history, pack years-smoked 18 (10-45) 42 (33-54) 0.11 
FEV1 (L) 3.10 ± 0.86 1.20 ± 0.46 <0.001 
FEV1 (%pred) 102 ± 14 43 ± 12 <0.001 
FVC (L) 4.07 ± 1.21 2.64 ± 1.12 <0.001 
FVC (%pred) 111.9 ± 15.4 84.7 ± 21.0 <0.001 
FEV1/FVC (%) 109 ± 15 78 ± 21 <0.001 
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The plasma concentrations of two reported regulators of S-glutathionylation, 
glutaredoxins and glutathione S-transferases were also assessed to address 
whether the decreased S-glutathionylation of plasma proteins in COPD patients 
could be attributed to alterations in its enzymatic mediators. With this manuscript 
we show that plasma Grx1 protein levels are decreased in COPD patients 
compared to healthy controls, as are the Grx1 mRNA levels in blood. Previously it 
was reported that Grx1 levels were decreased in the lungs of COPD patients and 
especially, the number of Grx1 positive macrophages was found to be lower in 
patients and positively related to lung function [16]. Here we also observe a 
positive correlation of Grx1 in plasma with lung function parameters FEV1%, FVC% 
and FEV1/FVC, indicating a protective function of this antioxidant enzyme not only 
in the lungs, but also in the circulation. We have published previously that cigarette 
smoke itself decreases Grx1 mRNA and protein expression in lung epithelial cells 
in vitro and have shown decreased levels of Grx1 in a mouse model of smoke 
exposure [17, 18]. The decreased plasma levels of Grx1 and the lower level of 
Grx1 mRNA expression in blood of COPD patients are in line with these previously 
reported findings. However, no significant correlation between plasma Grx1 and 
pack years smoked was observed, and plasma Grx1 levels were not different 
between current and ex smokers.  
Leucocytes are a likely source of plasma Grx1 as Grx1 mRNA expression in blood 
was positively associated with both total leukocyte counts and the percentage of 
neutrophils. Other cellular origins such as endothelial cells can however not be 
excluded. Regardless of the source, it remains a topic of further research how Grx1 
would be secreted from these cells as Grx1 does not contain a secretory lead 
sequence. Altered levels of Grx1 in culture medium of PBMCs have previously 
been attributed to alterations in expression, similar to what we have shown here in 
vivo [28].  
 
Table 5. Correlations of Grx1 mRNA expression in blood to lung function 
parameters.  
 
  FEV1 (% pred) FVC (%pred) FEV1/FVC 
Whole group COPD Whole group COPD Whole group COPD 
Grx1 
expression 
0.49 (<0.01) n.s. 0.36 (<0.05) n.s. 0.48 (<0.01) n.s. 
 
Previous papers reporting on glutathione S-transferases in COPD mainly focused 
on genetic polymorphisms that occur in these enzymes, with an emphasis on the 
importance of GST enzymes in detoxifying metabolites and compounds to which 
the lungs are exposed. Since many polymorphisms of GST enzymes have been 
associated with COPD, it has been proposed that the lack of properly functioning 
GST enzymes might be the cause of insufficient detoxification and anti-oxidant 
levels against cigarette smoke in COPD. Recently however, the function of 
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glutathione S-transferase P1 has been reported to also involve the pro-
glutathionylation of proteins and binding properties [19, 20, 24]. Although GST 
activity was reported to be elevated in plasma of COPD patients compared to 
healthy controls [30] in a Chinese population, we here show a significant decrease 
in total GST activity in plasma of COPD patients (Figure 4). This decreased GST 
activity in COPD patients implies that the metabolism of smoke-related compounds 
such as acrolein and other aldehydes is attenuated. With respect to GSTP1 
specifically, a previous study reported decreased plasma GSTP1 levels in COPD 
[31], whereas in this study, the protein level of GSTP1 in plasma was not found to 
be altered between controls and patients (Figure 5B). Given that the variability 
found in genetic studies could be attributed to different racial backgrounds, this 
might have to be taken into account for expression studies as well. Regardless, a 
protective role of GSTs is suggested by demonstrating for the first time that there is 
a positive association between GST activity and lung function parameters.  
No significant correlations between plasma PSSG levels and Grx1, GSTP1 or GST 
activity were detected in this study. This suggests that plasma PSSG levels in 
COPD are decreased irrespective of the alterations in the investigated mediator 
enzymes. The de-glutathionylation enzyme Grx1 was found to be decreased, but 
we are unable to asses overall Grx activity towards S-glutathionylated proteins. 
Conventional Grx activity assays use hydroxyethyldisulfide or cysteine sulphate as 
substrates and are therefore not specific. Also for the forward reaction of S-
glutathionylation, it has to be taken into account that the GST activity performed 
here uses the general CDNB substrate. To fully exclude links between PSSG and 
Grx and GSTs, (de)glutathionylation specific assays should be developed in the 
future. Other possible mechanisms for decreased plasma PSSG levels include 
non-investigated redox enzymes such as thioredoxin or alternatively PSSG 
decreases could be a function of increased oxidative stress levels per se. These 
alternatives remain to be investigated. 
Irrespective of the lack of an apparent interrelation between PSSG and Grx1, is the 
link between the PSSG/Grx1 axis and inflammation. Indeed, a negative correlation 
between the plasma PSSG level and CRP as well as IL6 was detected. These data 
are in line with the reported inhibitory effects of PSSG on inflammatory pathways 
as we and others have published previously. For instance, NF-κB, a major 
regulator of inflammation, as well as its upstream activators IKK alpha and beta 
can be inhibited by S-glutathionylation [14, 32], resulting in repressed inflammatory 
mediator production. In this study we show that plasma IL-6, a marker for systemic 
inflammation and transcriptionally regulated by NF- κB, negatively correlated with 
plasma PSSG levels, providing supporting evidence for the in vitro established link 
between PSSG and NF- -6 levels were also 
positively correlated with Grx1 levels, but only in COPD patients, whereas CRP 
levels did not correlate with Grx1. These data are difficult to interpret, especially 
since no significant correlation was observed between PSSG and Grx1. One 
complicating factor is that Grx1 levels have not only been shown to determine the 
112 
 
extent of NF-κB activation and inflammatory mediator production through 
alterations in S-glutathionylation status of pathway proteins such as IKKβ, but that 
inflammatory mediators such as LPS can also affect Grx1 expression [14, 33]. This 
latter study furthermore was not able to find substantial Grx1 expression in 
neutrophils recruited to the lungs, which is in contrast to the correlation of Grx1 
with the blood neutrophil percentage. More mechanistic studies will be needed to 
further unravel the intricate relation between the Grx1/PSSG axis and 
inflammation, for which this manuscript provides further clinical evidence. 
 
Conclusions 
 
We here report the first measurement of PSSG in plasma of COPD patients and 
show a positive correlation with lung function, while being negatively correlated 
with systemic inflammatory markers CRP and IL-6. Decreased glutaredoxin 1 
protein and mRNA levels and GST activity were observed in blood of COPD 
patients and controls as well, revealing interesting positive correlations between 
glutaredoxin 1 and GST activity and lung function.  Taken together, this study 
provides clinical evidence for the importance of plasma PSSG levels and its 
mediators Grx1 and GST in lung function and inflammation of COPD patients. 
Further research will elucidate further the intricacies of the PSSG-Grx1-GSTP1 
axis in COPD pathogenesis.  
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Abstract  
 
Many alterations in glutathione and associated enzymes have been demonstrated 
in asthma. Not investigated are the antioxidant enzyme glutaredoxin (Grx) and 
glutathione bound to proteins (PSSG). PSSG is a redox modification, named S-
glutathionylation that affects protein function and is reversed by Grx.  
In this study, we investigated Grx1 protein and PSSG levels in induced sputum of 9 
healthy controls and 34 asthmatics. 
Grx1 protein levels in sputum were significantly elevated in asthmatics compared 
to controls, whereas PSSG was significantly decreased in asthmatics. Grx1 protein 
levels were enhanced specifically in patients with eosinophilic and 
paucigranulocytic asthma. PSSG levels on the other hand were decreased in both 
eosinophilic and neutrophilic asthmatics compared to controls. PSSG levels 
positively correlated with the percentage of epithelial cells and lymphocytes and 
negatively correlated with Grx1 levels. With respect to lung function, FEV1% 
predicted negatively correlated with sputum Grx1 levels and positively with PSSG. 
In a separate study, primary bronchial epithelial cells of asthmatics expressed 
more Grx1 mRNA compared to controls. 
In this study we identify the Grx-PSSG axis as an important modulated redox 
pathway in asthmatics which has intricate connections to inflammation that remain 
to be further explored. 
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Introduction 
 
Asthma is a chronic lung disease, hallmarked by airway inflammation and oxidative 
stress. Pulmonary oxidative stress in asthmatics is attributed to bulk oxidant 
production by infiltrated inflammatory cells, and to inhalation of environmental 
agents causing exacerbations [1]. To protect itself from damaging oxidants, lung 
tissue is equipped with a range of anti-oxidant enzymes and most importantly with 
high concentrations of glutathione [2]. The ratio of reduced glutathione (GSH) and 
its oxidized form GSSG provides information on the redox status of cells and 
tissues and is used to assess oxidative stress. Total GSH is increased and in some 
studies also increased amounts of GSSG have been found in BAL fluid and 
sputum of asthma patients [3], [4]. The anti-oxidant enzymes glutathione 
reductase, glutathione peroxidase, γ-glutamyl-cysteinyl synthase, glutathione 
transferases and glutaredoxin, regulate the level and redox state of glutathione and 
some are found to be altered in asthma patients (reviewed in [5]). For instance, 
lungs of asthmatics have increased levels of extracellular glutathione peroxidase 
[6] and polymorphisms of glutathione-S-transferases are reported to be associated 
with asthma [7].  
 
GSH with its redox cycle partners serves to maintain the reduced state of protein 
thiol groups.  This can be achieved by direct scavenging of oxidants or by the 
covalent reversible binding of GSH to protein thiols. The latter occurs under 
physiological conditions, can be induced upon mild oxidative stress, and is known 
as S-glutathionylation or S-glutathiolation [8]. S-glutathionylation is believed to 
protect the targeted thiols from further irreversible oxidations. Additionally, S-
glutathionylation can modulate protein function. For instance, Inhibitory kappa B 
kinase β (IKKβ), the enzyme responsible for nuclear factor kappa B kinase (NF-κB) 
activation under pro-inflammatory conditions, can be inhibited through S-
glutathionylation in lung epithelial cells [9]. DNA binding of NF-κB and activator 
protein (AP)-1 can also inhibited by S-glutathionylation of their respective p50 and 
c-jun subunits [10, 11].  
 
Under physiological conditions S-glutathionylation can be reduced by glutaredoxins 
(Grx), members of the thiol-disulfide oxidoreductase family that contain a 
thioredoxin fold [12]. It has been shown that glutaredoxins remove glutathione from 
thiol groups and can thereby restore function of proteins targeted by S-
glutathionylation [13]. Several mammalian Grxs have been identified. Grx1 
localizes primarily to the cytosol and Grx2 is present in the mitochondria and 
nucleus. Grx1 can also reduce low molecular weight disulfides and proteins with 
functionally important disulfide bonds could thus also be affected by Grx1 
alterations. 
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In contrast to damaging oxidations and measurements of GSH per se, protein S-
glutathionylation and Grx have rarely been studied in lung diseases, and never in 
conjunction. The number of Grx1 positive alveolar macrophages in chronic 
obstructive pulmonary disease (COPD) was found to negatively correlate with lung 
function and disease progression. Additionally, during COPD exacerbations levels 
of Grx1 in sputum were significantly higher [14]. Grx2 was not detectable in this 
study. In contrast, Grx1 expression was decreased in patients with sarcoidosis and 
allergic alveolitis, but not with interstitial pneumonia [15]. In mouse models, 
nitrogen dioxide inhalation, but not bleomycin instillation augmented Grx1 in lungs, 
while both causing increased protein S-glutathionylation [16]. In a murine model of 
allergic airways disease Grx1 was found to be significantly increased in the airways 
of mice following immunization and challenge with ovalbumin (OVA)[17].  
Given the importance of oxidative stress in the pathogenesis of asthma and the 
critical role glutathione homeostasis plays herein, we conducted a study evaluating 
Grx1 levels and protein S-glutathionylation in induced sputum of patients with 
asthma. Furthermore, correlations between the Grx1-S-glutathionylation axis and 
inflammatory patterns as well as lung function were assessed. 
 
Methods 
 
Study design and subject characteristics 
Patient demographic and functional characteristics as well as sputum eosinophil 
and neutrophil percentages are given in Table 1. We studied 34 asthmatics, 
recruited at the asthma clinic at CHU Liege Sart-Tilman [18]. Significant pulmonary 
co-morbidities had been excluded on the basis of high resolution chest computed 
tomography. Healthy subjects were recruited among hospital and laboratory staff 
members. They all had normal spirometry and PC20M > 16 mg/ml. Both 
asthmatics and healthy subjects denied respiratory tract infections 4 weeks prior to 
sputum sampling. 
 
Sputum induction and processing 
After premedication with 400 μg inhaled salbutamol, sputum was induced by 
inhalation of hypertonic saline (NaCl 5%) when FEV1 postsalbutamol was ≥65% 
predicted and isotonic saline (NaCl 0.9%) when FEV1 was <65% predicted. Saline 
combined with salbutamol was delivered by an ultrasonic nebulizer (Ultra-Neb 
2000; Devilbiss, Somerset, PA, USA) [19]. Each subject inhaled the aerosol for 3 
consecutive periods of 5 min for a total time of 15 min. For safety reasons, FEV1 
was monitored every 5 min, and the induction stopped when FEV1 fell by more 
than 20% from post-bronchodilation values. 
Whole sputum was homogenized by adding three volumes of PBS, vortexed and 
centrifuged at 800g for 10 min at 4°C. Supernatant was separated from cell pellet, 
which was suspended in RPMI 1640 supplemented with 100 U penicillin/ml, 100 μg 
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streptomycin/ml, and centrifuged at 400g for 10 min at 4°C. Squamous cells, total 
cell counts, and cell viability checked by trypan blue exclusion were performed with 
a manual hemocytometer. The differential cell count was performed on cytospins 
stained with Diff-Quick after counting 400 cells.  
 
Table 1: Demographic and functional characteristics  
 
 
 
*represents p<0.05 vs healthy control subjects, §represents p<0.05 vs eosinophilic asthma, $represents 
p<0.05 vs neutrophilic asthma 
Data are expressed as mean and standard deviation, with the exception of FeNO, %eosinophils and 
%neutrophils which are expressed as median and range.  
CS, corticosteroids; LABA, long acting beta 2 agonist; LTRA, leukotriene receptor antagonist 
 
 
  Healthy 
controls      
Asthmatics eosinophilic neutrophilic paucigranulocytic 
Number of subjects 9 34 15 8 10 
Age 47.0 ± 8.1 44.6 ± 12.8 44.5  ± 3.7 47.2  ± 3.9 41.9  ± 4.0 
Sex, M/F 6/3 18/16 8/7 4/4 4/6 
Smoking status 
(never/ex or current) 
5/4 17/17 5/10 7/1 § 5/5 
Pack years 19.6 ± 26.8 21.4 ± 17.7 20.1  ± 7.4 60 13.9  ± 4.9 
BMI (kg/m
2
) 25.2 ± 4.2 25.7 ± 4.6 24.9  ± 1.0 24.7  ± 1.7 27.0  ± 1.7 
FEV1% predicted 108.6 ± 16.9 76.1 ± 22.2* 70.9  ± 7.1* 74.1  ± 7.1* 85.1  ± 4.5* 
FVC% predicted 113.2 ± 20.6 86.5 ± 22.7* 90.9  ± 5.0* 73.8  ± 13.3* 92.5  ± 4.0* 
FEV1/FVC 82.0 ± 8.9 69.8 ± 14.3* 65.0  ± 4.1* 67.8  ± 3.6* 76.8  ± 3.8 
FeNO (ppb) - 17.9 (3.7-235) 43 (10.6 - 235) 22.2 (5.4 - 66.3) 11 (3.7 – 80.9) 
§
 
Oral CS - - 1 2 1 
Inhaled CS(eq 
budesonide/day) 
- - 2000 (0-6000) 2000 (0-3000) 1600 (0-4000) 
LABA - - 11 7 8 
LTRA - - 7 4 5 
Theophylline - - 0 2 2 
% sputum eosinophils 0 (0-3.2) 
 
0.9 (0-72.2)* 
 
18.6 (3.4-72.2)* 
 
0 (0-0.8) 
§ 
 
0.4 (0-2.4) 
§
 
 
% sputum neutrophils 16 (0-62.8) 
 
48.3 (4-100)* 
 
44.2 (4-65) 
 
94.8 (75.7-100)
*, §
 
 
46.7 (17.6-69.6) 
$
 
 
ACQ  2.78 ±  1.32 
 
2.7  ± 0.4 
 
3.3  ± 0.5 
 
2.3  ± 0.3 
 
AQLQ  3.78 ±  1.10 
 
3.9  ± 0.3 
 
3.4  ± 0.4 
 
4.1  ± 0.4 
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Western Blotting for Grx1  
Laemmli sample buffer containing DTT was added to 25 μl of sputum and boiled 
for 10 minutes. Samples were loaded onto a 16,5% polyacrylamide gel and 
transferred onto a PVDF membrane. The membrane was blocked for 1h in 5% milk 
in Tris-buffered Saline (TBS) containing 0.05% Tween 20 (TBST). After two 
washes in TBST, the membrane was incubated overnight at 4°C with primary 
antibody against Grx1 (Imco). After three washes, peroxidase-conjugated 
secondary antibody was incubated for 1h and detected by chemiluminescence 
using the Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, IL, 
USA). Films were quantified and data expressed as arbitrary units relative to 
diluted human Grx1 recombinant standard (Labfrontier) on each gel. 
 
Quantitative determination of S-Glutathionylated proteins using 5,5’-dithio-bis(2-
nitrobenzoic acid) (dTNB) 
200 μl of sputum was acetone precipitated for 20 minutes at -20°C and spun for 5 
minutes. Protein pellets were resuspended and sonicated in 200 μl of ice-cold 
extraction buffer containing 0.2 % Triton-X 100 and 0.6 % sulfosalicyclic acid in 0.1 
M potassium phosphate buffer with 5mM EDTA disodium salt (KPE), pH 7.5. After 
2 freeze-thaw cycles, samples were centrifuged at 3000g for 4 min at 4°C. To 
remove glutathione (GSH) from proteins, the pellet was treated with 100 μl of 1% 
NaBH4 in water and neutralized with 40 μl of 30% metaphosphoric acid. Samples 
were centrifuged at 1000g for 15 min and the supernatant was used to determine 
the GSH content using the dTNB GSSG reductase recycling method [20]. 20 μl of 
KPE, GSH standards and samples were pipetted into a 96-well microtiter plate and 
freshly prepared, equal volumes of dTNB and GSSG reductase were added in the 
dark. After 30s, β-NADPH was added to start the conversion of dTNB to TNB and 
the absorbance at 412 nm was read every 30s for 2 minutes. A standard curve was 
performed using a concentration range of GSH. NaBH4 was omitted for each 
sample as a negative control. Values were corrected for protein content and data 
expressed as nmol GSH per milligram of protein. 
 
Primary bronchial epithelial cell culture, RNA isolation and cDNA synthesis  
Ciliated epithelial cells were isolated using cytology brushes during bronchoscopy 
 in 3 healthy controls and 3 asthma patients (Table 3). Cells were shaken off from  
the brushes and first plated onto 1% PureCol (Inamed Biomaterials, Nutacon, The 
 Netherlands)-coated 12-well plates for the basal cells to expand in submerged  
culture using bronchial epithelial growth medium (Lonza Verviers, Belgium)  
supplemented with 0.3% Fungizone ® antimycotic (Gibco, Invitrogen, Pailey, UK)  
and 1% Antibiotic-Antimycotic (Gibco). Cells at passage 1 to 3 were seeded into 
 1% PureCol-coated 6cm petri dishes for further expansion. When confluent, cells 
 were lysed, scraped off, and RNA was extracted using RNeasy Mini Kit  
Plus with QIAshredder homogenisation and DNaseI digestion (all from Qiagen, 
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 Crawley). RNA was quantified using NanoDrop spectrophotometer (Thermo  
Scientific, Wilmington DE) and cDNA synthesized using the SuperScript VILO 
 cDNA synthesis kit (Invitrogen).  
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Figure 1: The Grx1-PSSG axis in induced sputum in asthma. (A) Grx1 protein levels in induced sputum of  
healthy controls and asthma patients, assessed by Western blot. Data are expressed in arbitrary units (AU)  
where Grx1 levels were corrected for a sample of recombinant human Grx1 on each gel and represented  
as mean ±  SD. * represents p < 0.05. The insert is a representative Western blot loaded with recombinant  
human Grx1 sample in lane 1 (rGrx1), a molecular weight marker (MW), a healthy control sputum sample 
 (co) and 3 asthma sputa (A1, A2, A3). (B) Level of protein S-glutathionylation (PSSG) in induced sputum  
of healthy controls and asthma patients. Data are expressed as nmol GSH that was released per mg 
 protein and represented as mean ± SD. * represents p < 0.05. (C) Negative correlation between PSSG 
 and Grx1 protein levels in induced sputum in the whole study group. 
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QPCR analyses 
QPCR was performed in duplicate using primers for Grx1  
(FW: TCAGTCAATTGCCCATCAAA, Rev: AGATCACTGCATCCGCCTAT), 
 Grx2 (FW: TTTACAAATGACTGGTGAAAGAAC, Rev: TGTCAGTTGCACCTCCAATAA)  
and GAPDH (FW: CGTCTTCACCATCAT, Rev: CGGCCATCACGCCACAGTTT) 
as a housekeeper. Relative quantity (RQ) was calculated using the comparative 
CT method.  
 
Statistical analyses 
SPSS (version 15) was used for data analyses. Unless indicated otherwise, data 
are expressed as mean and standard deviation. Between-group comparisons were 
analyzed using the Kruskal-Wallis test, followed by Mann-Whitney U test and 
correlations between variables were determined using Spearman’s rho. Cell culture 
experiments were analysed by student’s t-test. A p-value <0.05 was considered 
statistically significant. 
 
Results 
 
Biochemical assessment of the Grx1-PSSG axis in induced sputum samples of 
asthmatics 
Healthy subjects and asthmatics were well matched for age, sex and smoking 
status (Table 1).  Asthmatics exhibited poorer lung function compared to healthy 
controls as reflected by lower values of FEV1, FVC and a lower FEV1/FVC ratio. 
Raised sputum eosinophil and neutrophil counts were observed in asthmatics 
compared to healthy subjects.  
The level of Grx1 protein detected in the sputum by Western blot was significantly 
increased in asthmatics compared to controls (Fig. 1A). Interestingly, an extra band 
was observed below that of Grx1 in 32% of patients which could indicate a 
degradation product (Fig. 1A, insert A3). Grx2 could not be detected in sputum 
supernatant. In line with Grx1’s function of removing GSH from proteins, the level 
of protein S-glutathionylation (PSSG) was significantly decreased in sputum of 
asthmatics compared to controls (Fig. 1B). Importantly, in the whole study group a 
negative correlation was observed between Grx1 protein levels and PSSG in 
sputum samples (Fig. 1C). 
 
The Grx1-PSSG axis in relation to asthma cellular phenotypes 
Since an intricate relation between Grx/PSSG and inflammation has been 
observed in in vitro as well as mouse models of disease, we next asked whether 
these observed alterations in the Grx-PSSG axis were different between asthma 
cellular phenotypes. Therefore, asthmatics were categorized as eosinohilic, 
neutrophilic, paucigranulocytic or mixed based on published values for sputum 
eosinophil percentages [21] and the internal reference value of 76% for neutrophils 
from our clinic. Based on these criteria, 15 patients were labelled eosinophilic, 8 
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Figure 2
neutrophilic and 10 paucigranulocytic. In this group of patients, none were of the 
mixed inflammatory subtype. Lung function did not differ significantly between the 
cellular phenotypes, nor did the asthma control or the quality of life score. The 
percentage eosinophils was greater in the eosophilic asthmatics compared to both 
neutrophilic and paucigranulocytic asthmatics as expected. Also, the percentage of 
sputum neutrophils was greater in neutrophilic asthmatics compared to eosinophilic 
and paucigranulocytic asthmatics (Table 1). Data in Figure 2A indicate that Grx1 
protein levels were specifically enhanced in induced sputum of eosinophilic and 
paucigranulocytic asthmatics, but not in that of neutrophilic asthmatics. PSSG 
levels were found to be decreased only in eosinophilic and neutrophilic asthmatics 
compared to healthy controls, but not in sputum of paucigranulocytic asthma 
patients (Fig. 2B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The Grx1-PSSG axis in relation to asthma cellular phenotypes. (A) Grx1 protein levels in 
induced sputum of healthy controls, eosinophilic, neutrophilic and paucigranulocytic asthma patients, 
assessed by Western blot. Data are expressed in arbitrary units (AU) where Grx1 levels were corrected 
for a sample of recombinant human Grx1 on each gel and represented as mean ±  SD. * represents p < 
0.05 compared to healthy controls. (B) Level of protein S-glutathionylation (PSSG) in induced sputum of 
healthy controls, eosinophilic, neutrophilic and paucigranulocytic asthma patients. Data are expressed 
as nmol GSH that was released per mg protein and represented as mean ± SD. * represents p < 0.05 
compared to healthy controls and # represents p < 0.05 compared to neutrophilic asthma.  
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Correlations between the Grx1-PSSG axis in induced sputum and lung function  
Importantly, FEV1% predicted negatively correlated with sputum Grx1 protein levels 
and positively with PSSG in the whole study group as shown in Figure 3. When 
restricting the analyses to all asthma patients, these correlations did not remain 
significant. However, Grx1 in eosinophilic asthmatics specifically still significantly 
negatively correlated with FEV1% predicted (r=-0.532 p=0.04) and PSSG positively 
correlated with FEV1% predicted in neutrophilic patients (r=0.750, p=0.05).  
Although the degree of asthma control assessed through the Juniper asthma 
control questionnaire (ACQ) was not significantly different between cellular 
phenotypes (Table 1), ACQ was found to be negatively associated with PSSG in 
neutrophilic asthmatics (r=-0.750, p=0.05), indicating that as the disease is less 
well controlled in these patients, the protein GSH pool is depleted more.   
 
 
 
 
Figure 3: Correlations between lung function and the Grx1-PSSG axis. (A) A negative correlation was 
observed between FEV1% predicted and Grx1 protein levels in induced sputum in the whole study 
group. (B) A positive correlation was observed between FEV1% predicted and Grx1 protein levels in 
induced sputum in the whole study group. 
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Correlations between the Grx1-PSSG axis in induced sputum and sputum cell 
counts in asthma 
Since Grx1 and PSSG levels in induced sputum are different between cellular 
asthma phenotypes we assessed their associations with total and differential cell 
percentages in the induced sputum. Total cell numbers were found to be positively 
related to Grx1 levels, and negatively to PSSG levels (Table 2). Grx1 was found 
not to correlate with any specific cell type in the induced sputum. PSSG levels on 
the other hand were positively related to the percentage epithelial cells, squamous 
cells and lymphocytes and negatively with the percentage of viable cells in the 
entire study population as well as in the asthma patients alone. 
 
Increased mRNA expression of Grx1 in primary bronchial epithelial cells of 
asthmatics 
Grx1 sputum levels correlated with total sputum cell counts, but not with any 
specific cell type in the sputum. Since we previously observed markedly increased 
expression in airway epithelial cells in the mouse model of allergic airways disease, 
we investigated Grx mRNA expression in primary bronchial epithelial cells obtained 
from asthma patients and controls. The results shown in Fig. 4 demonstrate that 
indeed a higher level of Grx1 mRNA expression is present in epithelial cells 
isolated from asthma patients compared to cells isolated from healthy controls. 
Grx2 mRNA levels were not different, and importantly, as shown previously in 
various epithelial cells and mouse lung tissue, were lower then Grx1 mRNA levels. 
 
Table 2: Correlations between the Grx1-PSSG axis in induced sputum and sputum 
cell counts in asthma 
    All subjects All asthmatics 
PSSG Total cell number 
%eosinophils 
-0.632 (0.000) 
n.s. 
-0.658 (0.000) 
n.s. 
  %epithelial cells 0.601 (0.000) 0.502 (0.003) 
  %neutrophils n.s. n.s. 
  %macrophages n.s. n.s. 
  %lymphocytes 0.362 (0.022) 0.462 (0.008) 
  %squamous cells 0.355 (0.025) 0.399 (0.024) 
  %viable cells -0.441 (0.004) -0.479 (0.006) 
Grx1 Total cell number 0.425 (0.006)  n.s. 
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Figure 4: Grx1 expression is increased in primary epithelial cells of asthmatics. Grx1 (black bars) and 
Grx2 (white bars) mRNA expression corrected for GAPDH in primary bronchial epithelial cells of healthy 
controls and patients with asthma. Data are expressed as mean RQ ± SEM * represents p < 0.05 
compared to healthy controls. 
 
Discussion 
 
In this manuscript, we show an increase in Grx1 protein levels in induced sputum 
of asthmatics compared to healthy controls (Fig. 1A). These findings are in line 
with the increase in Grx1 in lung tissue in a murine model of allergic airways 
disease we have shown previously [17]. A statistical increase was found to occur in 
sputum of patients with eosinophilic and paucigranulocytic asthma (Fig 2A). The 
increase in Grx1 could be part of the protective response of the lungs to oxidative 
stress that is observed in asthmatics, since the function of Grx1 is to release GSH 
from proteins. Enhancing extracellular Grx1 levels could thus serve to increase free 
-
glutamylcysteinyl ligase. It has been demonstrated that in human lungs, Grx1 is 
predominantly present in macrophages and epithelial cells [15]. Grx1 levels in 
induced sputum did not correlate with the percentage of macrophages, nor 
importantly with the percentage of viable cells. These results are in line with the 
study first describing Grx1 in sputum of COPD patients since it demonstrated that 
its presence herein is not due to cell death, but likely involves an active secretion 
mechanism [14]. Bronchial epithelial cells are the most likely source since we 
observed a higher level of Grx1 mRNA expression in primary bronchial epithelial 
cells isolated from asthmatics compared to controls. In vitro studies have 
furthermore demonstrated the presence of Grx1 in culture supernatant which 
reflected expression profiles [22].  
 
 
126 
 
Table 3: Characteristics of subjects from which primary bronchial epithelial cells 
were isolated for mRNA analyses 
 
  Healthy controls Asthmatics 
Number of subjects 3 3 
Age 36.0 ± 6.1 56.3 ±16.5 
Sex, M/F 1/2 2/1 
FEV1% predicted 104.3 ± 2.9 74.3 ± 32.3* 
FEV1/FVC 86.2 ± 32.8 68.8 ± 32.8 
*represents p<0.05 vs healthy control subjects 
 
Next to the increase in Grx1 protein levels in induced sputum of asthmatics, we 
also show in this study that the levels of protein S-glutathionylation in sputum 
significantly decreased in patients with asthma compared to healthy controls (Fig. 
1B). When assessing PSSG in the different inflammatory cell phenotypes, PSSG 
was found to be decreased only in the two inflammatory phenotypes compared to 
healthy controls. The level in neutrophilic asthmatics was furthermore decreased 
compared to paucigranulocytic patients. Importantly, Grx1 protein and PSSG levels 
were found to be negatively correlated (Fig. 1C). Although Grx1 levels were not 
found to correlate with sputum cells, PSSG levels were negatively associated with 
the percentage of viable cells in the whole study group as well as in the asthma 
patients alone (Table 3). Despite the lower level of PSSG in the inflammatory 
phenotypes, no correlation with the percentage of either eosinophils or neutrophils 
was observed. This is in agreement with earlier observed lack of PSSG reactivity in 
neutrophils [23]. On the other hand, positive correlations of PSSG with 
lymphocytes, epithelial cells and squamous cells were found. This positive relation 
of sputum epithelial cells to PSSG contrasts the likelihood of epithelial cells as a 
prominent source of sputum Grx1, although epithelial cells in sputum could 
represent a different pool then cells isolated by brushing.  
As described above, we hypothesize that GSH is removed from proteins to 
increase free GSH levels. The protein thiols could be returned to their reduced 
state, which is unlikely since the GSH/GSSG ratio is not increased in asthma [5]. 
On the other hand, S-glutathionylation of proteins is not only a sink for GSH it is 
also a reversible oxidation that protects proteins from further irreversible oxidation. 
A loss of this protective modification would thus leave proteins susceptible to 
damaging oxidations. Indeed, carbonylated albumin, as well as α1-antitrypsin have 
been detected in sputum of asthma patients [24]. Moreover, we recently reported 
that Grx1 itself is irreversibly oxidized and inhibited upon cigarette smoke extract 
exposure [25].  The observation of Grx1 of a lower then expected molecular weight 
in 32% of patients (Fig. 1A, insert) could be the result of such oxidative 
modification or possibly partial degradation.  
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With respect to lung function, there was a significant negative correlation of Grx1 
protein levels and a positive correlation of PSSG with FEV1% in the whole study 
group. These associations did not remain significant however when the analyses 
were restricted to the total group of asthma patients. FEV1 did remain significantly 
correlated with Grx1 in the eosinophilic phenotype and with PSSG in the 
neutrophilic phenotype (data not shown). A better lung function is thus associated 
with lower levels of Grx1 in induced sputum and a higher level of protein S-
glutathionylation. A previous report in COPD showed that the number of Grx1 
positive macrophages in lung tissue was positively correlated with FEV1% in the 
lungs of COPD patients, while there was no information on protein S-
glutathionylation [14]. Here we lack information on the levels of S-glutathionylation 
in specific cell types. Moreover, it is difficult to extrapolate the current findings in 
sputum to what might be occurring to the Grx—PSSG axis in lung tissue. The 
increased expression of Grx1 in bronchial epithelial cells of asthmatics is in line 
with our previously reported findings in the OVA model in mice. In this model 
inflammatory cells were however, not investigated in detail as was protein S-
glutathionylation [17]. Next to the positive correlation of PSSG with FEV1 in 
neutrophilic asthmatics and the relatively low level of sputum PSSG in this 
inflammatory phenotype compared to healthy controls and paucigranulocytic 
patients, PSSG in this phenotype also negatively correlated to the degree of 
disease control as assessed by the Juniper control questionnaire. So, there does 
appear to be a link between sputum PSSG and neutrophilic asthma that is 
associated with the degree of disease control. Together, these data show that Grx-
PSSG alterations either as a cause or a consequence of the disease are related to 
clinical manifestations. 
 
When reviewing the list of proteins which functions have been demonstrated to be 
regulated by S-glutathionylation, a number of these are of significant relevance in 
asthma. For instance, the calcium pump sarco/endoplasmic reticulum Ca
2+
-
ATPase (SERCA) has been shown to be activated by S-glutathionylation, 
increasing relaxation of smooth muscle [26]. Also with respect to muscle 
contractility, S-glutathionylation of the Ryanodine receptor calcium channel (RyR) 
was shown to be associated with impaired coupling [27].  Other potentially 
important effects include inhibition of caspase 3 [28], endothelial nitric oxide 
synthase (eNOS) [29] and phosphatase and tensin homologue (PTEN) [30], and 
inhibition of polymerization of G-actin [31]. With respect to inflammation, the 
transcription factors NF-κB [10], AP-1 [11] and signal transducer and activator of 
transcription factor (STAT)3 [32] have been shown to be negatively affected by S-
glutathionylation. Moreover, we demonstrated that the extent to which NF-κB can 
be activated and pro-inflammatory mediators produced in lung epithelial cells is 
determined by Grx1 levels [9]. PSSG levels were found to be specifically lower in 
patients with either neutrophilic or eosinophilic asthma compared to healthy 
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controls and to some extent paucigranulocytic asthmatics. Despite the significant 
correlation between sputum Grx1 and PSSG levels, these data with regard to 
inflammation indicate that PSSG as expected is influenced by Grx1 levels but likely 
also oxidative stress related to the inflammatory state of the lungs. Important to 
note is that anti-inflammatory therapy did not relate to PSSG or Grx1 levels. 
 
In addition to studying alterations in mRNA and protein levels, classical 
posttranslational modifications and generic antioxidants, these data show that 
PSSG of targets relevant to asthma should be further investigated as they could 
play a key role in pathophysiology and possibly treatment since Grx-PSSG 
alterations as a cause or a consequence of the disease are related to clinical 
manifestations. 
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CHAPTER 9 
 
Discussion 
 
 
 
Grx1 regulation 
 
Altered expression of glutaredoxin 1 has been reported in several pulmonary 
diseases, like IPF, lung cancer and COPD [1-3]. How glutaredoxins are regulated 
at the transcriptional level however, has not been investigated in detail before. The 
only published data to date are that TGFβ decreased Grx1 expression, while IFNγ 
and PMA augmented its levels [4, 5]. Regulation by transcription factors remained 
unknown. 
 
Regulation of the Glrx1 gene by NF-κB  
 
We know from previoulsy conducted research in our laboratory that Grx1 levels 
have an impact on NF-kB activation by altering S-glutathionylation of IKKβ [6]. In 
chapter 2 of this thesis we expanded on this knowledge by showing that LPS 
affects S-glutathionylation of IKKβ. Specifically, protein S-glutathionylation of IKKβ 
was shown at protracted time points relative to IKKβ-mediated phosphorylation of 
IκBα  the NF-κB pathway was activated by exposure to LPS. Overexpression 
of Grx1 prevented IKKβ protein S-glutathionylation in response to LPS, resulting in 
prolonged degradation of IκBα, Rel A phosphorylation and nuclear translocation, 
and led to further increased expression of NF-κB proinflammatory cytokines. 
Secondly, it was investigated whether NF-kB also influenced Grx1 expression. 
Indeed, activation of the NF-κB pathway by LPS as well as by genetic manipulation 
induced the expression of glutaredoxin 1 in lung epithelial cells and lung 
macrophages. ChIP assays revealed that, upon LPS exposure, Rel A binds to the 
Glrx1 promoter. Therefore, it can be speculated that the activation of the Glrx1 
gene by NFκB signaling can be seen as a feedforward mechanism to prolong NF-
κB activation by deglutathionylation of IKKβ. Figure 1 schematically represents how 
protein S-glutathionylation of IKKβ is suggested to be responsible for the 
glutaredoxin 1 regulated redox modulation of NFκB activation. Other members of 
the NF-κB family that were previously described to be functionally altered by S-
glutathionylation, including p50 and p65, were not investigated in this study and 
need attention in future research.  
 
NF-κB in addition to inflammation also regulates cell growth and wound healing. In 
our experiments, CA-IKKβ overexpression caused increased wound closure in lung 
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epithelial cells in vitro. When Grx1 expression was decreased using siRNA in the 
context of CA-IKKβ overexpression, the increased wound closure was found to be 
inhibited, suggesting a role for Grx1 regulation by NF-κB in the mediation of either 
cell proliferation or migration. These results correspond with earlier data reporting 
an inverse correlation of Grx1 and Grx2 with proliferation and differentiation in 
patients with non-small cell lung cancer [1]. 
 
Effects of cigarette smoke on Grx1  
 
The focus of our laboratory is on research into COPD. Since Grx1 has been 
reported to be decreased in macrophages and epithelial cells of COPD patients [2], 
we set out to investigate whether this could be due to cigarette smoke exposure. 
Both in vitro and in vivo, we have detected a decrease in Grx1 expression at the 
mRNA and protein level in lung cells after exposure to cigarette smoke.  In a 
human lung epithelial cell line as well as primary mouse epithelial cells of the 
trachea, diminished Grx1 mRNA expression in cigarette smoke extract exposed 
cells compared to controls was detectable after a minimum of 24 hours. This 
protracted time of measurable differences to controls implies that Grx1 expression 
is not directly impacted by cigarette smoke extract, but is more likely regulated 
through an indirect signaling pathway. The in vitro data can also be viewed in a 
different manner in that over time Grx1 expression is upregulated in control 
conditions, but not so when treated with cigarette smoke extract. The upregulation 
in control conditions might be attributed to NFκB activation due to proliferation that 
still occurs in cells at subconfluency. This hypothesis fits with the data presented in 
chapter 2. The lack of upregulation of Grx1 expression over time in the CSE 
exposed cells, giving it the appearance to be downregulated compared to controls 
at each timepoint, could then be attributed to a decrease in proliferation. To test 
this hypothesis it would be necessary to investigate whether cells proliferate less 
upon cigarette smoke extract exposure, compared to controls and therefore 
express less Grx1, or whether overexpression of Grx1 could restore normal 
proliferation or even provide a growth benefit as could be speculated based on the 
relation of Grx1 expression to lung cancer [1]. We showed here that Grx1 at least 
provided protection against cigarette smoke -induced cell death at higher 
concentrations of CSE. 
In accordance to our findings in vitro, lungs of mice exposed to cigarette smoke for 
four weeks expressed less Grx1 compared to their air exposed controls. A further 
reduction at 6 months of exposure was found (data are not shown in this thesis). 
Also, in lung tissue and plasma of patients with COPD compared to controls a 
decreased level of Grx1 protein was found. We did not examine where the 
differential regulation of Grx1 was occurring in response to cigarette smoke in 
mouse lung tissue or in patients with COPD. Grx1 is predominantly found in lung 
epithelial cells and macrophages [5], and it can therefore be speculated that 
altered expression in these cell types upon cigarette smoke exposure is 
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responsible for the decreased levels of Grx1 found in lungs of mice and humans. 
The decreased level in plasma could be attributed to a decreased expression of 
Grx1 mRNA in white blood cells as shown in chapter 7, although the lungs, 
endothelial cells or other organs cannot be excluded. 
We furthermore have shown that acrolein in cigarette smoke extract also directly 
affects Grx1 and its activity by binding to Grx1 itself, implying that cigarette smoke 
can affect Grx1 expression as well as modify Grx1 protein post-translationally. No 
effects of cigarette smoke  Grx2 mRNA were observed, in vitro, in the mouse 
model, as well as in the patient samples, which is in line with previous studies in 
which only levels of Grx1 were affected by the stimuli used [4]. Grx2 at the protein 
level could not always be assessed due to the lack of a good commercially 
available antibody. It is however also possible that the activity of Grx2 is altered by 
smoke exposure, as this isoform is activated when the active site is opened upon 
monomerization, which can be accomplished by oxidation [7]. The activity assay 
used in this thesis furthermore does not distinguish between the different isoforms 
of glutaredoxin. Together this could explain why the strong effects observed on 
Grx1 expression and on recombinant Grx1 activity after cigarette smoke exposure 
do not always translate into equally strong effects on total cellular Grx activity.  
Regulation of Grx1 by other pathways 
 
Besides NF-κB binding sites discussed in this thesis, putative activator protein-1 
(AP-1) sites and estrogen receptor binding elements (ERE) were previously 
reported in the mammalian Glrx1 gene [8, 9] and imply regulation of Grx1 by 
multiple pathways. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) induces 
expression of many antioxidant enzymes, like glutathione S-transferase, heme 
oxygenase-1, glutamate-cysteine ligase and NADPH quinone oxidoreductase 1, by 
binding to antioxidant response elements (ARE) in the upstream promoter region of 
their encoding genes [10]. Nrf2 overexpression provides a protective role in 
cigarette smoke induced emphysema in mice [11]. Furthermore, patients with 
advanced COPD have lower levels of Nrf2 [12, 13]. In this thesis we reported that 
Grx1 is decreased in patients with COPD, which positively correlates with lung 
function, and has a protective role in cigarette smoke induced cell death in vitro, 
trends that are similar to that of Nrf2. Upon closer examination of the promoter of 
the Glrx1 gene, we identified putative ARE sites and therefore started investigating 
whether Grx1 is indeed an Nrf2 dependent gene. This research is currently 
ongoing and provides an interesting and promising follow up for this particular 
chapter of the thesis.  
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Extracellular Grx1 
 
Grx1 is also present in induced sputum of healthy controls and levels were 
unaffected in stable COPD, in contrast to an observed decrease in lung tissue. In 
induced sputum of patients with acute disease exacerbations however, the Grx1 
level was increased compared to patients with stable disease (chapter 6). This 
increase in Grx1 in sputum of patients with acute exacerbations is in line with 
earlier reported data [2]. The difference from the lung tissue data could be due to 
the difference in reaction of newly recruited inflammatory cells versus more 
chronically exposed epithelial cells or resident macrophages whose regulatory 
pathways already have been affected by oxidative stress.  
Our laboratory previously has shown that Grx1 was significantly increased in the 
airways of mice following immunization and challenge with the antigen ovalbumin 
(OVA) as a  model of allergic airways disease [4]. In accordance with these data 
we show in chapter 8 of this thesis an increase in Grx1 protein levels in induced 
sputum of asthmatics compared to healthy controls.  
The increase in Grx1 in both stable asthma and COPD patients experiencing a 
disease exacerbation could be part of the protective response of the lungs to 
oxidative stress, since the function of Grx1 is to release GSH from proteins. 
Enhancing extracellular Grx1 levels could thus serve to increase free GSH in a 
direct manner as opposed to via tra -glutamylcysteinyl 
ligase. Since we have shown in chapter 3 that Grx1 can be irreversibly oxidized 
and inhibited upon cigarette smoke extract exposure, we might speculate that Grx1 
is less activate, either through oxidative modifications or possible partial 
degradation. Strengthening these speculations are the observations of a lower than 
expected molecular weight of Grx1 in the sputum of some of the refractory asthma 
patients and COPD patients experiencing an exacerbation (chapters 6 and 8). 
COPD and asthma are both chronic lung diseases with increased oxidative stress.  
 
It is still unknown from which cell types sputum Grx1 originates. It has been 
demonstrated that in human lungs, Grx1 is predominantly present in macrophages 
and epithelial cells [5], although no significant correlations with these cell 
proportions in sputa of COPD patients were detected in chapter 6 or in patients 
with asthma in chapter 8. A study that examined extracellular Grx found that only 
Grx1 could be detected in plasma and conditioned cell culture media, and not 
Grx2.  Extracellular Grx1 was furthermore mostly detected from non-adherent cells 
compared to adherent cells, making the macrophage the most likely origin of 
sputum Grx1 in COPD exacerbations [14]. In patients with asthma on the other 
hand, we found that Grx1 sputum levels correlated with total cell counts, but not 
with any specific cell type in the sputum. On the other hand, Grx1 protein levels 
were enhanced in induced sputum of eosinophilic and paucigranulocytic 
asthmatics, but not in that of neutrophilic patients. These data are in line with the 
findings of an absence of enhanced Grx1 levels in stable COPD. In addition, 
135 
 
primary epithelial cells isolated from asthma patients displayed a higher level of 
Grx1 mRNA expression compared to cells isolated from healthy controls.  
Sequence analysis of Grx1 did not identify classical secretory signal sequences 
[15].The fact that we and others have reported that Grx1 levels were positively 
correlated with the percentage of viable cells in the sputa proposes a non-classical 
export of the enzyme from cells [2], for which the mechanism remains to be 
established. 
 
Grx activity 
 
Grx1 expression data did not always match up with Grx activity measurements in 
our studies. Arguments can be made that this lack in correlation can be due to the 
fact that the activity assay performed for Grx activity is not specific for Grx1 alone, 
but is general for all glutaredoxins present in the sample. Changes in Grx2 activity, 
which could be provoked by oxidative modification, can mask altered Grx1 activity 
and vice versa. Also, the Grx activity assay uses a commercially available, 
chemically stable mixed disulfide L-cysteine-S-sulfate as a substrate, rather than 
an S-glutathionylated protein. Taken together, the Grx activity assay used is not 
specific for Grx1 nor is it specific for deglutathionylation. In order to obtain more 
specific Grx1 activity profiles, radiolabeled glutathionylated substrates could be 
used or purification of Grx1 prior to analyses can be performed. Summary of Grx 
activity measured in this thesis can be found in Table 1. 
 
Understanding changes in protein S-glutathionylation  
 
Mild oxidative stress can, in addition to direct oxidation of GSH to GSSG, induce 
the binding of glutathione to the sulfhydryl group of cysteine amino acids in 
proteins. As such, GSH binding to proteins has been proposed as a marker of 
oxidative stress and its measurement is more accurate then measuring the rapidly 
changing GSH/GSSG ratio. It should also be noted that PSSG contains an 
important pool of GSH that can be specifically liberated by glutaredoxins, but that it 
is typically overlooked in classical measurements of GSH/GSSG. 
Previously PSSG has been shown to be increased in the blood of smokers [16] 
and in this thesis we have expanded this knowledge by investigating PSSG levels 
in lung epithelial cells, mice exposed to cigarette smoke and lung tissue and 
plasma of COPD patients. 
Decreased PSSG levels, as observed in lungs of mice exposed to cigarette smoke 
for four weeks, in plasma of patients with stable COPD and sputum of stable 
asthma and exacerbating COPD patients, can be interpreted as the liberation of 
this reserve in GSH after the depletion of the pool of free GSH due to severe 
oxidative stress, especially in the extracellular milieu. On the other hand, because 
protein S-glutathionylation is believed to protect proteins from further irreversible 
oxidations, decreased PSSG might make proteins more prone for overoxidation. 
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Increased PSSG, as reported in cells exposed to CSE acutely and lungs of COPD 
patients could thus be interpreted as a response to protect proteins under 
conditions of mild oxidation stress, especially in tissue.  
This increased PSSG level in lung epithelial cells exposed in vitro to cigarette 
smoke extract and lung tissue of COPD patients was in accordance with a lower 
level of Grx1 expression (chapter 3 and 6). Also in sputum of asthmatics and 
COPD patients, as well as plasma of COPD patients PSSG levels negatively 
correlated with Grx1. PSSG levels were however not inversely correlated with Grx1 
expression in mice exposed to cigarette smoke; lowered Grx1 levels, as well as 
lower overall PSSG level in lung tissue was  found here (chapter 4). One could 
speculate whether the concentrations and frequency of cigarette smoke exposure 
to mice is too high and over-oxidation or irreversible oxidation occurs, without the 
possibility of the lungs to restore their anti-oxidant capacity. It is furthermore 
difficult to compare smoking in humans with forced cigarette smoke inhalation in 
mice; exact recapitulation of damage accumulated over years of exposure to 
cigarette smoke in humans is not possible in laboratory rodents. Another 
explanation for the decreased PSSG is that upon broncho alveolar lavage the 
inflammatory cells in the lungs are flushed away, leaving only the epithelial cells to 
contribute in the overall measured PSSG. This theory is further strengthened by 
increased levels of PSSG in the BAL fluid of mice exposed to cigarette smoke 
compared to mice exposed to air (chapter 4). Inflammatory cells in the BAL fluid 
may not yet have adapted to the chronic exposure of high concentrations of 
cigarette smoke, given their short lives and rapid turnover as well as their acute 
recruitment to the site of inflammation. Laslt, not only glutaredoxins, but multiple 
other factors determine the balance between reduced cysteines (PSSH), PSSG 
and overoxidation of proteins. Although protein S-glutathionylation can be achieved 
non-enzymatically upon the presence of mild oxidative stress, there is some 
evidence that glutathione-S-transferase P1 can catalyse this reaction [17, 18] and 
therefore counteract the actions of Grx1. In chapter 7, GSTP1 protein levels and 
mRNA expression were found to be unaltered in plasma of COPD patients. Total 
GST activity on the other hand was decreased in COPD patients compared to 
controls and was negatively associated with IL-6 and positively correlated to lung 
function. 
Lastly, targeted proteins can be functionally influenced by the binding of 
GSH, such as enzymes with catalytically important cysteines, including proteins 
that are of importance in lung physiology. With respect to inflammation, the 
transcription factors NF- [19], AP-1 [20] and STAT3 [21] have been shown to be 
negatively affected by S-glutathionylation. Second, the calcium ATPase pump 
SERCA has been shown to be activated by S-glutathionylation of cysteine 674, 
leading to increased relaxation of smooth muscle [22]. Also with respect to muscle 
contractility, S-glutathionylation of the Ryanodine receptor calcium channel (RyR) 
was shown to be associated with impaired coulping [23].  Other effects include 
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inhibition of caspase 3 [24], eNOS [25] and PTEN [26], and inhibition of 
polymerization of G-actin [27].  
 
Role of Grx1-PSSG in inflammation 
 
Given the intricate relation that was already shown between inflammation and the 
Grx1-PSSG axis, and the additional data we presented in the second chapter of 
this thesis, as well as in patients with COPD and asthma, we used a mouse model 
in which Glrx1 is ablated to investigate whether down regulation of Grx1 had a role 
in cigarette smoke-induced pulmonary inflammation. Although there was no 
difference in total cell counts between control and Glrx1 KO mice, the pattern of 
inflammation was altered in the absence of Grx1. Accumulation of macrophages, 
but lower levels of neutrophils and dendritic cells in the BAL fluid were reported, 
together with decreased levels of cytokines and chemokines. Our laboratory 
previously described the necessity of Grx1 in macrophage maturation in mice upon 
LPS exposure [28]. Although macrophage numbers were increased in response to 
smoke in Glrx1 KO mice, it is likely that these macrophages are less mature then in 
the wild type mice. In support of this hypothesis, Glrx1 KO macrophages did not 
induce KC production in response to CSE, but further increased PSSG levels. The 
level of maturity might also be the cause of enhanced macrophage accumulation in 
the BAL fluid. Investigating the impact of Glrx1 ablation on NF-κB activity in mice 
exposed to cigarette smoke was not possible because no nuclear NF-κB 
localization could be detected after the time lapse between the last cigarette smoke 
exposure and harvesting the mice. However, the cytokines altered by ablation of 
Glrx1 were all NF-κB dependent, implying that the NF-κB pathway was negatively 
regulated by the increased S-glutathionylation that resulted from Glrx1 ablation as 
our laboratory has shown previously [6, 28].  
 
Summary and future perspectives 
 
Given our currently level of understanding, direct investigations into the relevance 
of Grx1 alterations in COPD, especially given its role in cigarette smoke induced 
inflammation in mice and cell death in vitro, as demonstrated in this thesis, a 6 
month exposure model in Glrx1 KO mice should be performed. This is a true 
mouse model of emphysema and would help to determine the potential role of 
Grx1 in disease pathogenesis. Furthermore, the use of the Glrx1 KO mice and 
transgenic mice over-expressing Grx1 specifically within the parenchyma of the 
lung, would provide an invaluable resource for elucidating the role of Grx1 in 
disease as well as protein targets of smoke induced S-glutathionylation.  
Data published thus far have demonstrated roles for the AP-1 transcription factor 
and NF-kappa B transcription factor family in the regulation of Grx1 expression. 
Given the inflammatory nature of this proposed regulation, the question as to 
whether or not transcription of a redox response enzyme, i.e. Grx1, is regulated in 
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a redox response dependent manner, remains unanswered. Further investigation 
into this potential redox inducible regulation would lend credence to the feed-
forward, anti-oxidant function of the Grx1/protein S-glutathionylation axis laid out 
thus far in this thesis.  
In order to gain more insight into the influence on the activity of Grx1, a more 
specific activity assay would have to be created. Highly specific antibodies for S-
glutathionylated proteins would be helpful in determining targets that are affected 
by changes in Grx1 expression or in the presence of oxidative stress.  
In general, unravelling the impact of differences in the Grx1/protein S-
glutathionylation axis on protein function and cell homeostasis would make a 
stronger case for its pharmaceutical targeting in order to inhibit further oxidative 
damage. 
Taken together this thesis has attempted to answer the vigorously debated 
question as to whether or not Grx1 and PSSG are overall protective in regard to 
the pathophysiology of COPD. A definitive answer to this question, despite the data 
presented in this thesis, remains elusive. We have shown that Grx1 protects 
against CSE induced cell death, can mediate NF-κB regulated and smoke-induced 
inflammation and is positively correlated with lung function (chapter 6). Curiously 
however, given the role of Grx1 in reversing the S-glutathionylation of proteins, 
Grx1 expression inversely correlated with PSSG formation, which also positively 
correlated with lung function. This seeming paradox actually highlights several yet 
incompletely and unexplored facets of Grx1 and PSSG biology, namely the genetic 
regulation of Grx1 expression, and the mechanisms through which Grx1 targets 
and interacts with the proteins it ultimately deglutathionylates. As we have put forth 
previously in this thesis, protein S-glutathionylation, much like O-phosphorylation, 
has been reported to inhibit as well as enhance protein function depending on the 
target protein. To that same end, it has become abundantly clear in the decades 
following the discovery of protein kinases, that their activities are intimately 
dependent on the innumerable intermediary molecules (i.e. small G-proteins, linker 
proteins, phospholipids, etc.) that direct these enzymes to their intended 
substrates. We would speculate that ultimately the answer to the question of the 
role of Grx1 inthe pathogenesis COPD may lie in understanding what intermediary 
molecules regulate the spatial and temporal targeting of Grx1 to the reversal of any 
one particular S-glutathionylated protein.  
Our data in this thesis have convincingly established the correlation between the 
Grx1-PSSG axis and epithelial cell death, inflammation and lung function, all of 
which have been implicated in the pathogenesis of COPD. Defining the ultimate 
role of Grx1 in protein S-glutathionylation in the pathogenesis of COPD will require 
further understanding of the genetic as well as posttranslational regulation and 
targeting of Grx1. However, we do not think it is premature to consider therapeutic 
intervention of the Grx1-PSSG axis in the potential treatment of COPD.  
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Table 1: Summary of data on Grx1/PSSG axis in studies performed in this thesis. 
All data compared to respective controls. 
 
 PSSG Grx1 expression Grx activity 
CSE In vitro epithelial 
cells ↑ ↓ = 
4wks CS in mice lung 
tissue ↓ ↓ = 
4wks CS in mice BAL 
cells ↑ ↓  
COPD lung tissue ↑ ↓ ↓ 
COPD sputum stable = ↓ = 
COPD sputum 
exacerbation ↓ ↑ ↑ 
COPD plasma ↓ ↓  
Asthma sputum ↓ ↑ = 
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Samenvatting 
 
De binding van glutathion aan cysteines in eiwitten wordt ook eiwit S-
glutathionylatie genoemd en is omkeerbaar met behulp van antioxidant enzymen 
glutaredoxines. Eiwit S-glutathionylatie wordt gevormd wanneer er een lichte vorm 
van oxidatieve stress gedetecteerd wordt in de cel en doet dienst als bescherming 
tegen verdere, onomkeerbare oxidatieve stress schade. Vermits het roken van 
sigaretten een zware oxidatieve stress veroorzaakt in de longen en dit tot 
onomkeerbare schade en aandoeningen zoals COPD (chronisch longlijden) kan 
leiden, hebben we in dit proefschrift uitgezocht wat voor impact roken en COPD 
hebben op eiwit S-glutathionylatie en glutaredoxines. Hierdoor kan men beter 
begrijpen wat de oorzaak van onomkeerbare schade is en uiteindelijk proberen 
deze schade te verhinderen. De veranderingen in eiwit S-glutathionylatie en 
glutaredoxines na rookblootstellingen werden onderzocht in vitro, met behulp van 
cellijnen en rookextracten, alsook cellen geïsoleerd uit longen van aan rook 
blootgestelde muizen. In vivo werden de longen en broncho-alveolaire vloeistof 
van muizen blootgesteld aan rook onderzocht evenals sputum, plasma en 
longweefsel samples van patienten met COPD en astma. De resultaten waren niet 
altijd extrapoleerbaar van celkweek schaaltje naar organisme en ook niet van muis 
naar mens. We zijn er niet in geslaagd om een definitief antwoord te geven op de 
vraag of glutaredoxines en eiwit S-glutathionylatie een beschermende rol hebben 
voor de pathofysiologie van COPD. We kunnen echter wel concluderen op basis 
van data voorgelegd in dit proefschrift, dat glutaredoxine 1 een beschermende 
werking heeft tegen sigarettenrook extract geïnduceerde celdood en het ook de 
regulatie van NF-κB en rook-geinduceerde inflammatie kan mediëren en tenslotte 
ook positief correleerd met longfunctie. Hoewel de volledige rol van glutaredoxine 1 
en eiwit S-glutathionylatie in the pathogenese van COPD nog niet is beschreven 
en verder onderzoek nodig is, zijn wij er toch van overtuigd dat therapeutische 
interventie van de glutaredoxine 1- eiwit S-glutathionylatie as een positieve 
weerslag kan hebben voor COPD patiënten. 
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